,Rank,NCTId,OutcomeDenomUnits,OutcomeGroupDescription,OutcomeMeasurementUpperLimit,OutcomeGroupTitle,OutcomeMeasureAnticipatedPostingDate,OutcomeMeasureCalculatePct,OutcomeMeasureDenomUnitsSelected,OutcomeMeasureDescription,OutcomeMeasureDispersionType,OutcomeMeasureParamType,OutcomeMeasurePopulationDescription,OutcomeMeasureReportingStatus,OutcomeMeasureTimeFrame,OutcomeMeasureTitle,OutcomeMeasureType,OutcomeMeasureTypeUnitsAnalyzed,OutcomeMeasureUnitOfMeasure,OutcomeMeasurementComment,OutcomeMeasurementGroupId
0,1,['NCT04371159'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,2,['NCT04474496'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,3,['NCT02801266'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,4,['NCT01599390'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,5,['NCT00312702'],"['Participants', 'Participants']","['Falciparum Malaria Protein 11 with AS02A adjuvant\n\nFalciparum Malaria Protein 11 with AS02A adjuvant: vaccine', 'Falciparum Malaria Protein 11 with AS02A adjuvant\n\nFalciparum Malaria Protein 11 with AS02A adjuvant: vaccine', ""12 Subjects from the high dose group and 1 non immunized subject enrolled prior to challenge to serve as IC's for malaria sporozoite challenge.\n\n1 infectivity control subject out of the 6 came from this phase 1 study, the other 5 came from the phase 2 study (WRAIR 1250, NCT00312663). Both studies were included in one final clinical study report."", 'Falciparum Malaria Protein 11 with AS02A adjuvant\n\nFalciparum Malaria Protein 11 with AS02A adjuvant: vaccine', 'Falciparum Malaria Protein 11 with AS02A adjuvant\n\nFalciparum Malaria Protein 11 with AS02A adjuvant: vaccine']","['171.2', '220.2', '2855.6', '2207.3', 'NA', '64250.0', 'NA', '49800.0']","['10µg Dose FMP011', '50µg Dose FMP011', 'Infectivity Control', '10µg Dose FMP011', '50µg Dose FMP011']",[],[],[],"['An AE was defined as any reaction, side effect, or untoward event that occurred during the course of the trial whether or not the event was considered related to study drug or clinically significant.\n\nGrade 1: Mild Grade 2: Moderate Grade 3: Severe', 'Anti-LSA-1 Antibody Response in Titer Units on days 0, 28, 42 and 84']",['Full Range'],"['Number', 'Median']","[""The AE's were tabulated and summarized by subject and treatment groups. No additional analyses were performed. Grade 1 = mild, Grade 2 = moderate, Grade 3 = severe Infectivity Controls were not included in this analysis."", ""Low dose group didn't participate in challenge (day 42) and day 84""]","['Posted', 'Posted']","['30 days post vaccination', 'days 0, 28, 42 (challenge day) and 84']","['Safety - Most Frequently Reported Adverse Events and Grade', 'Anti-LSA-1 Antibody Response in Titer Units']","['Primary', 'Secondary']",[],"['Number of adverse events', 'Titer units']","[""Low dose group didn't participate in challenge (day 42)"", ""Low dose group didn't participate in day 84""]","['OG000', 'OG001', 'OG002', 'OG000', 'OG001', 'OG002', 'OG000', 'OG001', 'OG002', 'OG000', 'OG001', 'OG002', 'OG000', 'OG001', 'OG002', 'OG000', 'OG001', 'OG002', 'OG000', 'OG001', 'OG002', 'OG000', 'OG001', 'OG002', 'OG000', 'OG001', 'OG002', 'OG000', 'OG001', 'OG000', 'OG001', 'OG000', 'OG001', 'OG000', 'OG001']"
0,6,['NCT00312663'],"['Participants', 'Participants']","['Falciparum Malaria Protein 11 with AS01B adjuvant\n\nFalciparum Malaria Protein 11 with AS01B adjuvant.: malaria experimental vaccine', 'Falciparum Malaria Protein 11 with AS01B adjuvant\n\nFalciparum Malaria Protein 11 with AS01B adjuvant.: malaria experimental vaccine', ""10 Subject from the high dose group and six non immunized subjects enrolled prior to challenge to serve as IC's for malaria sporozoite challenge"", 'Falciparum Malaria Protein 11 with AS01B adjuvant\n\nFalciparum Malaria Protein 11 with AS01B adjuvant.: malaria experimental vaccine', 'Falciparum Malaria Protein 11 with AS01B adjuvant\n\nFalciparum Malaria Protein 11 with AS01B adjuvant.: malaria experimental vaccine', ""10 Subject from the high dose group and six non immunized subjects enrolled prior to challenge to serve as IC's for malaria sporozoite challenge.""]","['644.0', '475.9', 'NA', '3523.3', '6161.0', 'NA', 'NA', '85080.0', '248.5', 'NA', '18131.0', '235.4']","['10ug Dose FMP011', '50ug Dose FMP011', 'Infectivity Control (IC)', '10ug Dose FMP011', '50ug Dose FMP011', 'Infectivity Controls (IC)']",[],[],[],"['An AE was defined as any reaction, side effect, or untoward event that occurred during the course of the trial whether or not the event was considered related to the study drug or clinically significant. Grade 1: Mild Grade 2: Moderate Grade 3: Severe', 'Anti-LSA-1 Antibody Response in Titer Units on Days 0, 28, 42, and 84']",['Full Range'],"['Number', 'Median']","[""The AE's were tabulated and summarized by subject and treatment groups. No additional analyses were performed. Subjects from the IC group were not evaluated for AE's and there for not included in the data.\n\nGrade 1 = mild, Grade 2 = moderate, Grade 3 = severe"", 'nAnti-LSA-1 Antibody Response in Titer units on Days 0, 28, 42 and 84']","['Posted', 'Posted']","['30 days post vaccination', 'Days 0, 28, 42, and 84']","['Safety - Most Frequently Reported Adverse Events and Grade', 'Anti-LSA-1 Antibody Response in Titer Units on Days 0, 28, 42, and 84']","['Primary', 'Secondary']",[],"['adverse events', 'Titer units']","[""Didn't participate in phase"", ""Didn't participate in phase"", ""Didn't' participate in Challenge Phase"", ""Didn't' participate in Challenge Phase""]","['OG000', 'OG001', 'OG000', 'OG001', 'OG000', 'OG001', 'OG000', 'OG001', 'OG000', 'OG001', 'OG000', 'OG001', 'OG000', 'OG001', 'OG000', 'OG001', 'OG000', 'OG001', 'OG000', 'OG001', 'OG002', 'OG000', 'OG001', 'OG002', 'OG000', 'OG001', 'OG002', 'OG000', 'OG001', 'OG002']"
0,7,['NCT01153880'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,8,['NCT02019732'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,9,['NCT03972358'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,10,['NCT00948233'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,11,['NCT00026728'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,12,['NCT01211990'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,13,['NCT02663219'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,14,['NCT00121108'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,15,['NCT01861210'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,16,['NCT02911155'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,17,['NCT00724867'],"['Participants', 'Participants', 'Participants', 'Participants', 'Participants', 'Participants', 'Participants', 'Participants', 'Participants', 'Participants', 'Participants', 'Participants', 'Participants', 'Participants', 'Participants', 'Participants', 'Participants', 'Participants', 'Participants', 'Participants', 'Participants', 'Participants', 'Participants', 'Participants', 'Participants', 'Participants', 'Participants', 'Participants', 'Participants', 'Participants', 'Participants', 'Participants', 'Participants']","['Participants, who had received belimumab 1milligram per kilogram (mg/kg) or 10 mg/kg or placebo in study HGS1006-C1056 , received intravenous (IV) infusion of belimumab 10 mg/kg body weight over 1 hour every 28 days. The first dose of belimumab was given 4 weeks (2 to 8 weeks) after the last dose in the HGS1006-C1056 study. Treatment continued for five years from the time the last participant enrolled in the study or until there were 100 or fewer participants enrolled. All participants received standard of care (SoC) for systemic lupus erythematosus (SLE) during study participation.', 'Participants, who had received belimumab 1mg/kg or 10 mg/kg or placebo in study HGS1006-C1056 , received IV infusion of belimumab 10 mg/kg body weight over 1 hour every 28 days. The first dose of belimumab was given 4 weeks (2 to 8 weeks) after the last dose in the HGS1006-C1056 study. Treatment continued for five years from the time the last participant enrolled in the study or until there were 100 or fewer participants enrolled. All participants received SoC for systemic lupus erythematosus (SLE) during study participation.', 'Participants, who had received belimumab 1mg/kg or 10 mg/kg or placebo in study HGS1006-C1056 , received IV infusion of belimumab 10 mg/kg body weight over 1 hour every 28 days. The first dose of belimumab was given 4 weeks (2 to 8 weeks) after the last dose in the HGS1006-C1056 study. Treatment continued for five years from the time the last participant enrolled in the study or until there were 100 or fewer participants enrolled. All participants received SoC for systemic lupus erythematosus (SLE) during study participation.', 'Participants, who had received belimumab 1mg/kg or 10 mg/kg or placebo in study HGS1006-C1056 , received IV infusion of belimumab 10 mg/kg body weight over 1 hour every 28 days. The first dose of belimumab was given 4 weeks (2 to 8 weeks) after the last dose in the HGS1006-C1056 study. Treatment continued for five years from the time the last participant enrolled in the study or until there were 100 or fewer participants enrolled. All participants received SoC for systemic lupus erythematosus (SLE) during study participation.', 'Participants, who had received belimumab 1mg/kg or 10 mg/kg or placebo in study HGS1006-C1056 , received IV infusion of belimumab 10 mg/kg body weight over 1 hour every 28 days. The first dose of belimumab was given 4 weeks (2 to 8 weeks) after the last dose in the HGS1006-C1056 study. Treatment continued for five years from the time the last participant enrolled in the study or until there were 100 or fewer participants enrolled. All participants received SoC for systemic lupus erythematosus (SLE) during study participation.', 'Participants, who had received belimumab 1mg/kg or 10 mg/kg or placebo in study HGS1006-C1056 , received IV infusion of belimumab 10 mg/kg body weight over 1 hour every 28 days. The first dose of belimumab was given 4 weeks (2 to 8 weeks) after the last dose in the HGS1006-C1056 study. Treatment continued for five years from the time the last participant enrolled in the study or until there were 100 or fewer participants enrolled. All participants received SoC for systemic lupus erythematosus (SLE) during study participation.', 'Participants, who had received belimumab 1mg/kg or 10 mg/kg or placebo in study HGS1006-C1056 , received IV infusion of belimumab 10 mg/kg body weight over 1 hour every 28 days. The first dose of belimumab was given 4 weeks (2 to 8 weeks) after the last dose in the HGS1006-C1056 study. Treatment continued for five years from the time the last participant enrolled in the study or until there were 100 or fewer participants enrolled. All participants received SoC for systemic lupus erythematosus (SLE) during study participation.', 'Participants, who had received belimumab 1mg/kg or 10 mg/kg or placebo in study HGS1006-C1056 , received IV infusion of belimumab 10 mg/kg body weight over 1 hour every 28 days. The first dose of belimumab was given 4 weeks (2 to 8 weeks) after the last dose in the HGS1006-C1056 study. Treatment continued for five years from the time the last participant enrolled in the study or until there were 100 or fewer participants enrolled. All participants received SoC for systemic lupus erythematosus (SLE) during study participation.', 'Participants, who had received belimumab 1mg/kg or 10 mg/kg or placebo in study HGS1006-C1056 , received IV infusion of belimumab 10 mg/kg body weight over 1 hour every 28 days. The first dose of belimumab was given 4 weeks (2 to 8 weeks) after the last dose in the HGS1006-C1056 study. Treatment continued for five years from the time the last participant enrolled in the study or until there were 100 or fewer participants enrolled. All participants received SoC for systemic lupus erythematosus (SLE) during study participation.', 'Participants, who had received belimumab 1mg/kg or 10 mg/kg or placebo in study HGS1006-C1056 , received IV infusion of belimumab 10 mg/kg body weight over 1 hour every 28 days. The first dose of belimumab was given 4 weeks (2 to 8 weeks) after the last dose in the HGS1006-C1056 study. Treatment continued for five years from the time the last participant enrolled in the study or until there were 100 or fewer participants enrolled. All participants received SoC for systemic lupus erythematosus (SLE) during study participation.', 'Participants, who had received belimumab 1mg/kg or 10 mg/kg or placebo in study HGS1006-C1056 , received IV infusion of belimumab 10 mg/kg body weight over 1 hour every 28 days. The first dose of belimumab was given 4 weeks (2 to 8 weeks) after the last dose in the HGS1006-C1056 study. Treatment continued for five years from the time the last participant enrolled in the study or until there were 100 or fewer participants enrolled. All participants received SoC for systemic lupus erythematosus (SLE) during study participation.', 'Participants, who had received belimumab 1mg/kg or 10 mg/kg or placebo in study HGS1006-C1056 , received IV infusion of belimumab 10 mg/kg body weight over 1 hour every 28 days. The first dose of belimumab was given 4 weeks (2 to 8 weeks) after the last dose in the HGS1006-C1056 study. Treatment continued for five years from the time the last participant enrolled in the study or until there were 100 or fewer participants enrolled. All participants received SoC for systemic lupus erythematosus (SLE) during study participation.', 'Participants, who had received belimumab 1mg/kg or 10 mg/kg or placebo in study HGS1006-C1056 , received IV infusion of belimumab 10 mg/kg body weight over 1 hour every 28 days. The first dose of belimumab was given 4 weeks (2 to 8 weeks) after the last dose in the HGS1006-C1056 study. Treatment continued for five years from the time the last participant enrolled in the study or until there were 100 or fewer participants enrolled. All participants received SoC for systemic lupus erythematosus (SLE) during study participation.', 'Participants, who had received belimumab 1mg/kg or 10 mg/kg or placebo in study HGS1006-C1056 , received IV infusion of belimumab 10 mg/kg body weight over 1 hour every 28 days. The first dose of belimumab was given 4 weeks (2 to 8 weeks) after the last dose in the HGS1006-C1056 study. Treatment continued for five years from the time the last participant enrolled in the study or until there were 100 or fewer participants enrolled. All participants received SoC for systemic lupus erythematosus (SLE) during study participation.', 'Participants, who had received belimumab 1mg/kg or 10 mg/kg or placebo in study HGS1006-C1056 , received IV infusion of belimumab 10 mg/kg body weight over 1 hour every 28 days. The first dose of belimumab was given 4 weeks (2 to 8 weeks) after the last dose in the HGS1006-C1056 study. Treatment continued for five years from the time the last participant enrolled in the study or until there were 100 or fewer participants enrolled. All participants received SoC for systemic lupus erythematosus (SLE) during study participation.', 'Participants, who had received belimumab 1mg/kg or 10 mg/kg or placebo in study HGS1006-C1056 , received IV infusion of belimumab 10 mg/kg body weight over 1 hour every 28 days. The first dose of belimumab was given 4 weeks (2 to 8 weeks) after the last dose in the HGS1006-C1056 study. Treatment continued for five years from the time the last participant enrolled in the study or until there were 100 or fewer participants enrolled. All participants received SoC for systemic lupus erythematosus (SLE) during study participation.', 'Participants, who had received placebo in study HGS1006-C1056, received intravenous (IV) infusion of belimumab 10 mg/kg body weight over 1 hour every 28 days. The first dose of belimumab was given 4 weeks (2 to 8 weeks) after the last dose in the HGS1006-C1056 study. The dosing was continued for five years from the time the last participant enrolled in the study or until there were 100 or fewer participants enrolled. All participants received standard of care (SoC) for systemic lupus erythematosus (SLE) during study participation.', 'Participants, who had received belimumab 1mg/kg or 10 mg/kg in study HGS1006-C1056, received intravenous (IV) infusion of belimumab 10 mg/kg body weight over 1 hour every 28 days. The first dose of belimumab was given 4 weeks (2 to 8 weeks) after the last dose in the HGS1006-C1056 study. The dosing was continued for five years from the time the last participant enrolled in the study or until there were 100 or fewer participants enrolled. All participants received standard of care (SoC) for systemic lupus erythematosus (SLE) during study participation.', 'Participants, who had received placebo in study HGS1006-C1056, received intravenous (IV) infusion of belimumab 10 mg/kg body weight over 1 hour every 28 days. The first dose of belimumab was given 4 weeks (2 to 8 weeks) after the last dose in the HGS1006-C1056 study. The dosing was continued for five years from the time the last participant enrolled in the study or until there were 100 or fewer participants enrolled. All participants received standard of care (SoC) for systemic lupus erythematosus (SLE) during study participation.', 'Participants, who had received belimumab 1mg/kg or 10 mg/kg in study HGS1006-C1056, received intravenous (IV) infusion of belimumab 10 mg/kg body weight over 1 hour every 28 days. The first dose of belimumab was given 4 weeks (2 to 8 weeks) after the last dose in the HGS1006-C1056 study. The dosing was continued for five years from the time the last participant enrolled in the study or until there were 100 or fewer participants enrolled. All participants received standard of care (SoC) for systemic lupus erythematosus (SLE) during study participation.', 'Participants, who had received belimumab 1milligram per kilogram (mg/kg) or 10 mg/kg or placebo in study HGS1006-C1056 , received intravenous (IV) infusion of belimumab 10 mg/kg body weight over 1 hour every 28 days. The first dose of belimumab was given 4 weeks (2 to 8 weeks) after the last dose in the HGS1006-C1056 study. Treatment continued for five years from the time the last participant enrolled in the study or until there were 100 or fewer participants enrolled. All participants received standard of care (SoC) for systemic lupus erythematosus (SLE) during study participation.', 'Participants, who had received belimumab 1mg/kg or 10 mg/kg or placebo in study HGS1006-C1056 , received IV infusion of belimumab 10 mg/kg body weight over 1 hour every 28 days. The first dose of belimumab was given 4 weeks (2 to 8 weeks) after the last dose in the HGS1006-C1056 study. Treatment continued for five years from the time the last participant enrolled in the study or until there were 100 or fewer participants enrolled. All participants received SoC for systemic lupus erythematosus (SLE) during study participation.', 'Participants, who had received belimumab 1mg/kg or 10 mg/kg or placebo in study HGS1006-C1056 , received IV infusion of belimumab 10 mg/kg body weight over 1 hour every 28 days. The first dose of belimumab was given 4 weeks (2 to 8 weeks) after the last dose in the HGS1006-C1056 study. Treatment continued for five years from the time the last participant enrolled in the study or until there were 100 or fewer participants enrolled. All participants received SoC for systemic lupus erythematosus (SLE) during study participation.', 'Participants, who had received belimumab 1mg/kg or 10 mg/kg or placebo in study HGS1006-C1056 , received IV infusion of belimumab 10 mg/kg body weight over 1 hour every 28 days. The first dose of belimumab was given 4 weeks (2 to 8 weeks) after the last dose in the HGS1006-C1056 study. Treatment continued for five years from the time the last participant enrolled in the study or until there were 100 or fewer participants enrolled. All participants received SoC for systemic lupus erythematosus (SLE) during study participation.', 'Participants, who had received belimumab 1mg/kg or 10 mg/kg or placebo in study HGS1006-C1056 , received IV infusion of belimumab 10 mg/kg body weight over 1 hour every 28 days. The first dose of belimumab was given 4 weeks (2 to 8 weeks) after the last dose in the HGS1006-C1056 study. Treatment continued for five years from the time the last participant enrolled in the study or until there were 100 or fewer participants enrolled. All participants received SoC for systemic lupus erythematosus (SLE) during study participation.', 'Participants, who had received belimumab 1mg/kg or 10 mg/kg or placebo in study HGS1006-C1056 , received IV infusion of belimumab 10 mg/kg body weight over 1 hour every 28 days. The first dose of belimumab was given 4 weeks (2 to 8 weeks) after the last dose in the HGS1006-C1056 study. Treatment continued for five years from the time the last participant enrolled in the study or until there were 100 or fewer participants enrolled. All participants received SoC for systemic lupus erythematosus (SLE) during study participation.', 'Participants, who had received belimumab 1mg/kg or 10 mg/kg or placebo in study HGS1006-C1056 , received IV infusion of belimumab 10 mg/kg body weight over 1 hour every 28 days. The first dose of belimumab was given 4 weeks (2 to 8 weeks) after the last dose in the HGS1006-C1056 study. Treatment continued for five years from the time the last participant enrolled in the study or until there were 100 or fewer participants enrolled. All participants received SoC for systemic lupus erythematosus (SLE) during study participation.', 'Participants, who had received belimumab 1mg/kg or 10 mg/kg or placebo in study HGS1006-C1056 , received IV infusion of belimumab 10 mg/kg body weight over 1 hour every 28 days. The first dose of belimumab was given 4 weeks (2 to 8 weeks) after the last dose in the HGS1006-C1056 study. Treatment continued for five years from the time the last participant enrolled in the study or until there were 100 or fewer participants enrolled. All participants received SoC for systemic lupus erythematosus (SLE) during study participation.', 'Participants, who had received belimumab 1mg/kg or 10 mg/kg or placebo in study HGS1006-C1056 , received IV infusion of belimumab 10 mg/kg body weight over 1 hour every 28 days. The first dose of belimumab was given 4 weeks (2 to 8 weeks) after the last dose in the HGS1006-C1056 study. Treatment continued for five years from the time the last participant enrolled in the study or until there were 100 or fewer participants enrolled. All participants received SoC for systemic lupus erythematosus (SLE) during study participation.', 'Participants, who had received belimumab 1mg/kg or 10 mg/kg or placebo in study HGS1006-C1056 , received IV infusion of belimumab 10 mg/kg body weight over 1 hour every 28 days. The first dose of belimumab was given 4 weeks (2 to 8 weeks) after the last dose in the HGS1006-C1056 study. Treatment continued for five years from the time the last participant enrolled in the study or until there were 100 or fewer participants enrolled. All participants received SoC for systemic lupus erythematosus (SLE) during study participation.', 'Participants, who had received belimumab 1mg/kg or 10 mg/kg or placebo in study HGS1006-C1056 , received IV infusion of belimumab 10 mg/kg body weight over 1 hour every 28 days. The first dose of belimumab was given 4 weeks (2 to 8 weeks) after the last dose in the HGS1006-C1056 study. Treatment continued for five years from the time the last participant enrolled in the study or until there were 100 or fewer participants enrolled. All participants received SoC for systemic lupus erythematosus (SLE) during study participation.', 'Participants, who had received belimumab 1mg/kg or 10 mg/kg or placebo in study HGS1006-C1056 , received IV infusion of belimumab 10 mg/kg body weight over 1 hour every 28 days. The first dose of belimumab was given 4 weeks (2 to 8 weeks) after the last dose in the HGS1006-C1056 study. Treatment continued for five years from the time the last participant enrolled in the study or until there were 100 or fewer participants enrolled. All participants received SoC for systemic lupus erythematosus (SLE) during study participation.', 'Participants, who had received belimumab 1mg/kg or 10 mg/kg or placebo in study HGS1006-C1056 , received IV infusion of belimumab 10 mg/kg body weight over 1 hour every 28 days. The first dose of belimumab was given 4 weeks (2 to 8 weeks) after the last dose in the HGS1006-C1056 study. Treatment continued for five years from the time the last participant enrolled in the study or until there were 100 or fewer participants enrolled. All participants received SoC for systemic lupus erythematosus (SLE) during study participation.', 'Participants, who had received belimumab 1mg/kg or 10 mg/kg or placebo in study HGS1006-C1056 , received IV infusion of belimumab 10 mg/kg body weight over 1 hour every 28 days. The first dose of belimumab was given 4 weeks (2 to 8 weeks) after the last dose in the HGS1006-C1056 study. Treatment continued for five years from the time the last participant enrolled in the study or until there were 100 or fewer participants enrolled. All participants received SoC for systemic lupus erythematosus (SLE) during study participation.', 'Participants, who had received belimumab 1mg/kg or 10 mg/kg or placebo in study HGS1006-C1056 , received IV infusion of belimumab 10 mg/kg body weight over 1 hour every 28 days. The first dose of belimumab was given 4 weeks (2 to 8 weeks) after the last dose in the HGS1006-C1056 study. Treatment continued for five years from the time the last participant enrolled in the study or until there were 100 or fewer participants enrolled. All participants received SoC for systemic lupus erythematosus (SLE) during study participation.']","['201', '201', '201', '349', '2505', '1545', '556', '2305', '1873', '1188', '1765', '1863', '1018', '2648', '736', '521', '439', '45', '1608', '54.6', '183.1', '181.7', '1253.6', '668.7', '176.6', '1046.8', '831.8', '491', '778.1', '826.9', '406.5', '1217.4', '557.1', '365.2', '292', '-77.6', '700', '89', '160', '144', '157', '137', '133', '139', '150', '137', '193', '172', '161', '158', '147', '173', '177', '158', '173', '15', '25', '28', '29', '37', '31', '35', '38', '26', '40', '39', '36', '29', '34', '34', '35', '36', '22', '41', '281', '104.8', '192.9', '163.3', '161.2', '163.3', '206.1', '177.6', '175.7', '173.5', '159.7', '166.7', '137.1', '179', '185.5', '163.3', '195.2', '275', '200', '350', '270', '266.7', '250', '450', '433.3', '500', '566.7', '800', '600', '700', '900', '900', '1100', '100', '1066.7', '807', '433', '407', '278', '1528', '293', '500', '355', '238', '141', '248', '397', '113', '158', '120', '91', '57', '8', '364', '600', '452', '177', '204', '345', '216', '331', '407', '442', '414', '591', '443', '248', '381', '156', '755', '39', '29', '555', '585', '443', '145', '289', '316', '210', '324', '364', '452', '377', '597', '400', '227', '328', '156', '754', '42', '28', '603', '4274', '1613', '962', '221', '249', '322', '220', '128', '246', '136', '102', '38', '25', '70', '23', '18', '16', '2', '231', '177', '279', '275', '181', '686', '88', '342', '276', '196', '76', '166', '73', '46', '91', '81', '34', '32', '3', '167', '717', '371', '209', '176', '826', '243', '163', '140', '152', '127', '176', '67', '68', '69', '59', '62', '54', '7', '313', '2492', '1503', '561', '916', '472', '242', '233', '687', '288', '147', '61', '40', '56', '43', '29', '21', '10', '1', '457', '870', '393', '255', '446', '1513', '312', '225', '337', '214', '135', '75', '50', '64', '84', '47', '75', '28', '14', '221', '815', '437', '411', '281', '1559', '296', '510', '359', '245', '144', '301', '117', '114', '160', '121', '92', '58', '8', '368', '394.1', '216.7', '250', '1616.9', '250', '270.6', '82.4', '561.1', '156.3', '93.8', '2381.3', '102.9', '188.9', '172.2', '244.4', '105.9', '-42.9', '225', '4500', '4800', '2200', '33100', '6800', '4900', '2787.5', '5500', '4900', '10000', '11100', '24700', '29300', '2100', '1787.5', '100', '500', '6100', '4330', '1400', '2000', '4385.7', '1300', '6600', '1900', '1250', '1400', '1328.6', '3400', '3400', '4128.6', '2900', '1884.2', '10.5', '-79.4', '2000', '6352', '923.4', '2233.3', '422.2', '644.4', '863.6', '156', '35', '33.3', '-21.2', '-9.1', '-36.4', '-33.3', '-40', '-70', '-92.9', '-92.3', '610.7', '1420', '800', '700', '5616.7', '900', '3000', '1400', '3166.7', '500', '800', '533.3', '400', '500', '400', '200', '600', '-75', '1000', '337.5', '200', '150', '959', '100', '500', '100', '100', '66.7', '57.7', '233.3', '100', '300', '300', '510', '86.7', '-36.4', '433.3', '3000', '1331.6', '580', '502.9', '306.9', '325.7', '89.3', '263.6', '13.4', '14.3', '-16.7', '20', '-24.1', '-76', '-83.7', '-95.8', '-95.8', '453.1', '3400', '4700', '1200', '5500', '1000', '2566.7', '910', '586.4', '133.3', '300', '900', '2100', '1700', '200', '-11.1', '-75', '-71.4', '1600', '400', '214.3', '244.4', '1576.3', '153.3', '276.5', '82.4', '528.2', '141.2', '100', '75', '79.5', '125', '172.2', '250', '94.4', '-46.7', '178.6']","['Belimumab 10 mg/kg IV', 'Belimumab 10 mg/kg IV', 'Belimumab 10 mg/kg IV', 'Belimumab 10 mg/kg IV', 'Belimumab 10 mg/kg IV', 'Belimumab 10 mg/kg IV', 'Belimumab 10 mg/kg IV', 'Belimumab 10 mg/kg IV', 'Belimumab 10 mg/kg IV', 'Belimumab 10 mg/kg IV', 'Belimumab 10 mg/kg IV', 'Belimumab 10 mg/kg IV', 'Belimumab 10 mg/kg IV', 'Belimumab 10 mg/kg IV', 'Belimumab 10 mg/kg IV', 'Belimumab 10 mg/kg IV', 'Belimumab 10 mg/kg IV (Placebo)', 'Belimumab 10 mg/kg IV (Belimumab)', 'Belimumab 10 mg/kg IV (Placebo)', 'Belimumab 10 mg/kg IV (Belimumab)', 'Belimumab 10 mg/kg IV', 'Belimumab 10 mg/kg IV', 'Belimumab 10 mg/kg IV', 'Belimumab 10 mg/kg IV', 'Belimumab 10 mg/kg IV', 'Belimumab 10 mg/kg IV', 'Belimumab 10 mg/kg IV', 'Belimumab 10 mg/kg IV', 'Belimumab 10 mg/kg IV', 'Belimumab 10 mg/kg IV', 'Belimumab 10 mg/kg IV', 'Belimumab 10 mg/kg IV', 'Belimumab 10 mg/kg IV', 'Belimumab 10 mg/kg IV', 'Belimumab 10 mg/kg IV']",[],[],[],"['An AE is defined as any untoward medical occurrence in a participant (par.) temporally associated with the use of a investigational product (IP), whether or not considered related to the IP. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of an IP. An SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, is an important medical event that jeopardizes the participant or may require medical or surgical intervention to prevent one of the other outcomes listed in the above definition, or is associated with liver injury and impaired liver function. Only those participants available at the specified time points (represented by n=X, in the category titles) were analyzed.', 'AE rates by SOC adjusting for participant-years on study drug anytime post Baseline are summarized, which included the follow up visits. Only treatment-emergent adverse events (AEs) are summarized. The Baseline is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. The event rate of an AE was calculated as the number of events per 100 participant years: Event Rate = 100* Number of Events / Participant Years. Participant years were calculated as sum across all participants ([last visit of interval day - first visit of interval day + 1]/365). Participant years excluded between study gaps if participant had not started extension study on date of last visit of parent study.', 'SAE rates by SOC adjusting for participants-years on study drug anytime post Baseline are summarized, which included the follow up visits. Only treatment-emergent SAEs are summarized. The Baseline is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. The event rate of an SAE was calculated as the number of events per 100 participant years: Event Rate = 100* Number of Events / participants Years. participants years were calculated as = sum across all participants ([last visit of interval day - first visit of interval day + 1]/365). participants years excluded between study gaps if participant had not started extension study on date of last visit of parent study.', 'Hematology parameters were assessed at Baseline (BL) (Day 0), Week 4, 12, 24, 36 and 48 in first year, at Week 24 and 48 in subsequent years up to 440 weeks and at follow-up (up to 8 weeks post last infusion). Change from Baseline in APTT and PT is summarized. The Baseline is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Change from Baseline is defined as the difference between the post-dose post- Baseline visit value and the Baseline value. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.', 'Hematology parameters were assessed at Baseline (BL) (Day 0), Week 4, 12, 24, 36 and 48 in first year, at Week 24 and 48 in subsequent years up to440 weeks and at follow-up (up to 8 weeks post last infusion). Change from Baseline in basophils, eosinophils, lymphocytes, monocytes, neutrophils, neutrophils segmented and platelets is summarized. The Baseline is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Change from Baseline is defined as the difference between the post-dose post- Baseline visit value and the Baseline value. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.', 'Hematology parameters were assessed at Baseline (BL) (Day 0), at Week 4, 12, 24, 36 and 48 in first year, at Week 24 and 48 in subsequent years up to 440 weeks and at follow-up (up to 8 weeks post last infusion). Change from Baseline in erythrocytes is summarized. The Baseline is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Change from Baseline is defined as the difference between the post-dose post- Baseline visit value and the Baseline value. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.', 'Hematology parameters were assessed at Baseline (BL) (Day 0), Week 4, 12, 24, 36 and 48 in first year, at Week 24 and 48 in subsequent years up to 440 weeks and at follow-up (up to 8 weeks post last infusion). Change from Baseline in hematocrit is summarized. The Baseline is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Change from Baseline is defined as the difference between the post-dose post- Baseline visit value and the Baseline value. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.', 'Hematology parameters were assessed at Baseline (BL) (Day 0), Week 4, 12, 24, 36 and 48 in first year, at Week 24 and 48 in subsequent years up to 440 weeks and at follow-up (up to 8 weeks post last infusion). Change from Baseline in hemoglobin is summarized. The Baseline is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Change from Baseline is defined as the difference between the post-dose post- Baseline visit value and the Baseline value. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.', 'Clinical chemistry parameters were assessed at Baseline (BL) (Day 0), at Week 4, 12, 24, 36 and 48 in first year, at Week 24 and 48 in subsequent years up to 440 weeks and at follow-up (up to 8 weeks post last infusion). Change from Baseline in albumin and protein is summarized. The Baseline is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Change from Baseline is defined as the difference between the post-dose post- Baseline visit value and the Baseline value. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.', 'Clinical chemistry parameters were assessed at Baseline (BL) (Day 0), at Week 4, 12, 24, 36 and 48 in first year, at Week 24 and 48 in subsequent years up to 440 weeks and at follow-up (up to 8 weeks post last infusion). Change from Baseline in blood urea nitrogen, glucose, calcium, carbon dioxide, chloride, magnesium, phosphate, potassium and sodium is summarized. The Baseline is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Change from Baseline is defined as the difference between the post-dose post- Baseline visit value and the Baseline value. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.', 'Clinical chemistry parameters were assessed at Baseline (BL) (Day 0), at Week 4, 12, 24, 36 and 48 in first year, at Week 24 and 48 in subsequent years up to 440 weeks and at follow-up (up to 8 weeks post last infusion). Change from Baseline in urate, creatinine and bilirubin is summarized. The Baseline is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Change from Baseline is defined as the difference between the post-dose post- Baseline visit value and the Baseline value. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.', 'Clinical chemistry parameters were assessed at Baseline (BL) (Day 0), at Week 4, 12, 24, 36 and 48 in first year, at Week 24 and 48 in subsequent years up to 440 weeks and at follow-up (up to 8 weeks post last infusion). Change from Baseline in creatinine clearance is summarized. The Baseline is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Change from Baseline is defined as the difference between the post-dose post- Baseline visit value and the Baseline value. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.', 'Clinical chemistry parameters were assessed at Baseline (BL) (Day 0), at Week 4, 12, 24, 36 and 48 in first year, at Week 24 and 48 in subsequent years up to 440 weeks and at follow-up (up to 8 weeks post last infusion). Change from Baseline in BUN/creatinine is summarized. The Baseline is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Change from Baseline is defined as the difference between the post-dose post- Baseline visit value and the Baseline value. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.', 'Clinical chemistry parameters were assessed at Baseline (BL) (Day 0), at Week 4, 12, 24, 36 and 48 in first year, at Week 24 and 48 in subsequent years up to 432 weeks and at exit visit. Change from Baseline in alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase, gamma glutamyl transferase and lactate dehydrogenase is summarized. The Baseline is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Change from Baseline is defined as the difference between the post-dose post- Baseline visit value and the Baseline value. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.', 'Immunogenic response was assessed by binding confirmatory assay at Baseline (BL) (Day 0), at Week 24 and 48 in first year, at Week 24 and 48 in subsequent years up to 440 weeks and at follow-up (up to 8 weeks post last infusion). Number of participants with the indicated immunogenic response are summarized. The Baseline is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Results of binding confirmatory assay were categorized as negative, persistent positive (defined as a positive immunogenic response that occurs at least 2 consecutive assessments or a single result at the final assessment) or transient positive (defined as a single positive immunogenic response that does not occur at the final assessment). Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.', 'Systolic blood pressure (SBP) and diastolic blood pressure (DBP) was measured at Baseline (BL) (Day 0), at Week 24 and 48 in first year, at Week 24 and 48 in subsequent years up to 432 weeks and at exit visit. The Baseline is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.', 'Serum creatinine was assessed at Baseline (BL) (Day 0), at Week 4, 12, 24, 36 and 48 in first year, at Week 24 and 48 in subsequent years up to 440 weeks and at follow-up (up to 8 weeks post last infusion). Percentage of participants with at least 25% increase from baseline in creatinine are summarized. The Baseline is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.', 'Serum creatinine was assessed at Baseline (BL) (Day 0), at Week 4, 12, 24, 36 and 48 in first year, at Week 24 and 48 in subsequent years up to 440 weeks and at follow-up (up to 8 weeks post last infusion). Percentage of participants with at least 25% reduction from baseline in creatinine are summarized. The Baseline is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.', 'Serum immunoglobulin G (IgG) was collected at Baseline (BL) (Day 0), at Week 24 and Week 48 in first year, at Week 48 in subsequent years up to 8 years and at follow-up (up to 8 weeks post last infusion). Number of participants with serum immunoglobulins below the lower limit of normal (LLN) (<0.5 nanograms per milliliter [ng/mL]) are summarized. The Baseline is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.', 'The percentage of participants achieving a SLE Responder Index (SRI) response at Baseline (BL) (Day 0), at Week 4, 12, 24, 36 and 48 in first year, at Week 24 and 48 in subsequent years up to 440 weeks and at follow-up (up to 8 weeks post last infusion) are summarized. The BL is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Response is defined as:>=4 point reduction from the BL in the safety of estrogen in lupus national assessment (SELENA) SLE disease activity index (SLEDAI) score and no worsening (increase of <0.30 points from the BL) in Physicians Global Assessment (PGA), and no new British Isles Lupus Assessment Group (BILAG) A organ domain score or 2 new BILAG B organ domain scores compared with the BL. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.', 'Anti-double stranded deoxyribonucleic acid (anti-dsDNA) levels were assessed at Baseline (BL) (Day 0), at Week 24 and 48 in first year, at Week 24 and 48 in subsequent years up to 432 weeks in participants who were positive at baseline (anti-dsDNA >=30 International Units/milliliter [IU/mL]). Observed anti-dsDNA levels are summarized. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.', 'Anti-dsDNA levels were assessed at Baseline (BL) (Day 0), 24 and 48 in first year, at Week 24 and 48 in subsequent years up to 432 weeks and at exit visit in participants who were positive at baseline (anti-dsDNA ≥30 IU/mL). Median percent change from Baseline in anti-dsDNA levels are summarized. The Baseline is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Percent change from Baseline is calculated as: 100 x ([Post-Dose Visit Value - Baseline] / Baseline). Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.', 'Complement C3 and C4 levels were assessed at Baseline (BL) (Day 0), at Week 24 and 48 in first year, at Week 24 and 48 in subsequent years up to 440 weeks and at exit visit in participants with low complements at Baseline (C3 <90 milligram per deciliter (mg/dL) and C4 <16 mg/dL). Observed complement C3 and C4 levels are summarized. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.', 'Complement C3 and C4 levels were assessed at Baseline (BL) (Day 0), 24 and 48 in first year, at Week 24 and 48 in subsequent years up to 432 weeks and at exit visit in participants with low complements at Baseline (C3 <90 milligrams per decilitre (mg/dL) and C4 <16 mg/dL). Median percent change from Baseline in complement C3 and C4 levels are summarized. The Baseline is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Percent change from Baseline is calculated as: 100 x ([Post-Dose Visit Value - Baseline] / Baseline). Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.', 'Trends for reduction in prednisone use in participants receiving belimumab were observed up to 432 weeks. Percentage of participants with daily prednisone dose reduced to <=7.5 mg/day from >7.5 mg/kg at the Baseline are summarized. The Baseline is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.', 'Proteinuria is defined as the presence of an excess of serum proteins in the urine. Trends for reduction in proteinuria in participants receiving belimumab were assessed up to 432 weeks and at Exit visit. Percentage of participants with >= 50% reduction in proteinuria among participants with Baseline proteinuria >0.5 g/24 hour (hr) are summarized. The Baseline is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.', 'B-cell levels were assessed at Baseline (BL) (Day 0), Week (Wk) 24 and 48 in first year, at Week 24 and 48 in subsequent years up to 432 weeks and at exit visit. Observed absolute B cell subsets (CD20+), CD19+/27BRIGHT/38BRIGHT SLE subset, CD19+20-27hi+ short-lived plasma cells (SLPC), CD20+/138+ plasmacytoid, CD20+/27+ memory, CD20+/27- naïve, CD20+/69+activated, CD20-/138+ plasma cells, Total CD19+ B-cells (CD19+) levels are summarized. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.', 'B-cell levels were assessed at Baseline (BL) (Day 0), Week (Wk) 24 and 48 in first year, at Week 24 and 48 in subsequent years up to 432 weeks and at exit visit. Median percent change from Baseline in absolute B cell subsets (CD20+), CD19+/27BRIGHT/38BRIGHT SLE subset, CD19+20-27hi+ short-lived plasma cells (SLPC), CD20+/138+ plasmacytoid, CD20+/27+ memory, CD20+/27- naïve, CD20+/69+activated, CD20-/138+ plasma cells, Total CD19+ B-cells (CD19+) levels are summarized. The Baseline is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Percent change from Baseline is calculated as: 100 x ([Post-Dose Visit Value - Baseline] / Baseline). Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.', 'Systemic Lupus International Collaborative Clinics/American College of Rheumatology (SLICC/ACR) Damage Index is a tool used to assess non-reversible organ damage in SLE patients. Damage Index is used to assess 12 systems by 41 items. Score is given as 1 or sometimes 2, if occur more than once, so that that the maximum possible score is 47. Higher damage index scores early in disease are associated with a poor prognosis and with increased mortality. Damage index was assessed at BL (Day 0), Week 48 in first year, at Week 48 in subsequent years up to 8 years. Percentage of participants with worsening in damage index (change >0) are summarized. The BL is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Only those participants available at the specified time points were analyzed ( n=X).', 'The SF-36v2 is a participant-reported short form survey to measure functional health and well-being. There are 36 items grouped into eight health domains: Vitality, physical functioning, bodily pain, general health perceptions, physical role functioning, emotional role functioning, social role functioning and mental health. SF-36v2 gives a score (0-100) for each of these domains as well as summary score for the physical component score (PCS) and mental component score (MCS) based on the responses by participants. The lower the score the more disability and the higher the score the less disability. The BL is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Change from BL was calculated as the individual post-BL value minus the BL value. Only those participants available at the specified time points were analyzed ( n=X).', 'The SF-36v2 is a participant-reported survey to measure functional health and well-being. There are 36 items grouped into eight health domains: Vitality, physical functioning, bodily pain, general health perceptions, physical role functioning, emotional role functioning, social role functioning and mental health. SF-36v2 gives a score (0-100) for each of these domains as well as summary score for the physical component score (PCS) and mental component score (MCS) based on the responses by participants. The lower the score the more disability and the higher the score the less disability. The BL is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Change from BL was calculated as the individual post-BL value minus the BL value. Only those participants available at the specified time points were analyzed ( n=X).', 'The FACIT-F scale measures the severity and impact of fatigue on functioning and health related quality of life experienced in the past 7 days. FACIT-Fatigue scale total score was assessed at BL (Day 0), Wk 48 in first year, at Wk 48 in subsequent Yrs up to 8 Yrs.The level of fatigue is measured by 13 questions assessed on a four-point scale (0=not at all fatigued; 1=a little bit fatigued; 2=somewhat fatigued; 3=quite a bit fatigued; 4=very much fatigued; possible total score of 0 to 52). Change from BL in FACIT-Fatigue scale total score are summarized. The BL is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Change from BL was calculated as the individual post-BL value minus the BL value. A negative change from BL represents a worsening condition. Only those participants available at the specified time points were analyzed ( n=X).', 'The FACIT-F scale measures the severity and impact of fatigue on functioning and health related quality of life experienced in the past 7 days. FACIT-Fatigue scale total score was assessed at BL (Day 0), Week 48 in first year, at Week 48 in subsequent years up to 8 years. The level of fatigue is measured by 13 questions assessed on a four-point scale (0=not at all fatigued; 1=a little bit fatigued; 2=somewhat fatigued; 3=quite a bit fatigued; 4=very much fatigued; possible total score of 0 to 52). Percentage of participants with improvement in FACIT-Fatigue scale score exceeding the minimum clinically important difference (MCID) (>=4 points) are summarized. Only those participants available at the specified time points were analyzed ( n=X).']","['Standard Deviation', 'Standard Deviation', 'Standard Deviation', 'Standard Deviation', 'Standard Deviation', 'Standard Deviation', 'Standard Deviation', 'Standard Deviation', 'Standard Deviation', 'Standard Deviation', 'Standard Deviation', 'Standard Deviation', 'Full Range', 'Full Range', 'Full Range', 'Full Range', 'Full Range', 'Full Range', 'Standard Deviation', 'Standard Deviation', 'Standard Deviation']","['Number', 'Number', 'Number', 'Mean', 'Mean', 'Mean', 'Mean', 'Mean', 'Mean', 'Mean', 'Mean', 'Mean', 'Mean', 'Mean', 'Number', 'Mean', 'Number', 'Number', 'Number', 'Number', 'Median', 'Median', 'Median', 'Median', 'Number', 'Number', 'Median', 'Median', 'Number', 'Mean', 'Mean', 'Mean', 'Number']","['Modified Intent to Treat (MIIT) Population: The MITT Population comprised of all the participants enrolled in the study who received at least one dose of IP.', 'MITT Population', 'MITT Population', 'MITT Population', 'MITT Population', 'MITT Population', 'MITT Population', 'MITT Population', 'MITT Population', 'MITT Population', 'MITT Population', 'MITT Population', 'MITT Population', 'MITT Population', 'MITT Population', 'MITT Population', 'MITT Population', 'MITT Population. Only those subjects with abnormal (>124 umol/L) creatinine at baseline by year interval.', 'MITT Population', 'MIIT Population', 'MITT Population', 'MITT Population', 'MITT Population', 'MITT Population', 'MITT Population', 'MITT Population', 'MITT Population', 'MITT Population', 'MITT Population', 'MITT Population', 'MITT Population', 'MITT Population', 'MITT Population']","['Posted', 'Posted', 'Posted', 'Posted', 'Posted', 'Posted', 'Posted', 'Posted', 'Posted', 'Posted', 'Posted', 'Posted', 'Posted', 'Posted', 'Posted', 'Posted', 'Posted', 'Posted', 'Posted', 'Posted', 'Posted', 'Posted', 'Posted', 'Posted', 'Posted', 'Posted', 'Posted', 'Posted', 'Posted', 'Posted', 'Posted', 'Posted', 'Posted']","['Up to Week 440', 'Up Week 440', 'Up to Week 440', 'Up to Week 440', 'Up to Week 440', 'Up to Week 440', 'Up to Week 440', 'Up to Week 440', 'Up to Week 440', 'Up to Week 440', 'Up to Week 440', 'Up to Week 440', 'Up to Week 440', 'Up to Week 432', 'Up to Week 440', 'Up to Week 432', 'Up to Week 440', 'Up to Week 440', 'Up to Week 392', 'Up to Week 440', 'Up to Week 432', 'Up to Week 432', 'Up to Week 440', 'Up to Week 432', 'Up to Week 432', 'Up to Week 432', 'Up to Week 432', 'Up to Week 432', 'Up to Week 384', 'Up to Week 384', 'Up to Week 384', 'Up to Week 384', 'Up to Week 384']","['Number of Participants With the Indicated Type of Adverse Event (AEs) and Serious Adverse Event (SAEs)', 'AE Rates by System Organ Class (SOC) During the Study', 'SAE Rates by System Organ Class (SOC) During the Study', 'Change From Baseline in Activated Partial Thromboplastin Time (APTT) and Prothrombin Time (PT) at the Indicated Time Points', 'Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Neutrophils Segmented and Platelets at the Indicated Time Points', 'Change From Baseline in Erythrocytes at the Indicated Time Points', 'Change From Baseline in Hematocrit at the Indicated Time Points', 'Change From Baseline in Hemoglobin at the Indicated Time Points', 'Change From Baseline in Albumin and Protein at the Indicated Time Points', 'Change From Baseline in Blood Urea Nitrogen, Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points', 'Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points', 'Change From Baseline in Creatinine Clearance at the Indicated Time Points', 'Change From Baseline in BUN/Creatinine at the Indicated Time Points', 'Change From Baseline in Alanine Aminotransferase, Alkaline Phosphatase, Aspartate Aminotransferase, Gamma Glutamyl Transferase and Lactate Dehydrogenase at the Indicated Time Points', 'Number of Participants With the Indicated Immunogenic Response', 'Systolic Blood Pressure and Diastolic Blood Pressure at Indicated Time Points.', 'Percentage of Participants With at Least 25% Increase From Baseline in Creatinine at Indicated Time Points.', 'Percentage of Participants With at Least 25% Reduction From Baseline in Creatinine at Indicated Time Points. Amongst Subjects With Abnormal (>124 Umol/L) Creatinine at Baseline by Year Interval.', 'Number of Participants With Serum Immunoglobulins Below the Lower Limit of Normal at Indicated Time Points.', 'Percentage of Participants Achieving SRI Response at Indicated Time Points', 'Observed Anti-double Stranded DNA Levels at Indicated Time Points.', 'Median Percent Change From Baseline in Anti-double Stranded DNA at Indicated Time Points.', 'Observed Complement C3 and C4 Levels at Indicated Time Points', 'Median Percent Change From Baseline in Complement C3 and C4 Levels at Indicated Time Points', 'Percent of Participants With Daily Prednisone Dose Reduction at Indicated Time Points.', 'Percent of Participants With >= 50% Reduction in Proteinuria at Indicated Time Points.', 'Observed B-cell Levels at Indicated Time Points.', 'Median Percent Change From Baseline in B Cell Levels at Indicated Time Points.', 'Percentage of Participants With Worsening in SLICC/ACR Damage Index at Indicated Time Points', 'Change From Baseline in SF-36 Healthy Survey Overall Component Scores at Indicated Time Point', 'Change From Baseline in SF-36 Healthy Survey Overall Component Scores at Indicated Timepoints', 'Change From Baseline in FACIT-Fatigue Scale Total Score at Indicated Time Point', 'Percentage of Participants With Improvement in FACIT-Fatigue Scale Score Exceeding the MCID at Indicated Time Points']","['Primary', 'Primary', 'Primary', 'Primary', 'Primary', 'Primary', 'Primary', 'Primary', 'Primary', 'Primary', 'Primary', 'Primary', 'Primary', 'Primary', 'Primary', 'Primary', 'Primary', 'Primary', 'Secondary', 'Secondary', 'Secondary', 'Secondary', 'Secondary', 'Secondary', 'Secondary', 'Secondary', 'Secondary', 'Secondary', 'Secondary', 'Secondary', 'Secondary', 'Secondary', 'Secondary']",[],"['Participants', 'Adverse events/100 participant-years', 'Adverse events/100 participant-years', 'Seconds', 'Billion cells per liter', 'Trillions cells per liter', 'Percentage', 'Grams per liter', 'Grams per liter', 'Millimoles per liter', 'Micromoles per liter', 'Milliliters per second', 'Ratio', 'Units per liter', 'Participants', 'Millimeters of mercury', 'Percentage of Participants', 'Percentage of Participants', 'Participants', 'Percentage of Participants', 'International units per milliliter', 'Percentage change', 'Milligrams per deciliter', 'Percent Change', 'Percentage of Participants', 'Percentage of Participants', 'Cell count', 'Percentage change', 'Percentage of Participants', 'Score on a scale', 'Score on a scale', 'Score on a scale', 'Percentage of Participants']",[],"['OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG001', 'OG000', 'OG001', 'OG000', 'OG001', 'OG000', 'OG001', 'OG000', 'OG001', 'OG000', 'OG001', 'OG000', 'OG001', 'OG000', 'OG001', 'OG000', 'OG001', 'OG000', 'OG001', 'OG000', 'OG001', 'OG000', 'OG001', 'OG000', 'OG001', 'OG000', 'OG001', 'OG000', 'OG001', 'OG000', 'OG001', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000']"
0,18,['NCT03973905'],"['Participants', 'Participants', 'Participants', 'Participants']","['Infant subjects of at least 2 days old and less than (<) 2 months old, who met the pertussis diagnosis definition (laboratory confirmed pertussis, epidemiological linkage to a laboratory-confirmed case, clinically compatible illness), and who met the case infants inclusion criteria (resided in the catchment area on their cough onset date, were born in a hospital in their state of residence, had at least 37 weeks gestational age at birth, were neither adopted, nor in foster care and did not live in a residential care facility) This post-hoc analysis was limited to cases and controls whose mothers were either vaccinated with Boostrix or did not receive any Tdap vaccine. Cases with no remaining matched control were also excluded from the analysis and vice versa.', 'Infant subjects of at least 2 days old and less than (<) 2 months old, who did not have a pertussis diagnosis prior to the cough onset date and who met the inclusion criteria for control infants (were born on a hospital in their state of residence, were at least 37 weeks gestational age at birth, were neither adopted, nor in foster care, did not live in a residential care facility, were born at the same hospital as the case infant) This post-hoc analysis was limited to cases and controls whose mothers were either vaccinated with Boostrix or did not receive any Tdap vaccine. Cases with no remaining matched control were also excluded from the analysis and vice versa.', 'Infant subjects of at least 2 days old and less than (<) 2 months old, who met the pertussis diagnosis definition (laboratory confirmed pertussis, epidemiological linkage to a laboratory-confirmed case, clinically compatible illness), and who met the case infants inclusion criteria (resided in the catchment area on their cough onset date, were born in a hospital in their state of residence, had at least 37 weeks gestational age at birth, were neither adopted, nor in foster care and did not live in a residential care facility) This post-hoc analysis was limited to cases and controls whose mothers were either vaccinated with Boostrix or did not receive any Tdap vaccine. Cases with no remaining matched control were also excluded from the analysis and vice versa.', 'Infant subjects of at least 2 days old and less than (<) 2 months old, who did not have a pertussis diagnosis prior to the cough onset date and who met the inclusion criteria for control infants (were born on a hospital in their state of residence, were at least 37 weeks gestational age at birth, were neither adopted, nor in foster care, did not live in a residential care facility, were born at the same hospital as the case infant) This post-hoc analysis was limited to cases and controls whose mothers were either vaccinated with Boostrix or did not receive any Tdap vaccine. Cases with no remaining matched control were also excluded from the analysis and vice versa.', 'Infant subjects of at least 2 days old and less than (<) 2 months old, who met the pertussis diagnosis definition (laboratory confirmed pertussis, epidemiological linkage to a laboratory-confirmed case, clinically compatible illness), and who met the case infants inclusion criteria (resided in the catchment area on their cough onset date, were born in a hospital in their state of residence, had at least 37 weeks gestational age at birth, were neither adopted, nor in foster care and did not live in a residential care facility) This post-hoc analysis was limited to cases and controls whose mothers were either vaccinated with Boostrix or did not receive any Tdap vaccine. Cases with no remaining matched control were also excluded from the analysis and vice versa.', 'Infant subjects of at least 2 days old and less than (<) 2 months old, who did not have a pertussis diagnosis prior to the cough onset date and who met the inclusion criteria for control infants (were born on a hospital in their state of residence, were at least 37 weeks gestational age at birth, were neither adopted, nor in foster care, did not live in a residential care facility, were born at the same hospital as the case infant) This post-hoc analysis was limited to cases and controls whose mothers were either vaccinated with Boostrix or did not receive any Tdap vaccine. Cases with no remaining matched control were also excluded from the analysis and vice versa.', 'Infant subjects of at least 2 days old and less than (<) 2 months old, who met the pertussis diagnosis definition (laboratory confirmed pertussis, epidemiological linkage to a laboratory-confirmed case, clinically compatible illness), and who met the case infants inclusion criteria (resided in the catchment area on their cough onset date, were born in a hospital in their state of residence, had at least 37 weeks gestational age at birth, were neither adopted, nor in foster care and did not live in a residential care facility) This post-hoc analysis was limited to cases and controls whose mothers were either vaccinated with Boostrix or did not receive any Tdap vaccine. Cases with no remaining matched control were also excluded from the analysis and vice versa.', 'Infant subjects of at least 2 days old and less than (<) 2 months old, who did not have a pertussis diagnosis prior to the cough onset date and who met the inclusion criteria for control infants (were born on a hospital in their state of residence, were at least 37 weeks gestational age at birth, were neither adopted, nor in foster care, did not live in a residential care facility, were born at the same hospital as the case infant) This post-hoc analysis was limited to cases and controls whose mothers were either vaccinated with Boostrix or did not receive any Tdap vaccine. Cases with no remaining matched control were also excluded from the analysis and vice versa.']",[],"['Pertussis Case Group', 'Control Group', 'Pertussis Case Group', 'Control Group', 'Pertussis Case Group', 'Control Group', 'Pertussis Case Group', 'Control Group']",[],[],[],"['Vaccine effectiveness at preventing pertussis occurrence in infants < 2 months old is assessed by comparing the Boostrix immunization status during the third pregnancy trimester in mothers of infant pertussis cases and matched controls. The association between maternal Boostrix vaccination and pertussis in infants was analyzed using conditional logistic regression. The multivariate analysis was performed to obtain the adjusted values. Covariates that were statistically significant in the univariate analysis or considered as clinically significant were included in the multivariable conditional logistic regression model. Subjects with missing or unknown values, if any, for at least one of the risk factors were excluded from the model.', 'Vaccine effectiveness at preventing pertussis occurrence in infants < 2 months old is assessed by comparing the Boostrix immunization status before pregnancy, during first or second pregnancy trimester, after pregnancy in mothers of infant pertussis cases and matched controls. The association between maternal Boostrix vaccination and pertussis in infants was analyzed using conditional logistic regression. The multivariate analysis was performed to obtain the adjusted values. Covariates that were statistically significant in the univariate analysis or considered as clinically significant were included in the multivariable conditional logistic regression model. Subjects with missing or unknown values, if any, for at least one of the risk factors were excluded from the model.', 'Vaccine effectiveness at preventing pertussis occurrence in infants < 2 months old is assessed by comparing the Boostrix immunization status during pregnancy in mothers of infant pertussis cases and matched controls. The association between maternal Boostrix vaccination and pertussis in infants was analyzed using conditional logistic regression. The multivariate analysis was performed to obtain the adjusted values. Covariates that were statistically significant in the univariate analysis or considered as clinically significant were included in the multivariable conditional logistic regression model. Subjects with missing or unknown values, if any, for at least one of the risk factors were excluded from the model.', 'Vaccine effectiveness at preventing pertussis occurrence leading to hospitalization in infants < 2 months old is assessed by comparing the Boostrix immunization status before pregnancy, during first or second, third trimester, after pregnancy in mothers of infant pertussis cases and matched controls. The association between maternal Boostrix vaccination and pertussis in infants was analyzed using conditional logistic regression. The multivariate analysis was performed to obtain the adjusted values. Covariates that were statistically significant in the univariate analysis or considered as clinically significant were included in the multivariable conditional logistic regression model. Subjects with missing or unknown values, if any, for at least one of the risk factors were excluded from the model.']",[],"['Count of Participants', 'Count of Participants', 'Count of Participants', 'Count of Participants']","['The analysis includes cases and at least one matched control born from mothers either unvaccinated or vaccinated with Boostrix. Subjects with missing or unknown values, if any, for at least one of the risk factors were excluded from the model.', 'The analysis includes cases and at least one matched control born from mothers either unvaccinated or vaccinated with Boostrix. Subjects with missing or unknown values, if any, for at least one of the risk factors were excluded from the model.', 'The analysis includes cases and at least one matched control born from mothers either unvaccinated or vaccinated with Boostrix. Subjects with missing or unknown values, if any, for at least one of the risk factors were excluded from the model.', 'The analysis includes cases leading to hospitalization and at least one matched control born from mothers either unvaccinated or vaccinated with Boostrix. Subjects with missing or unknown values, if any, for at least one of the risk factors were excluded from the model.']","['Posted', 'Posted', 'Posted', 'Posted']","['During the data collection period (from 1 January 2011 to 31 December 2014)', 'During the data collection period (from 1 January 2011 to 31 December 2014)', 'During the data collection period (from 1 January 2011 to 31 December 2014)', 'During the data collection period (from 1 January 2011 to 31 December 2014)']","['Number of Pertussis Cases and Matched Controls Among Infants Born to Mothers Vaccinated With Boostrix Vaccine (During Third Trimester of Pregnancy) or Not Exposed to Any Tdap Vaccine During Pregnancy', 'Number of Pertussis Cases and Matched Controls Among Infants Born to Mothers Vaccinated With Boostrix Vaccine (Before Pregnancy, During First or Second Trimester, After Pregnancy) or Not Exposed to Any Tdap Vaccine During Pregnancy', 'Number of Pertussis Cases and Matched Controls Among Infants Born to Mothers Vaccinated With Boostrix Vaccine (During First, Second or Third Trimester) or Not Exposed to Any Tdap Vaccine During Pregnancy', 'Number of Pertussis Cases Leading to Hospitalization and Matched Controls in Infants Born to Mothers Vaccinated With Boostrix (Before Pregnancy, During First or Second, Third Trimester, After Pregnancy) or Not Exposed to Any Tdap Vaccine During Pregnancy']","['Primary', 'Secondary', 'Secondary', 'Secondary']",[],"['Participants', 'Participants', 'Participants', 'Participants']",[],"['OG000', 'OG001', 'OG000', 'OG001', 'OG000', 'OG001', 'OG000', 'OG001', 'OG000', 'OG001', 'OG000', 'OG001', 'OG000', 'OG001', 'OG000', 'OG001', 'OG000', 'OG001', 'OG000', 'OG001', 'OG000', 'OG001', 'OG000', 'OG001', 'OG000', 'OG001']"
0,19,['NCT00340457'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,20,['NCT02429284'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,21,['NCT02889263'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,22,['NCT03995745'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,23,['NCT00928694'],"['Participants', 'Participants']","['U.S. Formulation: single oral 160 mg dose of the U.S. formulation of fenofibrate with food.', 'UK Formulation: single oral 160 mg dose of the UK formulation of fenofibrate with food.', 'U.S. Formulation: single oral 160 mg dose of the U.S. formulation of fenofibrate with food.', 'UK Formulation: single oral 160 mg dose of the UK formulation of fenofibrate with food.']",[],"['U.S. Formulation (TRICOR™)', 'UK Formulation (SUPRALIP™)', 'U.S. Formulation (TRICOR™)', 'UK Formulation (SUPRALIP™)']",[],[],[],[],"['Standard Deviation', 'Standard Deviation']","['Least Squares Mean', 'Least Squares Mean']","['Healthy Male and Female subjects Aged 18 to 45', 'Healthy Male and Female subjects Aged 18 to 45']","['Posted', 'Posted']","['Predose and up to 168 hours postdose', 'Predose and up to 168 hours postdose']","['Area Under the Curve (AUC(0 to Infinity)) of Fenofibric Acid', 'Maximum Plasma Concentration (Cmax) of Fenofibric Acid']","['Primary', 'Primary']",[],"['μg·hr/mL', 'μg/mL']",[],"['OG000', 'OG001', 'OG000', 'OG001']"
0,24,['NCT02153996'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,25,['NCT00413673'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,26,['NCT03867409'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,27,['NCT04004260'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,28,['NCT04205877'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,29,['NCT01262079'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,30,['NCT00646438'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,31,['NCT00341588'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,32,['NCT04562636'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,33,['NCT03924505'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,34,['NCT02334462'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,35,['NCT03311295'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,36,['NCT03242278'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,37,['NCT03683134'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,38,['NCT04047316'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,39,['NCT03952364'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,40,['NCT04021030'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,41,['NCT02959827'],"['Participants', 'Participants', 'Participants', 'Participants', 'Participants', 'Iodine contrast exposure', 'Participants', 'Participants', 'Participants', 'Participants']","['Children under age 4, from the US-based Kaiser Permanente Northern California database, who were exposed to iodinated contrast agent through having a diagnostic procedure.', 'Participants who met the criteria to be a case of hypothyroidism were identified.', 'Participants who did not meet the criteria to be a case of hypothyroidism were identified.', 'Participants who met the criteria to be a case of hypothyroidism were identified.', 'Participants who did not meet the criteria to be a case of hypothyroidism were identified.', 'Participants who met the criteria to be a case of hypothyroidism were identified.', 'Participants who did not meet the criteria to be a case of hypothyroidism were identified.', 'Participants who met the criteria to be a case of hypothyroidism were identified.', 'Participants who did not meet the criteria to be a case of hypothyroidism were identified.', 'Participants who met the criteria to be a case of hypothyroidism were identified.', 'Participants who did not meet the criteria to be a case of hypothyroidism were identified.', 'Participants who had CT scan and met the criteria to be a case of hypothyroidism were identified.', 'Participants who had cardiac catheterization and met the criteria to be a case of hypothyroidism were identified.', 'Participants who had CT scan and met the criteria to be a case of hypothyroidism were identified.', 'Participants who had cardiac catheterization and met the criteria to be a case of hypothyroidism were identified.', 'Participants who met the criteria to be a case of hypothyroidism were identified.']",['22.0'],"['Iodine Contrast Agent', 'Hypothyroidism Cases', 'Non-hypothyroidism Cases', 'Hypothyroidism Cases', 'Non-hypothyroidism Cases', 'Hypothyroidism Cases', 'Non-hypothyroidism Cases', 'Hypothyroidism Cases', 'Non-hypothyroidism Cases', 'Hypothyroidism Cases', 'Non-hypothyroidism Cases', 'Hypothyroidism Cases With CT Scan', 'Hypothyroidism Cases With Cardiac Catheterization', 'Hypothyroidism Cases With CT Scan', 'Hypothyroidism Cases With Cardiac Catheterization', 'Hypothyroidism Cases']",[],[],['Iodine contrast exposure'],['Incidence density rates (IDR) were calculated as the number of cases over the person time at risk where the numerator was the number of cases and the denominator was the person years at risk.'],['95% Confidence Interval'],"['Mean', 'Count of Participants', 'Count of Participants', 'Count of Participants', 'Count of Units', 'Count of Participants', 'Count of Participants', 'Count of Participants', 'Count of Participants']",[],"['Posted', 'Posted', 'Posted', 'Posted', 'Posted', 'Posted', 'Posted', 'Posted', 'Posted']","['In the 365 days post exposure to an iodinated contrast agent', 'Up to 365 days after a diagnostic scan with iodinated contrast agent', 'Up to 365 days after a diagnostic scan with iodinated contrast agent', 'Up to 365 days after a diagnostic scan with iodinated contrast agent', 'Up to 365 days after a diagnostic scan with iodinated contrast agent', 'Up to 365 days after a diagnostic scan with iodinated contrast agent', 'Up to 365 days after a diagnostic scan with iodinated contrast agent', 'Up to 365 days after a diagnostic scan with iodinated contrast agent', 'Up to 365 days after a diagnostic scan with iodinated contrast agent']","['Incidence Rate of Hypothyroidism Detected in Routine Clinical Practice', 'Baseline Characteristics (Age) of the Cases With Hypothyroidism and of the Rest of the Cohort', 'Baseline Characteristics (Sex) of the Cases With Hypothyroidism and of the Rest of the Cohort', 'Baseline Characteristics (Year of Hypothyroidism Diagnosis) of the Cases With Hypothyroidism and of the Rest of the Cohort', 'Baseline Characteristics (Type of Iodine Contrast Exposure) of the Cases With Hypothyroidism and of the Rest of the Cohort', 'Baseline Characteristics (Race/Ethnicity) of the Cases With Hypothyroidism and of the Rest of the Cohort', 'Time From First Iodinated Contrast to First Hypothyroidism Event', 'Classification of Subclinical/Manifest Hypothyroidism by Type of Exposure', 'Classification of Hypothyroidism by Etiology']","['Primary', 'Secondary', 'Secondary', 'Secondary', 'Secondary', 'Secondary', 'Secondary', 'Secondary', 'Secondary']",['Iodine contrast exposure'],"['events per 1,000 person years', 'Participants', 'Participants', 'Participants', 'Iodine contrast exposure', 'Participants', 'Participants', 'Participants', 'Participants']",[],"['OG000', 'OG000', 'OG001', 'OG000', 'OG001', 'OG000', 'OG001', 'OG000', 'OG001', 'OG000', 'OG001', 'OG000', 'OG001', 'OG000', 'OG001', 'OG000', 'OG001', 'OG000', 'OG001', 'OG000', 'OG001', 'OG000', 'OG001', 'OG000', 'OG001', 'OG000', 'OG001', 'OG000', 'OG001', 'OG000', 'OG001', 'OG000', 'OG001', 'OG000', 'OG001', 'OG000', 'OG001', 'OG000', 'OG001', 'OG000', 'OG001', 'OG000', 'OG001', 'OG000', 'OG001', 'OG000', 'OG001', 'OG000', 'OG001', 'OG000', 'OG001', 'OG000', 'OG001', 'OG000', 'OG001', 'OG000', 'OG001', 'OG000', 'OG001', 'OG000', 'OG000']"
0,42,['NCT02395536'],['Participants'],"['Reveal LINQ insertions will be performed in office setting.\n\nInsertion of Reveal LINQ device in office or traditional hospital setting: The insterions will be performed in a Physician office setting or in Traditional Hospital Setting as per the arm the patient is randomized in.', 'Reveal LINQ insertions will be performed in IN-a traditional setting\n\nInsertion of Reveal LINQ device in office or traditional hospital setting: The insterions will be performed in a Physician office setting or in Traditional Hospital Setting as per the arm the patient is randomized in.']",[],"['In Office Outside Walls of Hospital', 'Traditional Hospital Setting']",[],[],[],"['Demonstrate that the untoward event rate associated with Reveal LINQ™ insertions performed in-office or in the traditional hospital setting (operating room, cardiac catheterization or EP laboratory) are comparable.\n\nUntoward events are a composite of unsuccessful Reveal LINQ™ or complications related to the Reveal LINQ™ insertion procedure or system.']",[],['Count of Participants'],['Subjects exiting prematurely (prior to 3-month visit) without an untoward event were excluded from primary analysis. There were 7 excluded from the In office arm (2 deaths unrelated to the REVEAL LINQ and 5 premature exits) and 4 excluded from the traditional hospital setting arm (all 4 due to premature exit)'],['Posted'],['3 Months post insertion'],['Untoward Event Rate Associated With LINQ™ Insertions Performed'],['Primary'],[],['Participants'],[],"['OG000', 'OG001']"
0,43,['NCT03628235'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,44,['NCT02787538'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,45,['NCT01290393'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,46,['NCT04263311'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,47,['NCT00875641'],"['Participants', 'Participants', 'Participants', 'Participants', 'Participants', 'Participants', 'Participants', 'Participants', 'Participants']","['HRV (Human Rotavirus) cohort consisted of infants aged less than 1 year, enrolled in the participating health insurance plans within 30 days of birth and who received at least one dose of Rotarix vaccination as part of their normal health care (with no previous dose of RotaTeq prior to or concurrent with the first Rotarix vaccination).', 'Concurrent control cohort consisted of infants aged less than 1 year, enrolled in the participating health insurance plans, who were contemporaneous with the Rotarix vaccinees and who received at least one dose of IPV (Inactivated Poliovirus vaccine) with or without RotaTeq vaccination (with no previous dose of Rotarix prior to or concurrent with the first IPV vaccination).', 'Recent historical control cohort consisted of infants aged less than 1 year of age, enrolled in participating health insurance plans, vaccinated with at least one dose of IPV (Inactivated Poliovirus vaccine) between 1 January 2004 (OptumInsight) or 1 January 2006 (HealthCore) and 31 July 2008 and who did not receive any dose of rotavirus vaccination during the study period.', 'HRV (Human Rotavirus) cohort consisted of infants aged less than 1 year, enrolled in the participating health insurance plans within 30 days of birth and who received at least one dose of Rotarix vaccination as part of their normal health care (with no previous dose of RotaTeq prior to or concurrent with the first Rotarix vaccination).', 'Concurrent control cohort consisted of infants aged less than 1 year, enrolled in the participating health insurance plans, who were contemporaneous with the Rotarix vaccinees and who received at least one dose of IPV (Inactivated Poliovirus vaccine) with or without RotaTeq vaccination (with no previous dose of Rotarix prior to or concurrent with the first IPV vaccination).', 'Recent historical control cohort consisted of infants aged less than 1 year of age, enrolled in participating health insurance plans, vaccinated with at least one dose of IPV (Inactivated Poliovirus vaccine) between 1 January 2004 (OptumInsight) or 1 January 2006 (HealthCore) and 31 July 2008 and who did not receive any dose of rotavirus vaccination during the study period.', 'HRV (Human Rotavirus) cohort consisted of infants aged less than 1 year, enrolled in the participating health insurance plans within 30 days of birth and who received at least one dose of Rotarix vaccination as part of their normal health care (with no previous dose of RotaTeq prior to or concurrent with the first Rotarix vaccination).', 'Concurrent control cohort consisted of infants aged less than 1 year, enrolled in the participating health insurance plans, who were contemporaneous with the Rotarix vaccinees and who received at least one dose of IPV (Inactivated Poliovirus vaccine) with or without RotaTeq vaccination (with no previous dose of Rotarix prior to or concurrent with the first IPV vaccination).', 'Recent historical control cohort consisted of infants aged less than 1 year of age, enrolled in participating health insurance plans, vaccinated with at least one dose of IPV (Inactivated Poliovirus vaccine) between 1 January 2004 (OptumInsight) or 1 January 2006 (HealthCore) and 31 July 2008 and who did not receive any dose of rotavirus vaccination during the study period.', 'HRV (Human Rotavirus) cohort consisted of infants aged less than 1 year, enrolled in the participating health insurance plans within 30 days of birth and who received at least one dose of Rotarix vaccination as part of their normal health care (with no previous dose of RotaTeq prior to or concurrent with the first Rotarix vaccination).', 'Concurrent control cohort consisted of infants aged less than 1 year, enrolled in the participating health insurance plans, who were contemporaneous with the Rotarix vaccinees and who received at least one dose of IPV (Inactivated Poliovirus vaccine) with or without RotaTeq vaccination (with no previous dose of Rotarix prior to or concurrent with the first IPV vaccination).', 'Recent historical control cohort consisted of infants aged less than 1 year of age, enrolled in participating health insurance plans, vaccinated with at least one dose of IPV (Inactivated Poliovirus vaccine) between 1 January 2004 (OptumInsight) or 1 January 2006 (HealthCore) and 31 July 2008 and who did not receive any dose of rotavirus vaccination during the study period.', 'HRV (Human Rotavirus) cohort consisted of infants aged less than 1 year, enrolled in the participating health insurance plans within 30 days of birth and who received at least one dose of Rotarix vaccination as part of their normal health care (with no previous dose of RotaTeq prior to or concurrent with the first Rotarix vaccination).', 'Concurrent control cohort consisted of infants aged less than 1 year, enrolled in the participating health insurance plans, who were contemporaneous with the Rotarix vaccinees and who received at least one dose of IPV (Inactivated Poliovirus vaccine) with or without RotaTeq vaccination (with no previous dose of Rotarix prior to or concurrent with the first IPV vaccination).', 'Recent historical control cohort consisted of infants aged less than 1 year of age, enrolled in participating health insurance plans, vaccinated with at least one dose of IPV (Inactivated Poliovirus vaccine) between 1 January 2004 (OptumInsight) or 1 January 2006 (HealthCore) and 31 July 2008 and who did not receive any dose of rotavirus vaccination during the study period.', 'HRV (Human Rotavirus) cohort consisted of infants aged less than 1 year, enrolled in the participating health insurance plans within 30 days of birth and who received at least one dose of Rotarix vaccination as part of their normal health care (with no previous dose of RotaTeq prior to or concurrent with the first Rotarix vaccination).', 'Concurrent control cohort consisted of infants aged less than 1 year, enrolled in the participating health insurance plans, who were contemporaneous with the Rotarix vaccinees and who received at least one dose of IPV (Inactivated Poliovirus vaccine) with or without RotaTeq vaccination (with no previous dose of Rotarix prior to or concurrent with the first IPV vaccination).', 'Recent historical control cohort consisted of infants aged less than 1 year of age, enrolled in participating health insurance plans, vaccinated with at least one dose of IPV (Inactivated Poliovirus vaccine) between 1 January 2004 (OptumInsight) or 1 January 2006 (HealthCore) and 31 July 2008 and who did not receive any dose of rotavirus vaccination during the study period.', 'HRV (Human Rotavirus) cohort consisted of infants aged less than 1 year, enrolled in the participating health insurance plans within 30 days of birth and who received at least one dose of Rotarix vaccination as part of their normal health care (with no previous dose of RotaTeq prior to or concurrent with the first Rotarix vaccination).', 'Concurrent control cohort consisted of infants aged less than 1 year, enrolled in the participating health insurance plans, who were contemporaneous with the Rotarix vaccinees and who received at least one dose of IPV (Inactivated Poliovirus vaccine) with or without RotaTeq vaccination (with no previous dose of Rotarix prior to or concurrent with the first IPV vaccination).', 'Recent historical control cohort consisted of infants aged less than 1 year of age, enrolled in participating health insurance plans, vaccinated with at least one dose of IPV (Inactivated Poliovirus vaccine) between 1 January 2004 (OptumInsight) or 1 January 2006 (HealthCore) and 31 July 2008 and who did not receive any dose of rotavirus vaccination during the study period.', 'HRV (Human Rotavirus) cohort consisted of infants aged less than 1 year, enrolled in the participating health insurance plans within 30 days of birth and who received at least one dose of Rotarix vaccination as part of their normal health care (with no previous dose of RotaTeq prior to or concurrent with the first Rotarix vaccination).', 'Concurrent control cohort consisted of infants aged less than 1 year, enrolled in the participating health insurance plans, who were contemporaneous with the Rotarix vaccinees and who received at least one dose of IPV (Inactivated Poliovirus vaccine) with or without RotaTeq vaccination (with no previous dose of Rotarix prior to or concurrent with the first IPV vaccination).', 'Recent historical control cohort consisted of infants aged less than 1 year of age, enrolled in participating health insurance plans, vaccinated with at least one dose of IPV (Inactivated Poliovirus vaccine) between 1 January 2004 (OptumInsight) or 1 January 2006 (HealthCore) and 31 July 2008 and who did not receive any dose of rotavirus vaccination during the study period.', 'HRV (Human Rotavirus) cohort consisted of infants aged less than 1 year, enrolled in the participating health insurance plans within 30 days of birth and who received at least one dose of Rotarix vaccination as part of their normal health care (with no previous dose of RotaTeq prior to or concurrent with the first Rotarix vaccination).', 'Concurrent control cohort consisted of infants aged less than 1 year, enrolled in the participating health insurance plans, who were contemporaneous with the Rotarix vaccinees and who received at least one dose of IPV (Inactivated Poliovirus vaccine) with or without RotaTeq vaccination (with no previous dose of Rotarix prior to or concurrent with the first IPV vaccination).', 'Recent historical control cohort consisted of infants aged less than 1 year of age, enrolled in participating health insurance plans, vaccinated with at least one dose of IPV (Inactivated Poliovirus vaccine) between 1 January 2004 (OptumInsight) or 1 January 2006 (HealthCore) and 31 July 2008 and who did not receive any dose of rotavirus vaccination during the study period.']","['0.055', '0.037', '0.037', '0.082', '0.032', '0.040', '0.070', '0.061', '0.054', '0.161', '0.075', '0.056', '0.278', '0.093', '0.101', '0.383', '0.162', '0.124', '0.058', '0.050', '0.047', '0.066', '0.033', '0.057', '0.137', '0.099', '0.070', '0.020', '0.019', '0.022', '0.034', '0.023', '0.035', '0.046', '0.031', '0.023', '0.310', '0.175', '0.183', '0.366', '0.166', '0.171', '0.326', '0.220', '0.235', '1.705', '1.415', '1.782', '1.962', '1.671', '2.177', '1.551', '1.208', '1.410', '1.972', '1.180', '1.722', '2.871', '1.575', '2.427', '1.354', '0.970', '1.162', '1.865', '1.519', '1.952', '2.252', '1.721', '2.412', '1.619', '1.414', '1.544', '0.091', '0.065', '0.087', '0.109', '0.092', '0.114', '0.128', '0.057', '0.081']","['HRV Cohort', 'Concurrent Control Cohort', 'Recent Historical Control Cohort', 'HRV Cohort', 'Concurrent Control Cohort', 'Recent Historical Control Cohort', 'HRV Cohort', 'Concurrent Control Cohort', 'Recent Historical Control Cohort', 'HRV Cohort', 'Concurrent Control Cohort', 'Recent Historical Control Cohort', 'HRV Cohort', 'Concurrent Control Cohort', 'Recent Historical Control Cohort', 'HRV Cohort', 'Concurrent Control Cohort', 'Recent Historical Control Cohort', 'HRV Cohort', 'Concurrent Control Cohort', 'Recent Historical Control Cohort', 'HRV Cohort', 'Concurrent Control Cohort', 'Recent Historical Control Cohort', 'HRV Cohort', 'Concurrent Control Cohort', 'Recent Historical Control Cohort']",[],[],[],"['Incidence rates were calculated following the first 2 doses of study vaccine as the number of events divided by the sum of the person-time in that risk period. Person-time was defined as the number of days at risk for the study outcomes. Person-time was calculated in months by dividing the number of person-days by (365.25/12).', 'Incidence rates were calculated following the first 2 doses of study vaccine as the number of events divided by the sum of the person-time in that risk period. Person-time was defined as the number of days at risk for the study outcomes. Person-time was calculated in months by dividing the number of person-days by (365.25/12).', 'Incidence rates were calculated following the first 2 doses of study vaccine as the number of events divided by the sum of the person-time in that risk period. Person-time was defined as the number of days at risk for the study outcomes. Person-time was calculated in months by dividing the number of person-days by (365.25/12).', 'Incidence rates were calculated following the first 2 doses of study vaccine as the number of events divided by the sum of the person-time in that risk period. Person-time was defined as the number of days at risk for the study outcomes. Person-time was calculated in months by dividing the number of person-days by (365.25/12).', 'Incidence rates were calculated following the first 2 doses of study vaccine as the number of events divided by the sum of the person-time in that risk period. Person-time was defined as the number of days at risk for the study outcomes. Person-time was calculated in months by dividing the number of person-days by (365.25/12).', 'Incidence rates were calculated following the first 2 doses of study vaccine as the number of events divided by the sum of the person-time in that risk period. Person-time was defined as the number of days at risk for the study outcomes. Person-time was calculated in months by dividing the number of person-days by (365.25/12).', 'Incidence rates were calculated following the first 2 doses of study vaccine as the number of events divided by the sum of the person-time in that risk period. Person-time was defined as the number of days at risk for the study outcomes. Person-time was calculated in months by dividing the number of person-days by (365.25/12).', 'Incidence rates were calculated following the first 2 doses of study vaccine as the number of events divided by the sum of the person-time in that risk period. Person-time was defined as the number of days at risk for the study outcomes. Person-time was calculated in months by dividing the number of person-days by (365.25/12).', 'Incidence rates were calculated following the first 2 doses of study vaccine as the number of events divided by the sum of the person-time in that risk period. Person-time was defined as the number of days at risk for the study outcomes. Person-time was calculated in months by dividing the number of person-days by (365.25/12).']","['95% Confidence Interval', '95% Confidence Interval', '95% Confidence Interval', '95% Confidence Interval', '95% Confidence Interval', '95% Confidence Interval', '95% Confidence Interval', '95% Confidence Interval', '95% Confidence Interval']","['Number', 'Number', 'Number', 'Number', 'Number', 'Number', 'Number', 'Number', 'Number']","['Analysis was performed on study population comprising of birth cohorts affiliated with 2 participating health insurance plans, United Healthcare & WellPoint, which were eligible for rotavirus vaccination according to routine recommendations. Within this population of infants, HRV, Concurrent Control & Recent Historical Control cohorts were defined.', 'Analysis was performed on study population comprising of birth cohorts affiliated with 2 participating health insurance plans, United Healthcare & WellPoint, which were eligible for rotavirus vaccination according to routine recommendations. Within this population of infants, HRV, Concurrent Control & Recent Historical Control cohorts were defined.', 'Analysis was performed on study population comprising of birth cohorts affiliated with 2 participating health insurance plans, United Healthcare & WellPoint, which were eligible for rotavirus vaccination according to routine recommendations. Within this population of infants, HRV, Concurrent Control & Recent Historical Control cohorts were defined.', 'Analysis was performed on study population comprising of birth cohorts affiliated with 2 participating health insurance plans, United Healthcare & WellPoint, which were eligible for rotavirus vaccination according to routine recommendations. Within this population of infants, HRV, Concurrent Control & Recent Historical Control cohorts were defined.', 'Analysis was performed on study population comprising of birth cohorts affiliated with 2 participating health insurance plans, United Healthcare & WellPoint, which were eligible for rotavirus vaccination according to routine recommendations. Within this population of infants, HRV, Concurrent Control & Recent Historical Control cohorts were defined.', 'Analysis was performed on study population comprising of birth cohorts affiliated with 2 participating health insurance plans, United Healthcare & WellPoint, which were eligible for rotavirus vaccination according to routine recommendations. Within this population of infants, HRV, Concurrent Control & Recent Historical Control cohorts were defined.', 'Analysis was performed on study population comprising of birth cohorts affiliated with 2 participating health insurance plans, United Healthcare & WellPoint, which were eligible for rotavirus vaccination according to routine recommendations. Within this population of infants, HRV, Concurrent Control & Recent Historical Control cohorts were defined.', 'Analysis was performed on study population comprising of birth cohorts affiliated with 2 participating health insurance plans, United Healthcare & WellPoint, which were eligible for rotavirus vaccination according to routine recommendations. Within this population of infants, HRV, Concurrent Control & Recent Historical Control cohorts were defined.', 'Analysis was performed on study population comprising of birth cohorts affiliated with 2 participating health insurance plans, United Healthcare & WellPoint, which were eligible for rotavirus vaccination according to routine recommendations. Within this population of infants, HRV, Concurrent Control & Recent Historical Control cohorts were defined.']","['Posted', 'Posted', 'Posted', 'Posted', 'Posted', 'Posted', 'Posted', 'Posted', 'Posted']","['60 days following each vaccination', '7 days following each vaccination', '30 days following each vaccination', '60 days following each vaccination', '60 days following each vaccination', '60 days following each vaccination', '7 days following each vaccination', '30 days following each vaccination', '60 days following each vaccination']","['Incidence Rates of Intussusceptions (IS) Among the HRV Cohort and Comparator Cohorts', 'Incidence Rates of IS Among the HRV Cohort and Comparator Cohorts', 'Incidence Rates of IS Among the HRV Cohort and Comparator Cohorts', 'Incidence Rates of Kawasaki Disease Among the HRV Cohort and Comparator Cohorts', 'Incidence Rates of Convulsions Among the HRV Cohort and Comparator Cohorts', 'Incidence Rates of Acute Lower Respiratory Tract Infection (LRTI) Hospitalisation Among the HRV Cohort and Comparator Cohorts', 'Incidence Rates of Acute LTRI Hospitalisation Among the HRV Cohort and Comparator Cohorts', 'Incidence Rates of Acute LTRI Hospitalisation Among the HRV Cohort and Comparator Cohorts', 'Incidence Rates of All-cause Mortality Among the HRV Cohort and Comparator Cohorts']","['Primary', 'Primary', 'Primary', 'Secondary', 'Secondary', 'Secondary', 'Secondary', 'Secondary', 'Secondary']",[],"['Incidences/Person-Month', 'Incidences/Person-Month', 'Incidences/Person-Month', 'Incidences/Person-Month', 'Incidences/Person-Month', 'Incidences/Person-Month', 'Incidences/Person-Month', 'Incidences/Person-Month', 'Incidences/Person-Month']",[],"['OG000', 'OG001', 'OG002', 'OG000', 'OG001', 'OG002', 'OG000', 'OG001', 'OG002', 'OG000', 'OG001', 'OG002', 'OG000', 'OG001', 'OG002', 'OG000', 'OG001', 'OG002', 'OG000', 'OG001', 'OG002', 'OG000', 'OG001', 'OG002', 'OG000', 'OG001', 'OG002', 'OG000', 'OG001', 'OG002', 'OG000', 'OG001', 'OG002', 'OG000', 'OG001', 'OG002', 'OG000', 'OG001', 'OG002', 'OG000', 'OG001', 'OG002', 'OG000', 'OG001', 'OG002', 'OG000', 'OG001', 'OG002', 'OG000', 'OG001', 'OG002', 'OG000', 'OG001', 'OG002', 'OG000', 'OG001', 'OG002', 'OG000', 'OG001', 'OG002', 'OG000', 'OG001', 'OG002', 'OG000', 'OG001', 'OG002', 'OG000', 'OG001', 'OG002', 'OG000', 'OG001', 'OG002', 'OG000', 'OG001', 'OG002', 'OG000', 'OG001', 'OG002', 'OG000', 'OG001', 'OG002']"
0,48,['NCT03199846'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,49,['NCT04587245'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,50,['NCT02773979'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,51,['NCT03274726'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,52,['NCT01283828'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,53,['NCT04191824'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,54,['NCT03197688'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,55,['NCT02813577'],"['Participants', 'Participants', 'Participants', 'Participants', 'Participants', 'Participants', 'Participants', 'Participants', 'Participants', 'Participants', 'Participants', 'Participants', 'Participants']","['This is a single-arm study. Female subjects will receive the Lutonix® 035 Drug Coated Balloon PTA Catheter.\n\nLutonix® 035 Drug Coated Balloon PTA Catheter: Female subjects will receive the Lutonix® 035 Drug Coated Balloon PTA Catheter.', 'This is a single-arm study. Female subjects will receive the Lutonix® 035 Drug Coated Balloon PTA Catheter.\n\nLutonix® 035 Drug Coated Balloon PTA Catheter: Female subjects will receive the Lutonix® 035 Drug Coated Balloon PTA Catheter.', 'This is a single-arm study. Female subjects will receive the Lutonix® 035 Drug Coated Balloon PTA Catheter.\n\nLutonix® 035 Drug Coated Balloon PTA Catheter: Female subjects will receive the Lutonix® 035 Drug Coated Balloon PTA Catheter.', 'This is a single-arm study. Female subjects will receive the Lutonix® 035 Drug Coated Balloon PTA Catheter.\n\nLutonix® 035 Drug Coated Balloon PTA Catheter: Female subjects will receive the Lutonix® 035 Drug Coated Balloon PTA Catheter.', 'This is a single-arm study. Female subjects will receive the Lutonix® 035 Drug Coated Balloon PTA Catheter.\n\nLutonix® 035 Drug Coated Balloon PTA Catheter: Female subjects will receive the Lutonix® 035 Drug Coated Balloon PTA Catheter.', 'This is a single-arm study. Female subjects will receive the Lutonix® 035 Drug Coated Balloon PTA Catheter.\n\nLutonix® 035 Drug Coated Balloon PTA Catheter: Female subjects will receive the Lutonix® 035 Drug Coated Balloon PTA Catheter.', 'This is a single-arm study. Female subjects will receive the Lutonix® 035 Drug Coated Balloon PTA Catheter.\n\nLutonix® 035 Drug Coated Balloon PTA Catheter: Female subjects will receive the Lutonix® 035 Drug Coated Balloon PTA Catheter.', 'This is a single-arm study. Female subjects will receive the Lutonix® 035 Drug Coated Balloon PTA Catheter.\n\nLutonix® 035 Drug Coated Balloon PTA Catheter: Female subjects will receive the Lutonix® 035 Drug Coated Balloon PTA Catheter.', 'This is a single-arm study. Female subjects will receive the Lutonix® 035 Drug Coated Balloon PTA Catheter.\n\nLutonix® 035 Drug Coated Balloon PTA Catheter: Female subjects will receive the Lutonix® 035 Drug Coated Balloon PTA Catheter.', 'This is a single-arm study. Female subjects will receive the Lutonix® 035 Drug Coated Balloon PTA Catheter.\n\nLutonix® 035 Drug Coated Balloon PTA Catheter: Female subjects will receive the Lutonix® 035 Drug Coated Balloon PTA Catheter.', 'This is a single-arm study. Female subjects will receive the Lutonix® 035 Drug Coated Balloon PTA Catheter.\n\nLutonix® 035 Drug Coated Balloon PTA Catheter: Female subjects will receive the Lutonix® 035 Drug Coated Balloon PTA Catheter.', 'This is a single-arm study. Female subjects will receive the Lutonix® 035 Drug Coated Balloon PTA Catheter.\n\nLutonix® 035 Drug Coated Balloon PTA Catheter: Female subjects will receive the Lutonix® 035 Drug Coated Balloon PTA Catheter.', 'This is a single-arm study. Female subjects will receive the Lutonix® 035 Drug Coated Balloon PTA Catheter.\n\nLutonix® 035 Drug Coated Balloon PTA Catheter: Female subjects will receive the Lutonix® 035 Drug Coated Balloon PTA Catheter.']",[],"['Lutonix® 035 Drug Coated Balloon PTA Catheter', 'Lutonix® 035 Drug Coated Balloon PTA Catheter', 'Lutonix® 035 Drug Coated Balloon PTA Catheter', 'Lutonix® 035 Drug Coated Balloon PTA Catheter', 'Lutonix® 035 Drug Coated Balloon PTA Catheter', 'Lutonix® 035 Drug Coated Balloon PTA Catheter', 'Lutonix® 035 Drug Coated Balloon PTA Catheter', 'Lutonix® 035 Drug Coated Balloon PTA Catheter', 'Lutonix® 035 Drug Coated Balloon PTA Catheter', 'Lutonix® 035 Drug Coated Balloon PTA Catheter', 'Lutonix® 035 Drug Coated Balloon PTA Catheter', 'Lutonix® 035 Drug Coated Balloon PTA Catheter', 'Lutonix® 035 Drug Coated Balloon PTA Catheter']",[],[],[],"['Index limb amputation includes above or below the ankle amputations.', 'Primary patency is defined as freedom from target lesion restenosis (TLR) and from binary restenosis. Binary restenosis is adjudicated by the independent Core Laboratory based on Peak Systolic Velocity Ratio (PSVR) ≥ 2.5 and / or abnormal waveforms, or based on angiographic ≥ 50% diameter stenosis.']",[],"['Number', 'Number']","['Study was terminated.', 'Study was terminated.', 'Study was terminated.', 'Study terminated.', 'Study was terminated.', 'Study was terminated.', 'Study was terminated.', 'Study was terminated.', 'Study was terminated.', 'Study was terminated.', 'Study was terminated.']","['Posted', 'Posted', 'Posted', 'Posted', 'Posted', 'Posted', 'Posted', 'Posted', 'Posted', 'Posted', 'Posted', 'Posted', 'Posted']","['12 months post index procedure', '12 months post index procedure', '30 days post index procedure', '30 days', '30 days post index procedure', '1, 6, 12 and 24 months post index procedure', '1, 6, 12 and 24 months post index procedure', '1, 6, 12 and 24 months post index procedure', '1, 6, 12 and 24 months post index procedure', '1, 6, 12 and 24 months', '1, 6, 12 and 24 months post index procedure', '1, 6, 12 and 24 months post index procedure', '1, 6, 12 and 24 months post index procedure']","['Number of Participants With Freedom From the Following: All-cause Peri-operative Death at 30 Days, Index Limb Amputation Within 1 Year, Index Limb Re-intervention Within 1 Year, and Index-limb-Related Death Within 1 Year Post Index Procedure', 'Effectiveness: Number of Participants With Primary Patency of the Target Lesion at 12 Month Post Index Procedure.', 'Number of Participants With Freedom From All-cause Perioperative (≤ 30 Day) Death and Freedom From the Following: Index Limb Amputation, Index Limb Re-intervention, and Index-Limb-Related Death.', 'Number of Major Vascular Complications at 30 Days Post Index Procedure', 'Number of Deaths (All Causes) at 30 Days Post Index Procedure', 'Number of Participants With Clinically Driven Target Lesion Revascularization (TLR) at 1, 6, 12, and 24 Month Post Index Procedure', 'Number of Participants With Target Vessel Revascularization (TVR) at 1, 6, 12, and 24 Months Post Index Porcedure', 'Number of Participants With Reintervention for Treatment of Thrombosis of the Target Vessel or Embolization to Its Distal Vasculature at 1, 6, 12, and 24 Months Post Index Procedure', 'Number of Participants With Unanticipated and Anticipated Device Related Serious Adverse Events at 1, 6, 12, and 24 Months Post Index Procedure', 'Number of Participants With Amputation (Above the Ankle)-Free Survival (AFS) at 1, 6, 12, and 24 Months Post Index Procedure.', 'Change in Rutherford Classification Scores at 1, 6, 12, and 24 Months Post Index Procedure Compared to Baseline', 'Number of Participants With Sustained Clinical Benefit at 1, 6, 12, and 24 Months Post Index Procedure', 'Change of Resting Ankle Brachial Index (ABI) Scores at 1, 6, 12, and 24 Months Post Index Procedure Compared to Baseline']","['Primary', 'Primary', 'Secondary', 'Secondary', 'Secondary', 'Secondary', 'Secondary', 'Secondary', 'Secondary', 'Secondary', 'Secondary', 'Secondary', 'Secondary']",[],"['Complications', 'Participants']",[],"['OG000', 'OG000']"
0,56,['NCT00666380'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,57,['NCT01287247'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,58,['NCT04163341'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,59,['NCT02987335'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,60,['NCT02867722'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,61,['NCT03276637'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,62,['NCT03192891'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,63,['NCT03373045'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,64,['NCT04229212'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,65,['NCT02848781'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,66,['NCT00385047'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,67,['NCT02993120'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,68,['NCT03045120'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,69,['NCT01154296'],"['Participants', 'Participants', 'Participants', 'Participants', 'Participants', 'Participants']","['Individuals who screen as eligible will complete written informed consent procedures, be enrolled, be tested for STIs, and be asked to complete a baseline assessment using audio computer-assisted self interview (ACASI). Then participants randomized to group 1 will receive rapid HIV testing and RESPECT-2 counseling.\n\nRESPECT-2 Counseling: Specifically designed for use with the rapid HIV test, involves a brief (approximately 20-40 minute) counseling session which includes an orientation to the rapid testing procedure, an explanation of the testing window period, routes of HIV transmission and the meaning of test results, a personalized exploration of risk, the creation of a risk-reduction plan, identification of sources for support and referrals, and HIV test results.', 'Individuals who screen as eligible will complete written informed consent procedures, be enrolled, be tested for STIs, and be asked to complete a baseline assessment using audio computer-assisted self interview (ACASI). Then participants randomized to group 2 will receive rapid HIV testing with information only.', 'Individuals who screen as eligible will complete written informed consent procedures, be enrolled, be tested for STIs, and be asked to complete a baseline assessment using audio computer-assisted self interview (ACASI). Then participants randomized to group 1 will receive rapid HIV testing and RESPECT-2 counseling.\n\nRESPECT-2 Counseling: Specifically designed for use with the rapid HIV test, involves a brief (approximately 20-40 minute) counseling session which includes an orientation to the rapid testing procedure, an explanation of the testing window period, routes of HIV transmission and the meaning of test results, a personalized exploration of risk, the creation of a risk-reduction plan, identification of sources for support and referrals, and HIV test results.', 'Individuals who screen as eligible will complete written informed consent procedures, be enrolled, be tested for STIs, and be asked to complete a baseline assessment using audio computer-assisted self interview (ACASI). Then participants randomized to group 2 will receive rapid HIV testing with information only.', 'Individuals who screen as eligible will complete written informed consent procedures, be enrolled, be tested for STIs, and be asked to complete a baseline assessment using audio computer-assisted self interview (ACASI). Then participants randomized to group 1 will receive rapid HIV testing and RESPECT-2 counseling.\n\nRESPECT-2 Counseling: Specifically designed for use with the rapid HIV test, involves a brief (approximately 20-40 minute) counseling session which includes an orientation to the rapid testing procedure, an explanation of the testing window period, routes of HIV transmission and the meaning of test results, a personalized exploration of risk, the creation of a risk-reduction plan, identification of sources for support and referrals, and HIV test results.', 'Individuals who screen as eligible will complete written informed consent procedures, be enrolled, be tested for STIs, and be asked to complete a baseline assessment using audio computer-assisted self interview (ACASI). Then participants randomized to group 2 will receive rapid HIV testing with information only.', 'Individuals who screen as eligible will complete written informed consent procedures, be enrolled, be tested for STIs, and be asked to complete a baseline assessment using audio computer-assisted self interview (ACASI). Then participants randomized to group 1 will receive rapid HIV testing and RESPECT-2 counseling.\n\nRESPECT-2 Counseling: Specifically designed for use with the rapid HIV test, involves a brief (approximately 20-40 minute) counseling session which includes an orientation to the rapid testing procedure, an explanation of the testing window period, routes of HIV transmission and the meaning of test results, a personalized exploration of risk, the creation of a risk-reduction plan, identification of sources for support and referrals, and HIV test results.', 'Individuals who screen as eligible will complete written informed consent procedures, be enrolled, be tested for STIs, and be asked to complete a baseline assessment using audio computer-assisted self interview (ACASI). Then participants randomized to group 2 will receive rapid HIV testing with information only.', 'Individuals who screen as eligible will complete written informed consent procedures, be enrolled, be tested for STIs, and be asked to complete a baseline assessment using audio computer-assisted self interview (ACASI). Then participants randomized to group 1 will receive rapid HIV testing and RESPECT-2 counseling.\n\nRESPECT-2 Counseling: Specifically designed for use with the rapid HIV test, involves a brief (approximately 20-40 minute) counseling session which includes an orientation to the rapid testing procedure, an explanation of the testing window period, routes of HIV transmission and the meaning of test results, a personalized exploration of risk, the creation of a risk-reduction plan, identification of sources for support and referrals, and HIV test results.', 'Individuals who screen as eligible will complete written informed consent procedures, be enrolled, be tested for STIs, and be asked to complete a baseline assessment using audio computer-assisted self interview (ACASI). Then participants randomized to group 2 will receive rapid HIV testing with information only.', 'Individuals who screen as eligible will complete written informed consent procedures, be enrolled, be tested for STIs, and be asked to complete a baseline assessment using audio computer-assisted self interview (ACASI). Then participants randomized to group 1 will receive rapid HIV testing and RESPECT-2 counseling.\n\nRESPECT-2 Counseling: Specifically designed for use with the rapid HIV test, involves a brief (approximately 20-40 minute) counseling session which includes an orientation to the rapid testing procedure, an explanation of the testing window period, routes of HIV transmission and the meaning of test results, a personalized exploration of risk, the creation of a risk-reduction plan, identification of sources for support and referrals, and HIV test results.', 'Individuals who screen as eligible will complete written informed consent procedures, be enrolled, be tested for STIs, and be asked to complete a baseline assessment using audio computer-assisted self interview (ACASI). Then participants randomized to group 2 will receive rapid HIV testing with information only.']",[],"['Rapid HIV Testing w/ Counseling (Group 1)', 'Rapid HIV Testing & Information Only (Group 2)', 'Rapid HIV Testing w/ Counseling (Group 1)', 'Rapid HIV Testing & Information Only (Group 2)', 'Rapid HIV Testing w/ Counseling (Group 1)', 'Rapid HIV Testing & Information Only (Group 2)', 'Rapid HIV Testing w/ Counseling (Group 1)', 'Rapid HIV Testing & Information Only (Group 2)', 'Rapid HIV Testing w/ Counseling (Group 1)', 'Rapid HIV Testing & Information Only (Group 2)', 'Rapid HIV Testing w/ Counseling (Group 1)', 'Rapid HIV Testing & Information Only (Group 2)']",[],[],[],"['Composite STI incidence (Yes/No) at 6-month follow-up in which a person is considered positive for STIs if they are positive on any tested STI.', 'Self-reported continuous variables to determine number of (vaginal and/or anal) sex acts.', 'Self-reported continuous variables to determine number of unprotected (vaginal and/or anal) sex acts', 'Self-reported continuous variables to determine number of partners with whom the participant had (vaginal and/or anal) sex.', 'Self-reported continuous variables to determine number of partners with whom the participant had unprotected (vaginal and/or anal) sex.', 'Self-reported continuous variables to determine number of (vaginal and/or anal) sex acts in which the participant reported using substances before the sex act.']","['Standard Error', 'Standard Error', 'Standard Error', 'Standard Error']","['Number', 'Least Squares Mean', 'Least Squares Mean', 'Least Squares Mean', 'Least Squares Mean', 'Number']",[],[],"['6 months post randomization', '6 months post randomization', '6 months post randomization', '6 months post randomization', '6 months post randomization', '6 months post randomization']","['STI Incidence', 'Sexual Risk Behavior -- # of Sex Acts', 'Sexual Risk Behavior -- # of Unprotected Sex Acts', 'Sexual Risk Behavior -- # of Partners', 'Sexual Risk Behavior -- # of Unprotected Partners', 'Sexual Risk Behavior -- # of Sex Acts With Substance Use']","['Primary', 'Secondary', 'Secondary', 'Secondary', 'Secondary', 'Secondary']",[],"['participants', 'sex acts', 'unprotected sex acts', 'partners', 'unprotected partners', 'sex acts with substance use']",[],"['OG000', 'OG001', 'OG000', 'OG001', 'OG000', 'OG001', 'OG000', 'OG001', 'OG000', 'OG001', 'OG000', 'OG001']"
0,70,['NCT02857764'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,71,['NCT00412568'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,72,['NCT03353480'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,73,['NCT00800267'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,74,['NCT00601835'],"['Participants', 'Participants', 'Participants']","['Participants received the Canadian manufactured Tetanus and Diphtheria Toxoids Adsorbed vaccine for Adult Use (TENIVAC™)', 'Participants received the US manufactured Tetanus and Diphtheria Toxoids Adsorbed vaccine for Adult Use (DECAVAC®)', 'Participants received the Canadian manufactured Tetanus and Diphtheria Toxoids Adsorbed vaccine for Adult Use (TENIVAC™)', 'Participants received the US manufactured Tetanus and Diphtheria Toxoids Adsorbed vaccine for Adult Use (DECAVAC®)', 'Participants received the Canadian manufactured Tetanus and Diphtheria Toxoids Adsorbed vaccine for Adult Use (TENIVAC™)', 'Participants received the US manufactured Tetanus and Diphtheria Toxoids Adsorbed vaccine for Adult Use (DECAVAC®)']","['7.77', '8.26', '0.567', '0.504']","['Canadian Td Vaccine Group', 'United States Td Vaccine Group', 'Canadian Td Vaccine Group', 'United States Td Vaccine Group', 'Canadian Td Vaccine Group', 'United States Td Vaccine Group']",[],[],[],"['Seroprotection and booster responses for both tetanus and diphtheria were considered to be an antibody level of ≥ 0.10 IU/mL 28 days post-vaccination with either the Canadian-manufactured Tetanus and Diphtheria Toxoids Adsorbed vaccine or the US-manufactured Tetanus and Diphtheria Toxoids Adsorbed vaccine in participants ≥ 60 years of age.', 'Solicited injection site reactions: Pain, Redness, and Swelling. Solicited systemic reactions: Chills, Diarrhea, Fever (temperature), Headache, Malaise, Muscle weakness, Nausea, Pain in joints, Rash, and Vomiting.']",['95% Confidence Interval'],"['Number', 'Geometric Mean', 'Number']","['Seroprotection and Booster Responses to Tetanus and Diphtheria were determined in subjects ≥ 60 years of age in the per-protocol immunogenicity population.', 'Geometric mean titers were determined in subjects ≥ 60 years of age in the per-protocol immunogenicity population', 'Solicited safety parameters were in all enrolled and vaccinated participants ≥ 60 years of age and one third of participants 11 to 59 years of age. A subset of the intend-to-treat population.']","['Posted', 'Posted', 'Posted']","['28 Days post-vaccination', '28 Days post-vaccination', '0-14 days post-vaccination']","['Percentage of Participants ≥ 60 Years of Age With Antibody Levels ≥ 0.10 IU/mL to Tetanus and Diphtheria.', 'Post-vaccination Geometric Mean Titer (GMT) to Tetanus and Diphtheria in Participants ≥ 60 Years Vaccinated With Canadian-manufactured or US-manufactured Tetanus and Diphtheria Toxoids Adsorbed Vaccine.', 'Number of Participants Reporting Solicited Injection Site and Systemic Reactions Post-vaccination With Canadian-Manufactured or US-Manufactured Tetanus and Diphtheria Toxoids Adsorbed Vaccine.']","['Primary', 'Secondary', 'Other Pre-specified']",[],"['Percentage of participants', 'Titers', 'Participants']",[],"['OG000', 'OG001', 'OG000', 'OG001', 'OG000', 'OG001', 'OG000', 'OG001', 'OG000', 'OG001', 'OG000', 'OG001', 'OG000', 'OG001', 'OG000', 'OG001', 'OG000', 'OG001', 'OG000', 'OG001', 'OG000', 'OG001', 'OG000', 'OG001', 'OG000', 'OG001', 'OG000', 'OG001', 'OG000', 'OG001', 'OG000', 'OG001', 'OG000', 'OG001', 'OG000', 'OG001', 'OG000', 'OG001', 'OG000', 'OG001', 'OG000', 'OG001', 'OG000', 'OG001', 'OG000', 'OG001', 'OG000', 'OG001', 'OG000', 'OG001', 'OG000', 'OG001', 'OG000', 'OG001', 'OG000', 'OG001', 'OG000', 'OG001', 'OG000', 'OG001']"
0,75,['NCT01087905'],"['Participants', 'Participants', 'Participants']","['Participants in this intervention group received a two-week supply of Nicotine Replacement Therapy (NRT). This intervention is considered to be the standard intervention in terms of duration of NRT; it will be compared to the enhanced NRT duration intervention which is six weeks of NRT. Approximately half the total sample was randomized to the standard intervention (two weeks of NRT) and half to the enhanced intervention (six weeks of NRT).', 'Participants in this intervention group received a six-week supply of Nicotine Replacement Therapy (NRT). This intervention is considered to be the enhanced intervention in terms of duration of NRT; it will be compared to the standard NRT duration intervention which is two weeks of NRT. Approximately half the total sample was randomized to the standard intervention (two weeks of NRT) and half to the enhanced intervention (six weeks of NRT).', 'Participants in this intervention group received a single Nicotine Replacement Therapy (NRT) consisting of the Nicotine Patch only. This intervention is considered to be the standard intervention in terms of type of NRT; it will be compared to the enhanced NRT type intervention which is combination NRT consisting of Nicotine Patch plus Nicotine Gum (Combo NRT). Approximately half the total sample was randomized to the standard intervention (Nicotine Patch Only) and half to the enhanced intervention (Nicotine Patch plus Nicotine Gum).', 'Participants in this intervention group received Combination Nicotine Replacement Therapy (NRT) consisting of the Nicotine Patch plus Nicotine Gum. This intervention is considered to be the enhanced intervention in terms of type of NRT; it will be compared to the standard NRT type intervention which is NRT Monotherapy consisting of the Nicotine Patch Only. Approximately half the total sample was randomized to the standard intervention (Nicotine Patch Only) and half to the enhanced intervention (Nicotine Patch plus Nicotine Gum).', 'Participants in this intervention group received standard quitline cessation counseling consisting of 4 proactive counseling calls. This intervention is considered to be the standard intervention in terms of cessation counseling; it will be compared to the enhanced cessation counseling intervention which consists of Standard Cessation Counseling plus Cognitive Medication Adherence Counseling (CMAC). Approximately half the total sample was randomized to the standard intervention (Standard Cessation Counseling, No CMAC) and half to the enhanced intervention (Standard Cessation Counseling plus CMAC).', 'Participants in this intervention group received standard quitline cessation counseling consisting of 4 proactive counseling calls plus Cognitive Medication Adherence Counseling (CMAC). This intervention is considered to be the enhanced intervention in terms of cessation counseling; it will be compared to the standard cessation counseling intervention which consists of Standard Cessation Counseling only (no CMAC). Approximately half the total sample was randomized to the standard intervention (Standard Cessation Counseling, No CMAC) and half to the enhanced intervention (Standard Cessation Counseling plus CMAC).', 'Participants in this treatment group received Two Weeks of Nicotine Patch Only.', 'Participants in this treatment group received Two Weeks of Nicotine Patch plus Nicotine Gum.', 'Participants in this treatment group received Six Weeks of Nicotine Patch Only.', 'Participants in this treatment group received Six Weeks of Nicotine Patch plus Nicotine Gum.', 'Participants in this treatment group received Two Weeks of Nicotine Patch Only.', 'Participants in this treatment group received Two Weeks of Nicotine Patch plus Nicotine Gum.', 'Participants in this treatment group received Six Weeks of Nicotine Patch Only.', 'Participants in this treatment group received Six Weeks of Nicotine Patch plus Nicotine Gum.']",[],"['Two Weeks of Nicotine Replacement Therapy (NRT)', 'Six Weeks of Nicotine Replacement Therapy (NRT)', 'NRT Monotherapy (Nicotine Patch Only)', 'NRT Combination Therapy (Nicotine Patch Plus Nicotine Gum)', 'Standard Cessation Counseling (No CMAC)', 'Standard Cessation Counseling Plus CMAC)', 'Two Weeks of Nicotine Patch Only', 'Two Weeks of Combination NRT (Nicotine Patch + Nicotine Gum)', 'Six Weeks of Nicotine Patch Only', 'Six Weeks of Combination NRT (Nicotine Patch + Nicotine Gum)', 'Two Weeks of Nicotine Patch Only', 'Two Weeks of Combination NRT (Nicotine Patch + Nicotine Gum)', 'Six Weeks of Nicotine Patch Only', 'Six Weeks of Combination NRT (Nicotine Patch + Nicotine Gum)']",[],[],[],"['Self-reported total abstinence from any tobacco use (even a single puff) for the seven days preceding the target follow-up day.', 'Self-reported total abstinence from any tobacco use (even a single puff) for the seven days preceding the target follow-up day.', 'For cost analyses, we computed the costs of intervention per caller, the cost per quit based on the 6-month ITT 7-day PPA, and the incremental cost-effectiveness ratio (ICER. Intervention costs included direct costs associated with registration, provision of NRT and counseling (standard and MAC), and mailing of a quit guide (all participants) and a MAC information sheet (MAC participants only). Facility space, supplies, and physician supervision time were included in the call costs; research-related costs were excluded. ICER ratio is a measure of the added cost per added quit for two treatments. ICER was computed as the cost difference between the least intensive treatment group (2 weeks of nicotine patch only) and a more intensive comparison group divided by the difference in the quit rates of the two groups being compared; e.g., the ICER for the group that received 2 weeks of nicotine patch and nicotine gum = (213-178)/(.482-.384) = $357.']",[],"['Number', 'Number', 'Number']","['The study was originally powered to detect at least a 6.4% increase in the abstinence rate due to an enhanced intervention (e.g., 6 wks NRT); this effect size was based on prior quitline studies; we predicted that abstinence rates at 6 months would be approximately 12% in a standard intervention vs. 18.4% in an enhanced intervention.', 'The study was originally powered to detect at least a 6.4% increase in the abstinence rate due to an enhanced intervention (e.g., 6 wks NRT); this effect size was based on prior quitline studies; we predicted that abstinence rates at 6 months would be approximately 12% in a standard intervention vs. 18.4% in an enhanced intervention.', 'No ""a priori"" power analysis was conducted for this secondary outcome.']","['Posted', 'Posted', 'Posted']","['26 weeks after the target quit smoking date', '26 weeks after the target quit smoking date', '26 weeks after the target quit smoking date']","['7-Day Point Prevalence Abstinence From Smoking by Intervention', '7-Day Point Prevalence Abstinence From Smoking by Nicotine Replacement Therapy (NRT) Group', 'Incremental Cost-Effectiveness Ratio for 7-Day Point Prevalence Abstinence From Smoking at 26 Weeks Post-Quit by Nicotine Replacement Therapy (NRT) Group']","['Primary', 'Primary', 'Secondary']",[],"['Percentage of participants not smoking', 'Percentage of participants not smoking', 'U.S. Dollars']",[],"['OG000', 'OG001', 'OG002', 'OG003', 'OG004', 'OG005', 'OG000', 'OG001', 'OG002', 'OG003', 'OG000', 'OG001', 'OG002', 'OG003']"
0,76,['NCT02616198'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,77,['NCT00007540'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,78,['NCT02163525'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,79,['NCT03310112'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,80,['NCT02766634'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,81,['NCT02971709'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,82,['NCT03801928'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,83,['NCT01641029'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,84,['NCT02128542'],"['Participants', 'Participants', 'Participants', 'Participants', 'Participants', 'Participants']","['Treatment-naive participants received SOF 400 mg tablet once daily + RBV tablets (1000 or 1200 mg daily based on weight) for 12 weeks.', 'Treatment-experienced participants received SOF 400 mg tablet once daily + RBV tablets (1000 or 1200 mg daily based on weight) for 12 weeks.', 'All participants received SOF 400 mg tablet once daily + RBV tablets (1000 or 1200 mg daily based on weight) for 12 weeks.', 'Treatment-naive participants received SOF 400 mg tablet once daily + RBV tablets (1000 or 1200 mg daily based on weight) for 12 weeks.', 'Treatment-experienced participants received SOF 400 mg tablet once daily + RBV tablets (1000 or 1200 mg daily based on weight) for 12 weeks.', 'Treatment-naive participants received SOF 400 mg tablet once daily + RBV tablets (1000 or 1200 mg daily based on weight) for 12 weeks.', 'Treatment-experienced participants received SOF 400 mg tablet once daily + RBV tablets (1000 or 1200 mg daily based on weight) for 12 weeks.', 'SOF 400 mg tablet once daily + RBV tablets (1000 or 1200 mg daily based on weight) for 12 weeks.', 'SOF 400 mg tablet once daily + RBV tablets (1000 or 1200 mg daily based on weight) for 12 weeks.', 'All participants received SOF 400 mg tablet once daily + RBV tablets (1000 or 1200 mg daily based on weight) for 12 weeks.']","['87.7', '96.6', '89.3', '98.7']","['SOF+RBV 12 Weeks (TN)', 'SOF+RBV 12 Weeks (TE)', 'SOF+RBV 12 Weeks (All)', 'SOF+RBV 12 Weeks (TN)', 'SOF+RBV 12 Weeks (TE)', 'SOF+RBV 12 Weeks (TN)', 'SOF+RBV 12 Weeks (TE)', 'SOF+RBV 12 Weeks (TN)', 'SOF+RBV 12 Weeks (TE)', 'SOF+RBV 12 Weeks (All)']",[],[],[],"['SVR12 was defined as HCV RNA < the lower limit of quantitation (LLOQ; ie, 25 IU/mL) at 12 weeks after stopping study treatment.', 'SVR4 was defined as HCV RNA < LLOQ at 4 weeks following the last dose of study drug.', 'Viral breakthrough was defined as either:\n\nHCV RNA ≥ LLOQ after having previously had HCV RNA < LLOQ while receiving treatment\nHCV RNA ≥ LLOQ at the last available on-treatment measurement with no subsequent follow-up values', 'Viral relapse was defined as HCV RNA ≥ LLOQ during the posttreatment period after having achieved HCV RNA < LLOQ at end of treatment.', 'Deep sequencing of the HCV NS5B gene was attempted for all participants who had virologic failure at pretreatment and posttreatment time points if the level of HCV RNA in the plasma sample was ≥ 1000 IU/L.']","['95% Confidence Interval', '95% Confidence Interval']","['Number', 'Number', 'Number', 'Number', 'Number', 'Number']","['Full Analysis Set: participants who were enrolled into the study and received at least 1 dose of study drug', 'Safety Analysis Set: participants who received at least 1 dose of study drug', 'Full Analysis Set', 'Full Analysis Set', 'Participants in the Full Analysis Set with available data were analyzed\n\n.', 'Participants who relapsed and qualified for sequencing analysis were analyzed.']","['Posted', 'Posted', 'Posted', 'Posted', 'Posted', 'Posted']","['Posttreatment Week 12', 'Up to 12 weeks', 'Posttreatment Week 4', 'Up to Posttreatment Weak 12', 'Up to Posttreatment Week 12', 'Pretreatment and Posttreatment Week 12']","['Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy', 'Percentage of Participants Who Permanently Discontinued Any Study Drug Due to an Adverse Event', 'Percentage of Participants With Sustained Virologic Response at 4 Weeks After Discontinuation of Therapy (SVR4)', 'Percentage of Participants Experiencing Viral Breakthrough', 'Percentage of Participants Experiencing Viral Relapse', 'Number of Participants With Nonstructural Protein 5B (NS5B) Nucleoside Inhibitor (NI) Resistance-Associated Variants (RAVs) and RBV RAVs at Pretreatment and Posttreatment']","['Primary', 'Primary', 'Secondary', 'Secondary', 'Secondary', 'Secondary']",[],"['Percentage of participants', 'Percentage of participants', 'percentage of participants', 'Percentage of participants', 'Percentage of participants', 'participants']",[],"['OG000', 'OG001', 'OG000', 'OG000', 'OG001', 'OG000', 'OG001', 'OG000', 'OG001', 'OG000', 'OG000', 'OG000', 'OG000']"
0,85,['NCT00573976'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,86,['NCT00306007'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,87,['NCT02766647'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,88,['NCT04460898'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,89,['NCT00413517'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,90,['NCT02882100'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,91,['NCT00533975'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,92,['NCT02109757'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,93,['NCT00959933'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,94,['NCT00960479'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,95,['NCT03266497'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,96,['NCT02207569'],"['Participants', 'Participants', 'Participants', 'Participants', 'Participants', 'Participants', 'Participants', 'Participants', 'Participants', 'Participants', 'Participants', 'Participants', 'Participants', 'Participants', 'Participants']","['The CoreValve Evolut R System is a transcatheter aortic valve implantation system comprised of the following three components:\n\nEvolut R Transcatheter Aortic Valve (TAV)\n\n>\n\nEnVeo R Delivery Catheter System (DCS) with EnVeo R InLine Sheath\n\n>\n\nEnVeo R Loading System (LS)\n\n>\n\n> CoreValve Evolut R TAVR system', 'The CoreValve Evolut R System is a transcatheter aortic valve implantation system comprised of the following three components:\n\nEvolut R Transcatheter Aortic Valve (TAV)\n\n>\n\nEnVeo R Delivery Catheter System (DCS) with EnVeo R InLine Sheath\n\n>\n\nEnVeo R Loading System (LS)\n\n>\n\n> CoreValve Evolut R TAVR system', 'The CoreValve Evolut R System is a transcatheter aortic valve implantation system comprised of the following three components:\n\nEvolut R Transcatheter Aortic Valve (TAV)\n\n>\n\nEnVeo R Delivery Catheter System (DCS) with EnVeo R InLine Sheath\n\n>\n\nEnVeo R Loading System (LS)\n\n>\n\n> CoreValve Evolut R TAVR system', 'The CoreValve Evolut R System is a transcatheter aortic valve implantation system comprised of the following three components:\n\nEvolut R Transcatheter Aortic Valve (TAV)\n\n>\n\nEnVeo R Delivery Catheter System (DCS) with EnVeo R InLine Sheath\n\n>\n\nEnVeo R Loading System (LS)\n\n>\n\n> CoreValve Evolut R TAVR system', 'The CoreValve Evolut R System is a transcatheter aortic valve implantation system comprised of the following three components:\n\nEvolut R Transcatheter Aortic Valve (TAV)\n\n>\n\nEnVeo R Delivery Catheter System (DCS) with EnVeo R InLine Sheath\n\n>\n\nEnVeo R Loading System (LS)\n\n>\n\n> CoreValve Evolut R TAVR system', 'The CoreValve Evolut R System is a transcatheter aortic valve implantation system comprised of the following three components:\n\nEvolut R Transcatheter Aortic Valve (TAV)\n\n>\n\nEnVeo R Delivery Catheter System (DCS) with EnVeo R InLine Sheath\n\n>\n\nEnVeo R Loading System (LS)\n\n>\n\n> CoreValve Evolut R TAVR system', 'The CoreValve Evolut R System is a transcatheter aortic valve implantation system comprised of the following three components:\n\nEvolut R Transcatheter Aortic Valve (TAV)\n\n>\n\nEnVeo R Delivery Catheter System (DCS) with EnVeo R InLine Sheath\n\n>\n\nEnVeo R Loading System (LS)\n\n>\n\n> CoreValve Evolut R TAVR system', 'The CoreValve Evolut R System is a transcatheter aortic valve implantation system comprised of the following three components:\n\nEvolut R Transcatheter Aortic Valve (TAV)\n\n>\n\nEnVeo R Delivery Catheter System (DCS) with EnVeo R InLine Sheath\n\n>\n\nEnVeo R Loading System (LS)\n\n>\n\n> CoreValve Evolut R TAVR system', 'The CoreValve Evolut R System is a transcatheter aortic valve implantation system comprised of the following three components:\n\nEvolut R Transcatheter Aortic Valve (TAV)\n\n>\n\nEnVeo R Delivery Catheter System (DCS) with EnVeo R InLine Sheath\n\n>\n\nEnVeo R Loading System (LS)\n\n>\n\n> CoreValve Evolut R TAVR system', 'The CoreValve Evolut R System is a transcatheter aortic valve implantation system comprised of the following three components:\n\nEvolut R Transcatheter Aortic Valve (TAV)\n\n>\n\nEnVeo R Delivery Catheter System (DCS) with EnVeo R InLine Sheath\n\n>\n\nEnVeo R Loading System (LS)\n\n>\n\n> CoreValve Evolut R TAVR system', 'The CoreValve Evolut R System is a transcatheter aortic valve implantation system comprised of the following three components:\n\nEvolut R Transcatheter Aortic Valve (TAV)\n\n>\n\nEnVeo R Delivery Catheter System (DCS) with EnVeo R InLine Sheath\n\n>\n\nEnVeo R Loading System (LS)\n\n>\n\n> CoreValve Evolut R TAVR system', 'The CoreValve Evolut R System is a transcatheter aortic valve implantation system comprised of the following three components:\n\nEvolut R Transcatheter Aortic Valve (TAV)\n\n>\n\nEnVeo R Delivery Catheter System (DCS) with EnVeo R InLine Sheath\n\n>\n\nEnVeo R Loading System (LS)\n\n>\n\n> CoreValve Evolut R TAVR system', 'The CoreValve Evolut R System is a transcatheter aortic valve implantation system comprised of the following three components:\n\nEvolut R Transcatheter Aortic Valve (TAV)\n\n>\n\nEnVeo R Delivery Catheter System (DCS) with EnVeo R InLine Sheath\n\n>\n\nEnVeo R Loading System (LS)\n\n>\n\n> CoreValve Evolut R TAVR system', 'The CoreValve Evolut R System is a transcatheter aortic valve implantation system comprised of the following three components:\n\nEvolut R Transcatheter Aortic Valve (TAV)\n\n>\n\nEnVeo R Delivery Catheter System (DCS) with EnVeo R InLine Sheath\n\n>\n\nEnVeo R Loading System (LS)\n\n>\n\n> CoreValve Evolut R TAVR system', 'The CoreValve Evolut R System is a transcatheter aortic valve implantation system comprised of the following three components:\n\nEvolut R Transcatheter Aortic Valve (TAV)\n\n>\n\nEnVeo R Delivery Catheter System (DCS) with EnVeo R InLine Sheath\n\n>\n\nEnVeo R Loading System (LS)\n\n>\n\n> CoreValve Evolut R TAVR system']","['5.5', '6.6', '75.5', '98.5', '1.6', '3.0', '19.7', '3.9', '11.2', '26.0', '11.7']","['CoreValve Evolut R TAVR System', 'CoreValve Evolut R TAVR System', 'CoreValve Evolut R TAVR System', 'CoreValve Evolut R TAVR System', 'CoreValve Evolut R TAVR System', 'CoreValve Evolut R TAVR System', 'CoreValve Evolut R TAVR System', 'CoreValve Evolut R TAVR System', 'CoreValve Evolut R TAVR System', 'CoreValve Evolut R TAVR System', 'CoreValve Evolut R TAVR System', 'CoreValve Evolut R TAVR System', 'CoreValve Evolut R TAVR System', 'CoreValve Evolut R TAVR System', 'CoreValve Evolut R TAVR System']",[],[],[],"['Percentage of patients that died by any cause at 30 days', 'Stroke Diagnostic Criteria:\n\n>\n\nAcute episode of focal or global neurological deficit with at least 2 of the following:\n\nchange in level of consciousness >\nhemiplegia, hemiparesis\nnumbness or sensory loss affecting 1 side >\ndysphasia or aphasia\nhemianopia\namaurosis fugax >\n\nother neurological signs or symptoms consistent with stroke\n\n2.) No other readily identifiable non-stroke cause or the clinical presentation, to be determined by or in conjunctions with the designated neurologist\n\n3.) Confirmation of the diagnosis by at least 1 of the following:\n\nNeurological specialist >\nNeuroimaging procedure, or on clincial grounds alone > Stroke: durations of neural deficit > 24 h if available neuroimaging documents a new hemofrrhage or infarct; or the neurological deficit results in death\n\nDefined by VARC II:\n\n> An mRS (Modified Rankin Score) of 2 or more at 90 days and an increase in at least 1 mRS category from pre-stroke baseline', 'Percentage of patients with Device Success defined as:\n\nAbsence of procedural mortality, AND\nCorrect positioning of a single Evolut R valve into the proper anatomical location, AND\nAbsence of patient-prosthesis mismatch, and mean gradient , 20 mm Hg (or peak velocity < 3m/sec, AND\nAbsence of moderate or severe prosthetic valve regurgitation', 'Percentage of patience with none, trace or mild total prosthetic regurgitation at early post procedure echo cardiogram (24 hours to 7 days) as evaluated by echo core lab.', 'Percentage of patients with any valve dysfunction that requires repeat procedure (e.g. balloon valvuloplasty, TAVI, or surgical AVR), per VARC II definition.', 'Angiographic or echocardiographic evidence of a new, partial or complete, obstruction of a coronary ostium, either by the Evolut R prosthesis itself, the native leaflets, calcifications, or dissection, occurring during or after the TAVI procedure.', 'VARC II composite safety endpoint rate includes percent freedom from the following components:\n\nAll-cause mortality\nAll stroke (disabling and non-disabling)\nLife-threatening bleeding\nAcute kidney injury: stage 2 or 3 (including renal replacement therapy).\nCoronary artery obstruction requiring intervention.\nMajor vascular complication.\nValve-related dysfunction requiring repeat procedure (BAV, TAVI, or SAVR)', 'Stage 2\n\nIncrease in serum creatinine to 200%-299% (2.0%-2.99% increase compared with baseline) OR\n\n>\n\nUrine output <0.5 mL/kg/h for >12 but <24 h > Stage 3 >\n\n1) Increase in serum creatinine to ≥300% (>3 x increase compared with baseline) OR serum creatinine of ≥4.0 mg/dL (≥354 mmol/L) with an acute increase of at least 0.5 mg/dL (44 mmol/L) OR\n\nUrine output <0.3 ml/kg/h for ≥24 h OR\n\n>\n\nAnuria for ≥12 h', 'Fatal bleeding (BARC type 5) OR\n\n>\n\nBleeding in a critical organs, such as intracranial, intraspinal,\n\n> intraocular, or pericardial necessitating pericardiocentesis, or intramuscular with compartment syndrome (BARC type 3b and 3c) OR\n\n>\n\nBleeding causing hypovolemic shock or severe hypotension requiring vasopressors or surgery (BARC type 3b) OR\n\n>\n\nOvert source of bleeding with drop in hemoglobin ≥5 g/dL or whole blood or packed red blood cells (RBCs) transfusion ≥4 units* > (BARC type 3b)', 'Percent of patients who underwent implantation of new permanent pacemaker or ICD during or after index procedure', 'Resheath or recapture success rate (where attempted) where a successful resheath is defined as the intended portion of the Evolut R is resheathed into the capsule of the delivery catheter to the intended amount, as verified by flouroscopy; and a successful recapture is defined as the entire Evolut R TAV (including the frame) is full resheathed into the capsule of the delivery catheter until there is no gap between the capsule and the tip , as verified by flouroscopy. Resheath or recapture wa attempted in a subset of patients. Success rate is calculated as successful resheath or recaputure events in the number of total events. Resheath anad recapture is only possible during the index procedure.', 'Mean gradient by Doppler echocardiography.', 'Any aortic dissection, aortic rupture, annulus rupture, left ventricle perforation, or new apical aneurysm/pseudoaneurysm OR\n\n>\n\nAccess-related vascular injury (dissection, stenosis, perforation, rupture, arterio-venous fistula, pseudoaneurysm, hematoma, irreversible nerve injury, compartment syndrome, percutaneous closure device failure) leading to death, life-threatening or major bleeding, visceral ischemia, or neurological impairment OR\n\n>\n\nDistal embolization (noncerebral) from a vascular source requiring surgery or resulting in amputation or irreversible end-organ damage OR\n\n>\n\nThe use of unplanned endovascular or surgery associated with death, major bleeding, visceral ischemia or neurological impairment OR\n\n>\n\nAny new ipsilateral lower extremity ischemia documented by patient symptoms, physical exam, and/or decreased or absent blood flow on lower extremity angiogram OR\n\n>\n\nSurgery for access site nerve injury OR\n\n>\n\nPermanent access related nerve injury', 'Hemodynamic performance by Doppler echocardiography - Aortic Valve Area cm2', 'Hemodynamic performance: the percent of patients who have a degree of total prosthetic valve regurgitation that is moderate or severe.']","['95% Confidence Interval', '95% Confidence Interval', '95% Confidence Interval', '95% Confidence Interval', '95% Confidence Interval', '95% Confidence Interval', '95% Confidence Interval', '95% Confidence Interval', '95% Confidence Interval', '95% Confidence Interval', 'Standard Deviation', '95% Confidence Interval', 'Standard Deviation']","['Number', 'Number', 'Number', 'Number', 'Number', 'Number', 'Number', 'Number', 'Number', 'Number', 'Number', 'Mean', 'Number', 'Mean', 'Number']","['All subjects who are brought into the procedure room and any of the following have occurred: anesthesia administered, vascular line placed, TEE placed, or any monitoring line placed.', 'All subjects who are brought into the procedure room and any of the following have occurred: anesthesia administered, vascular line placed, TEE placed, or any monitoring line placed.', 'All subjects implanted with the Evolut R TAV, defined as the Evolut R TAV is placed in the aortic annulus and completely released from the Enveo catheter delivery system', 'Subset includes all subjects who are implanted with the Evolut R TAV, defined as the Evolut R TAV is placed in the aortic annulus and completely released from the Enveo catheter delivery system', 'The safety subset includes all subjects who are brought into the procedure room and any of the following have occurred: anesthesia administered, vascular line placed, or any monitoring line placed.', 'All subjects who are brought into the procedure room and any of the following have occurred: anesthesia administered, vascular line placed, TEE placed, or any monitoring line placed.', 'All subjects who are brought into the procedure room and any of the following have occurred: anesthesia administered, vascular line placed, TEE placed, or any monitoring line placed.', 'All subjects who are brought into the procedure room and any of the following have occurred: anesthesia administered, vascular line placed, TEE placed, or any monitoring line placed.', 'All subjects who are brought into the procedure room and any of the following have occurred: anesthesia administered, vascular line placed, TEE placed, or any monitoring line placed.', 'All subjects who are brought into the procedure room and any of the following have occurred: anesthesia administered, vascular line placed, TEE placed, or any monitoring line placed. Additionally, these patients did NOT have ICD or PPM at the time of the index procedure.', '65 patients had resheath or recapture feature used during the 241 attempted procedures.', 'The Implanted population consisted of all As Treated Subjects who underwent an index procedure and were implanted with the Evolut R system. Only subjects with echo can be analyzed.', 'The Implanted population consisted of all As Treated Subjects who underwent an index procedure and were implanted with the Evolut R system.', 'The hemodynamic performance subset includes all subjects implanted with the Evolut R TAV for more than 24 hours post implantation - only subjects with echo can be analyzed.', 'The hemodynamic performance subset includes all subjects implanted with the Evolut R TAV for more than 24 hours post implantation. Only subjects with echo can be analyzed.']","['Posted', 'Posted', 'Posted', 'Posted', 'Posted', 'Posted', 'Posted', 'Posted', 'Posted', 'Posted', 'Posted', 'Posted', 'Posted', 'Posted', 'Posted']","['Assessed at 30 days post-implantation', 'Assessed at 30 days post-implantation', 'Assessed at 24 hours to seven days post implantation', 'Assessed at 24 hours to 7 days post implantation', 'Assessed at 30 days post-implantation', 'Assessed at 30 days post-implantation', 'Assessed at 30 days post-implantation', 'Assessed at 30 days post-implantation', 'Assessed at 30 days post-implantation', 'Assessed at 30 days', 'Assessed intra-procedurally', 'Assessed at baseline, 30 days, 6 months, and 1 year', 'Assessed at 30 days post-implantation', 'Assessed at baseline, 30 days, 6 months, and 1 year', 'Assessed at 30 days, 6 months, and 1 year']","['All-cause Mortality at 30 Days by Percent', 'Percentage of Patients With Disabling Stroke at 30 Days', 'Percent Device Success Rate Between 24 and 7 Day', 'Percentage of Patients With Less Than Moderate Prosthetic Regurgitation at Early Post Procedure Echocardiogram (24 Hours to 7 Days)', 'Individual Component of VARC II Safety Endpoint: Percentage of People Requiring Valve-related Dysfunction Requiring Repeat Procedure (BAV, TAVI, or SAVR)', 'Coronary Artery Obstruction Requiring Intervention.', 'Percent VARC II Combined Safety Endpoint at 30 Days', 'Percent of Patients With Acute Kidney Injury: Stage 2 or 3 (Including Renal Replacement Therapy).', 'Percentage of Patients With Life-threatening or Disabling Bleeding Event Rate', 'Percent Rate of Patients Who Received New Permanent Pacemaker Implant at 30 Days', 'Percent Resheath and Recapture Success Rate', 'Hemodynamic Performance -Mean Gradient', 'Major Vascular Complication', 'Hemodynamic Performance - Aortic Valve Area', 'Hemodynamic Performance: Total Prosthetic Valve Regurgitation Graded as Moderate or Severe']","['Primary', 'Primary', 'Primary', 'Primary', 'Secondary', 'Secondary', 'Secondary', 'Secondary', 'Secondary', 'Secondary', 'Secondary', 'Secondary', 'Secondary', 'Secondary', 'Secondary']",[],"['percentage of partcipants', 'percentage of participants', 'percentage of overall device success', 'percentage of partcipants', 'percentage of overall patients', 'percentage of participants', 'percentage of participants', 'percentage of participants', 'percentage of participants', 'percentage of participants', 'percentage of resheath or recapture', 'mmHg', 'percentage of participants', 'cm²', 'percentage of participants']",[],"['OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000']"
0,97,['NCT02569632'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,98,['NCT02069925'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,99,['NCT03433131'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,100,['NCT02746809'],"['Participants', 'Participants', 'Participants', 'Participants', 'Participants', 'Participants', 'Participants', 'Participants', 'Participants', 'Participants', 'Participants', 'Participants', 'Participants', 'Participants', 'Participants']","['Treatment of Aortic Stenosis with Medtronic CoreValve Evolut R 34R TAVR System.', 'Treatment of Aortic Stenosis with Medtronic CoreValve Evolut R 34R TAVR System.\n\nCoreValve Evolut 34R TAVR system: The CoreValve Evolut 34R System is a transcatheter aortic valve implantation system comprised of the following three components:\n\nEvolut 34R Transcatheter Aortic Valve (TAV)\nEnVeo R Delivery Catheter System (DCS) with EnVeo R InLine Sheath\nEnVeo R Loading System (LS)', 'Treatment of Aortic Stenosis with Medtronic CoreValve Evolut R 34R TAVR System.\n\n>\n\n>\n\nCoreValve Evolut 34R TAVR system: The CoreValve Evolut 34R System is a transcatheter aortic valve implantation system comprised of the following three components:\n\nEvolut 34R Transcatheter Aortic Valve (TAV)\n\n>\n\nEnVeo R Delivery Catheter System (DCS) with EnVeo R InLine Sheath\n\n>\n\nEnVeo R Loading System (LS)', 'Treatment of Aortic Stenosis with Medtronic CoreValve Evolut R 34R TAVR System.\n\n>\n\n>\n\nCoreValve Evolut 34R TAVR system: The CoreValve Evolut 34R System is a transcatheter aortic valve implantation system comprised of the following three components:\n\nEvolut 34R Transcatheter Aortic Valve (TAV)\n\n>\n\nEnVeo R Delivery Catheter System (DCS) with EnVeo R InLine Sheath\n\n>\n\nEnVeo R Loading System (LS)', 'Treatment of Aortic Stenosis with Medtronic CoreValve Evolut R 34R TAVR System.\n\n>\n\n>\n\nCoreValve Evolut 34R TAVR system: The CoreValve Evolut 34R System is a transcatheter aortic valve implantation system comprised of the following three components:\n\nEvolut 34R Transcatheter Aortic Valve (TAV)\n\n>\n\nEnVeo R Delivery Catheter System (DCS) with EnVeo R InLine Sheath\n\n>\n\nEnVeo R Loading System (LS)', 'Treatment of Aortic Stenosis with Medtronic CoreValve Evolut R 34R TAVR System.\n\n>\n\n>\n\nCoreValve Evolut 34R TAVR system: The CoreValve Evolut 34R System is a transcatheter aortic valve implantation system comprised of the following three components:\n\nEvolut 34R Transcatheter Aortic Valve (TAV)\n\n>\n\nEnVeo R Delivery Catheter System (DCS) with EnVeo R InLine Sheath\n\n>\n\nEnVeo R Loading System (LS)', 'Treatment of Aortic Stenosis with Medtronic CoreValve Evolut R 34R TAVR System.\n\n>\n\n>\n\nCoreValve Evolut 34R TAVR system: The CoreValve Evolut 34R System is a transcatheter aortic valve implantation system comprised of the following three components:\n\nEvolut 34R Transcatheter Aortic Valve (TAV)\n\n>\n\nEnVeo R Delivery Catheter System (DCS) with EnVeo R InLine Sheath\n\n>\n\nEnVeo R Loading System (LS)', 'Treatment of Aortic Stenosis with Medtronic CoreValve Evolut R 34R TAVR System.\n\n>\n\n>\n\nCoreValve Evolut 34R TAVR system: The CoreValve Evolut 34R System is a transcatheter aortic valve implantation system comprised of the following three components:\n\nEvolut 34R Transcatheter Aortic Valve (TAV)\n\n>\n\nEnVeo R Delivery Catheter System (DCS) with EnVeo R InLine Sheath\n\n>\n\nEnVeo R Loading System (LS)', 'Treatment of Aortic Stenosis with Medtronic CoreValve Evolut R 34R TAVR System.\n\n>\n\n>\n\nCoreValve Evolut 34R TAVR system: The CoreValve Evolut 34R System is a transcatheter aortic valve implantation system comprised of the following three components:\n\nEvolut 34R Transcatheter Aortic Valve (TAV)\n\n>\n\nEnVeo R Delivery Catheter System (DCS) with EnVeo R InLine Sheath\n\n>\n\nEnVeo R Loading System (LS)', 'Treatment of Aortic Stenosis with Medtronic CoreValve Evolut R 34R TAVR System.\n\n>\n\n>\n\nCoreValve Evolut 34R TAVR system: The CoreValve Evolut 34R System is a transcatheter aortic valve implantation system comprised of the following three components:\n\nEvolut 34R Transcatheter Aortic Valve (TAV)\n\n>\n\nEnVeo R Delivery Catheter System (DCS) with EnVeo R InLine Sheath\n\n>\n\nEnVeo R Loading System (LS)', 'Treatment of Aortic Stenosis with Medtronic CoreValve Evolut R 34R TAVR System.\n\n>\n\n>\n\nCoreValve Evolut 34R TAVR system: The CoreValve Evolut 34R System is a transcatheter aortic valve implantation system comprised of the following three components:\n\nEvolut 34R Transcatheter Aortic Valve (TAV)\n\n>\n\nEnVeo R Delivery Catheter System (DCS) with EnVeo R InLine Sheath\n\n>\n\nEnVeo R Loading System (LS)', 'Treatment of Aortic Stenosis with Medtronic CoreValve Evolut R 34R TAVR System.\n\n>\n\n>\n\nCoreValve Evolut 34R TAVR system: The CoreValve Evolut 34R System is a transcatheter aortic valve implantation system comprised of the following three components:\n\nEvolut 34R Transcatheter Aortic Valve (TAV)\n\n>\n\nEnVeo R Delivery Catheter System (DCS) with EnVeo R InLine Sheath\n\n>\n\nEnVeo R Loading System (LS)', 'Treatment of Aortic Stenosis with Medtronic CoreValve Evolut R 34R TAVR System.\n\n>\n\n>\n\nCoreValve Evolut 34R TAVR system: The CoreValve Evolut 34R System is a transcatheter aortic valve implantation system comprised of the following three components:\n\nEvolut 34R Transcatheter Aortic Valve (TAV)\n\n>\n\nEnVeo R Delivery Catheter System (DCS) with EnVeo R InLine Sheath\n\n>\n\nEnVeo R Loading System (LS)', 'Treatment of Aortic Stenosis with Medtronic CoreValve Evolut R 34R TAVR System.\n\n>\n\n>\n\nCoreValve Evolut 34R TAVR system: The CoreValve Evolut 34R System is a transcatheter aortic valve implantation system comprised of the following three components:\n\nEvolut 34R Transcatheter Aortic Valve (TAV)\n\n>\n\nEnVeo R Delivery Catheter System (DCS) with EnVeo R InLine Sheath\n\n>\n\nEnVeo R Loading System (LS)', 'Treatment of Aortic Stenosis with Medtronic CoreValve Evolut R 34R TAVR System.\n\n>\n\n>\n\nCoreValve Evolut 34R TAVR system: The CoreValve Evolut 34R System is a transcatheter aortic valve implantation system comprised of the following three components:\n\nEvolut 34R Transcatheter Aortic Valve (TAV)\n\n>\n\nEnVeo R Delivery Catheter System (DCS) with EnVeo R InLine Sheath\n\n>\n\nEnVeo R Loading System (LS)']","['11.2', '6.1', '89.2', '100.0', '14.7', '11.4', '11.4', '6.1', '6.1', '6.1', '34.3']","['CoreValve Evolut 34R TAVR System', 'CoreValve Evolut 34R TAVR System', 'CoreValve Evolut 34R TAVR System', 'CoreValve Evolut 34R TAVR System', 'CoreValve Evolut 34R TAVR System', 'CoreValve Evolut 34R TAVR System', 'CoreValve Evolut 34R TAVR System', 'CoreValve Evolut 34R TAVR System', 'CoreValve Evolut 34R TAVR System', 'CoreValve Evolut 34R TAVR System', 'CoreValve Evolut 34R TAVR System', 'CoreValve Evolut 34R TAVR System', 'CoreValve Evolut 34R TAVR System', 'CoreValve Evolut 34R TAVR System', 'CoreValve Evolut 34R TAVR System']",[],[],[],"['Percentage of participants with all-cause mortality at 30 days', 'Percentage of participants with disabling stroke (VARC-II definitions) at 30 days', 'Device Success defined as:\n\nAbsence of procedural mortality, AND\nCorrect positioning of a single prosthetic heart valve into the proper anatomical location, AND\nIntended performance of the prosthetic heart valve, defined as the absence of patient prosthesis-mismatch and mean gradient < 20 mmHg (or peak velocity < 3 m/sec), AND\nAbsence of moderate or severe prosthetic valve regurgitation', 'The percentage of subjects with no more than mild prosthetic regurgitation at early post procedure echocardiogram as assessed by echo core laboratory', 'VARC II composite safety endpoint includes the following components:\n\nAll-cause mortality\nAll stroke (disabling and non-disabling)\nLife-threatening bleeding\nAcute kidney injury: stage 2 or 3 (including renal replacement therapy).\nCoronary artery obstruction requiring intervention.\nMajor vascular complication.\nValve-related dysfunction requiring repeat procedure (BAV, TAVR, or SAVR)', 'Percentage of participants with life threatening or disabling bleeding - see VARC-2 definitions for classification details', 'Percentage of participants with Major vascular complication - see VARC-2 definitions for additional details', 'Percentage of participants with Acute Kidney Injury: Stage 2 or 3 - see VARC-2 definitions for additional details', 'Percentage of participants with coronary artery obstruction - see VARC-2 definitions for additional details', 'Percentage of subjects with valve-related dysfunction requiring repeat procedure - see VARC-2 definitions for additional details', 'Percentage of subjects with new permanent pacemaker implant at 30 days.', 'Successful resheathing is defined as Evolut R TAV (including frame) was resheathed into the capsule of the delivery cathether to the desired amount intended, as verified by fluoroscopy.\n\nSuccessful recapture is defined as the entire Evolut R TAV (including frame) is resheathed into the capsule of the delivery catheter until there is no gap between the capsule and the tip, as verified by fluoroscopy.', 'Mean gradient (mmHg) as measured by transthoracic echocardiogram and assessed by echo core laboratory', 'Aortic valve area as measured by transthoracic echocardiogram and assessed by echo core laboratory', 'Total prosthetic regurgitation (none/trace) as measured by transthoracic echocardiogram and assessed by echo core laboratory']","['95% Confidence Interval', '95% Confidence Interval', '95% Confidence Interval', '95% Confidence Interval', '95% Confidence Interval', '95% Confidence Interval', '95% Confidence Interval', '95% Confidence Interval', '95% Confidence Interval', '95% Confidence Interval', '95% Confidence Interval', 'Standard Deviation', 'Standard Deviation']","['Number', 'Number', 'Number', 'Number', 'Number', 'Number', 'Number', 'Number', 'Number', 'Number', 'Number', 'Number', 'Mean', 'Mean', 'Number']","['Subjects with pre-existing pacemaker or internal cardiac defibrillator were excluded from analysis.', 'Success could only be analyzed in subjects where the resheath/recapture feature was used.', 'Only participants with echo could be analyzed.', 'Only participants with echo could be analyzed.', 'Only participants with echo could be analyzed.']","['Posted', 'Posted', 'Posted', 'Posted', 'Posted', 'Posted', 'Posted', 'Posted', 'Posted', 'Posted', 'Posted', 'Posted', 'Posted', 'Posted', 'Posted']","['30 Days', '30 Days', '24 hours to 7 days post implantation', '24 hours to 7 days post implantation', '30 days post-implantation', '30 days post-implantation', '30 days', '30 days', '30 days', '30 days', '30 days', 'Implant procedure', 'Baseline, 30 days, and 6 months', 'Baseline, 30 Days, and 6 Months', '30 days and 6 months']","['Percentage of Participants With All-cause Mortality', 'Percentage of Participants With Stroke (Disabling)', 'Device Success Rate', 'The Percentage of Subjects With no More Than Mild Prosthetic Regurgitation at Early Post Procedure Echocardiogram', 'Percentage of Participants With VARC II Combined Safety Endpoint Event at 30 Days', 'Percentage of Participants With Life Threatening or Disabling Bleeding', 'Percentage of Participants With Major Vascular Complication', 'Percentage of Participants With Acute Kidney Injury: Stage 2 or 3', 'Percentage of Participants With Coronary Artery Obstruction', 'Percentage of Subjects With Valve-related Dysfunction Requiring Repeat Procedure', 'Percentage of Subjects With Permanent Pacemaker Implant at 30 Days', 'Percentage of Resheath and Recapture Success', 'Hemodynamic Performance Metrics - Mean Gradient', 'Hemodynamic Performance Metrics- Aortic Valve Area', 'Hemodynamic Performance Metrics - Total Prosthetic Regurgitation Graded as None/Trace']","['Primary', 'Primary', 'Primary', 'Primary', 'Secondary', 'Secondary', 'Secondary', 'Secondary', 'Secondary', 'Secondary', 'Secondary', 'Secondary', 'Secondary', 'Secondary', 'Secondary']",[],"['percentage of participants', 'percentage of participants', 'percentage of participants', 'percentage of participants', 'percentage of participants', 'percentage of participants', 'percentage of participants', 'percentage of participants', 'percentage of participants', 'percentage of participants', 'percentage of participants', 'percentage of participants', 'mmHg', 'cm2', 'percentage of participants']",[],"['OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000']"
0,101,['NCT00328380'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,102,['NCT04552535'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,103,['NCT03293875'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,104,['NCT01235260'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,105,['NCT03390660'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,106,['NCT00837499'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,107,['NCT01629537'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,108,['NCT00351741'],"['Participants', 'Participants', 'Participants', 'Participants', 'Participants', 'Participants', 'Participants']","['Intervention with high frequency percussive ventilation', 'Low-tidal volume ventilation', 'Intervention with high frequency percussive ventilation', 'Low-tidal volume ventilation', 'Intervention with high frequency percussive ventilation', 'Low-tidal volume ventilation', 'Intervention with high frequency percussive ventilation', 'Low-tidal volume ventilation', 'Intervention with high frequency percussive ventilation', 'Low-tidal volume ventilation', 'Intervention with high frequency percussive ventilation', 'Low-tidal volume ventilation', 'Intervention with high frequency percussive ventilation', 'Low-tidal volume ventilation']",[],"['High Frequency', 'Conventional', 'High Frequency', 'Conventional', 'High Frequency', 'Conventional', 'High Frequency', 'Conventional', 'High Frequency', 'Conventional', 'High Frequency', 'Conventional', 'High Frequency', 'Conventional']",[],[],[],"['The primary end point was ventilator-free days in the first 28 days, defined as the number of days after randomization from day 0 to day 28 alive without ventilator assistance for at least 48 consecutive hrs.', 'days free from nonpulmonary organ failure as adapted from the ARDSnet study in the first 28 days.', 'In-hospital death.', 'Those who develop both clinical and microscopic evidence of pulmonary infection while on the ventilator.', 'Subjects who did not meet predetermined oxygenation and ventilation goals on the study mode despite ventilator- specific optimization were switched to a rescue mode of ventilation.', 'Defined as a new pneumothorax, pneumomediastinum, subcutaneous emphysema, interstitial emphysema, or pneumatocele >2 cm in diameter not associated with a vascular procedure, lung biopsy, or thoracentesis.', 'Defined as carinal or mainstem airway friability and sloughing with associated bleeding. Only diagnosed after the patient had spent at least 7 days on the assigned ventilator mode and had not been diagnosed with inhalation injury on admission']","['Standard Deviation', 'Standard Deviation']","['Mean', 'Mean', 'Number', 'Number', 'Number', 'Number', 'Number']",[],"['Posted', 'Posted', 'Posted', 'Posted', 'Posted', 'Posted', 'Posted']","['28 days', '28', 'during hospitalization', '28 days', '28 days', '28 days', 'checked daily']","['Ventilator-free Days During the First 28 Days', 'Days Free From Nonpulmonary Organ Failure', 'Death', 'Ventilator Associated Pneumonia', 'Need for Rescue Ventilator', 'Barotrauma', 'Ventilator Associated Tracheobronchitis (VATB)']","['Primary', 'Secondary', 'Secondary', 'Secondary', 'Secondary', 'Secondary', 'Secondary']",[],"['Days', 'Days', 'Participants', 'Participants', 'Participants', 'Participants', 'Participants']",[],"['OG000', 'OG001', 'OG000', 'OG001', 'OG000', 'OG001', 'OG000', 'OG001', 'OG000', 'OG001', 'OG000', 'OG001', 'OG000', 'OG001']"
0,109,['NCT01965561'],"['Participants', 'Participants']","['Use of Combat Ready Clamp (CRoC)', 'Use of Abdominal Aortic and Junctional Tourniquet (AAJT)', 'Use of Junctional Emergency Treatment Tool (JETT)', 'SAM Junctional Tourniquet (SJT)', 'Use of Combat Ready Clamp (CRoC)', 'Use of Abdominal Aortic and Junctional Tourniquet (AAJT)', 'Use of Junctional Emergency Treatment Tool (JETT)', 'SAM Junctional Tourniquet (SJT)']",[],"['CRoC', 'AAJT', 'JETT', 'SJT Tourniquet', 'CRoC', 'AAJT', 'JETT', 'SJT Tourniquet']",[],[],[],"['Percentage of participants whose distal pulse ceased within 1 minute of junctional tourniquet application.', 'Pain during tourniquet application as measured on a visual analog scale (VAS). The pain scale was a 100-mm-long line on a piece of paper. The subject made a cross mark on the line, which went from the left limit (0 mm) at no pain to the right limit (100 mm) at very severe pain.']",['Standard Deviation'],"['Number', 'Mean']",[],"['Posted', 'Posted']","['1 min', '1 minute']","['Effectiveness at Stopping Distal Pulse', 'Pain During Tourniquet Application']","['Primary', 'Secondary']",[],"['percentage of participants', 'mm on VAS']",[],"['OG000', 'OG001', 'OG002', 'OG003', 'OG000', 'OG001', 'OG002', 'OG003']"
0,110,['NCT01927835'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,111,['NCT01704235'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,112,['NCT01306266'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,113,['NCT00796315'],"['Participants', 'Participants']","['Ages 2-5 years. Subjects received a dose of either 3.125 or 4.17 mg Doxylamine Succinate USP (exact dose dependent upon body weight)', 'Ages 6-11 years. Subjects received a dose of 4.17 or 6.25 or 8.33 or 10.42 mg Doxylamine Succinate USP (exact dose dependent upon body weight). Note: One subject (age group 6-11) was unable to meet protocol criteria (spit out a portion of his dosage) and was discontinued.', 'Ages 12-17 years. All subjects received a dose of 12.5 mg Doxylamine Succinate USP', 'Ages 2-5 years. Doxylamine Succinate USP', 'Ages 6-11 years. Doxylamine Succinate USP', 'Ages 12-17 years. Doxylamine Succinate USP']",[],"['Subjects Aged 2-5 Years', 'Subjects Aged 6-11 Years', 'Subjects Aged 12-17 Years', 'Subjects Aged 2-5 Years', 'Subjects Aged 6-11 Years', 'Subjects Aged 12-17 Years']",[],[],[],"['Area under the time-concentration curve for Doxylamine from 0 to 72 hours post-dose plus an extrapolated area from 72 hours to infinity.', 'Maximum concentration of Doxylamine from 0 to 72 hours post-dose']","['Geometric Coefficient of Variation', 'Geometric Coefficient of Variation']","['Geometric Mean', 'Geometric Mean']",[],"['Posted', 'Posted']","['72 Hours', '72 Hours']","['AUC of Doxylamine', 'Cmax of Doxylamine']","['Primary', 'Primary']",[],"['ng*h/mL', 'ng/mL']",[],"['OG000', 'OG001', 'OG002', 'OG000', 'OG001', 'OG002']"
0,114,['NCT00005463'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,115,['NCT03382418'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,116,['NCT00054743'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,117,['NCT00730964'],"['Participants', 'Participants']","['Open Label with 1039 subjects that received Optison to evaluate the safety of the product.', 'Open Label with 1039 subjects that received Optison to evaluate the safety of the product']",[],"['Arm 1 - Optison', 'Arm 1 - Optison']",[],[],[],"['A Serious Adverse Reaction or (SAR) is considered causally related to the Optison product administered by the investigator. This reaction, should it occur, will be counted as a serious adverse reaction.', 'The frequency of any serious adverse event (SAE) whether it is related to the Optison product or not, after the administration of the Optison product during contrast enhanced echocardiography.']",[],"['Number', 'Number']",[],"['Posted', 'Posted']","['Within 24 hours post contrast administration', 'Within 24 hours post contrast administration']","[""The Frequency of Serious Adverse Reactions (SAR)'s Among Subjects Who Receive Optison (Causally Related to the Product)During Contrast Enhanced Echocardiography in Routine Clinical Practice."", ""The Frequency of Overall Serious Adverse Events (SAE's) Among Subjects Who Receive Optison (Whether Related to the Product or Not) During Contrast Enhanced Echocardiography in Routine Clinical Practice.""]","['Primary', 'Secondary']",[],"['Serious Adverse Reactions', 'Serious adverse events']",[],"['OG000', 'OG000']"
0,118,['NCT02886689'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,119,['NCT00005455'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,120,['NCT01150695'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,121,['NCT00245076'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,122,['NCT00935623'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,123,['NCT03688126'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,124,['NCT02053506'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,125,['NCT03933215'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,126,['NCT03933202'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,127,['NCT00005171'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,128,['NCT01256164'],"['Participants', 'Participants', 'Participants', 'Participants', 'Participants']","['After identification of a Target Bleeding Site (TBS), topical Fibrocaps powder will be applied using the Fibrospray device for general surgeries; and either the Fibrospray device or direct application for spinal and vascular surgeries, followed by application of Gelfoam and manual pressure with sterile gauze.', 'Treatment will be Gelfoam followed by manual pressure with sterile gauze. If hemostasis has not been achieved within 10 minutes of the Start Time,the subject will be considered a treatment failure and the surgeon will implement additional hemostatic measures.', 'After identification of a Target Bleeding Site (TBS), topical Fibrocaps powder will be applied using the Fibrospray device for general surgeries; and either the Fibrospray device or direct application for spinal and vascular surgeries, followed by application of Gelfoam and manual pressure with sterile gauze.', 'Treatment will be Gelfoam followed by manual pressure with sterile gauze. If hemostasis has not been achieved within 10 minutes of the Start Time,the subject will be considered a treatment failure and the surgeon will implement additional hemostatic measures.', 'After identification of a Target Bleeding Site (TBS), topical Fibrocaps powder will be applied using the Fibrospray device for general surgeries; and either the Fibrospray device or direct application for spinal and vascular surgeries, followed by application of Gelfoam and manual pressure with sterile gauze.', 'Treatment will be Gelfoam followed by manual pressure with sterile gauze. If hemostasis has not been achieved within 10 minutes of the Start Time,the subject will be considered a treatment failure and the surgeon will implement additional hemostatic measures.', 'After identification of a Target Bleeding Site (TBS), topical Fibrocaps powder will be applied using the Fibrospray device for general surgeries; and either the Fibrospray device or direct application for spinal and vascular surgeries, followed by application of Gelfoam and manual pressure with sterile gauze.', 'Treatment will be Gelfoam followed by manual pressure with sterile gauze. If hemostasis has not been achieved within 10 minutes of the Start Time,the subject will be considered a treatment failure and the surgeon will implement additional hemostatic measures.', 'After identification of a Target Bleeding Site (TBS), topical Fibrocaps powder will be applied using the Fibrospray device for general surgeries; and either the Fibrospray device or direct application for spinal and vascular surgeries, followed by application of Gelfoam and manual pressure with sterile gauze.', 'Treatment will be Gelfoam followed by manual pressure with sterile gauze. If hemostasis has not been achieved within 10 minutes of the Start Time,the subject will be considered a treatment failure and the surgeon will implement additional hemostatic measures.']",[],"['Fibrocaps + Gelfoam', 'Gelfoam', 'Fibrocaps + Gelfoam', 'Gelfoam', 'Fibrocaps + Gelfoam', 'Gelfoam', 'Fibrocaps + Gelfoam', 'Gelfoam', 'Fibrocaps + Gelfoam', 'Gelfoam']",[],[],[],"['Time to hemostasis recorded from the first application of study treatment until cessation of bleeding', 'Number of participants with Adverse events and clinically-significant changes/findings on labs and physical examination as well as incidence of re-operation for bleeding at the TBS']",['Standard Deviation'],"['Mean', 'Number', 'Number', 'Number', 'Number']","['All subjects treated with a time to hemostasis were included in the analysis', 'All subjects treated were analyzed for safety.']","['Posted', 'Posted', 'Posted', 'Posted', 'Posted']","['0-10 minutes', '28 Days', '3 minutes', '5 minutes', '10 minutes']","['Mean Time to Hemostasis (TTH)', 'Safety', 'Number of Subjects Achieving Hemostasis at 3 Minutes', 'Number of Participants Achieving Hemostasis at 5 Minutes', 'Number of Patients Achieving Hemostasis at 10 Minutes']","['Primary', 'Secondary', 'Secondary', 'Secondary', 'Secondary']",[],"['minutes', 'participants', 'participants', 'participants', 'participants']",[],"['OG000', 'OG001', 'OG000', 'OG001', 'OG000', 'OG001', 'OG000', 'OG001', 'OG000', 'OG001']"
0,129,['NCT03631472'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,130,['NCT03699709'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,131,['NCT00237263'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,132,['NCT02939131'],"['Participants', 'site', 'Participants', 'site', 'Participants', 'site', 'Participants', 'site', 'Participants', 'site', 'Participants', 'site']","['Health and Wellness Cognitive Behavioral Therapy and Medication Management (COMB-R) intervention', 'Enhanced Standard of Care (ESC)\n\nOngoing psychopharmacological and psychosocial counseling and treatment for depression at HIV clinical treatment centers enhanced by providing clinicians with up-to-date information and didactic training', 'Health and Wellness Cognitive Behavioral Therapy and Medication Management (COMB-R) intervention', 'Enhanced Standard of Care (ESC)\n\nOngoing psychopharmacological and psychosocial counseling and treatment for depression at HIV clinical treatment centers enhanced by providing clinicians with up-to-date information and didactic training', 'Health and Wellness Cognitive Behavioral Therapy and Medication Management (COMB-R) intervention', 'Enhanced Standard of Care (ESC)\n\nOngoing psychopharmacological and psychosocial counseling and treatment for depression at HIV clinical treatment centers enhanced by providing clinicians with up-to-date information and didactic training', 'Health and Wellness Cognitive Behavioral Therapy and Medication Management (COMB-R) intervention', 'Enhanced Standard of Care (ESC)\n\nOngoing psychopharmacological and psychosocial counseling and treatment for depression at HIV clinical treatment centers enhanced by providing clinicians with up-to-date information and didactic training', 'Health and Wellness Cognitive Behavioral Therapy and Medication Management (COMB-R) intervention', 'Enhanced Standard of Care (ESC)\n\nOngoing psychopharmacological and psychosocial counseling and treatment for depression at HIV clinical treatment centers enhanced by providing clinicians with up-to-date information and didactic training', 'Health and Wellness Cognitive Behavioral Therapy and Medication Management (COMB-R) intervention', 'Enhanced Standard of Care (ESC)\n\nOngoing psychopharmacological and psychosocial counseling and treatment for depression at HIV clinical treatment centers enhanced by providing clinicians with up-to-date information and didactic training']","['9.7', '12.3', '85.5', '28.9', '73.0', '26.8', '940', '842', '2.97', '2.65', '16.14', '22.53', '19.40', '15.79', '13.18', '4.10']","['COMB-R', 'Enhanced Standard of Care', 'COMB-R', 'Enhanced Standard of Care', 'COMB-R', 'Enhanced Standard of Care', 'COMB-R', 'Enhanced Standard of Care', 'COMB-R', 'Enhanced Standard of Care', 'COMB-R', 'Enhanced Standard of Care']","['01/2021', '01/2021', '01/2021', '01/2021', '01/2021', '01/2021', '01/2021', '01/2021', '01/2021', '01/2021', '01/2021', '01/2021', '01/2021', '01/2021', '01/2021', '01/2021', '01/2021', '01/2021', '01/2021', '01/2021', '01/2021', '01/2021', '01/2021', '01/2021', '01/2021', '01/2021', '01/2021', '01/2021', '01/2021']",[],"['site', 'site', 'site', 'site', 'site', 'Participants', 'Participants', 'Participants', 'Participants', 'Participants', 'Participants', 'Participants', 'Participants', 'Participants', 'Participants', 'Participants', 'Participants', 'Participants', 'Participants', 'Participants', 'Participants', 'Participants', 'Participants', 'Participants', 'Participants', 'Participants', 'Participants', 'Participants', 'Participants', 'Participants', 'Participants', 'Participants', 'Participants', 'site', 'Participants']","['The QIDS-SR ranges from 0-27 and assesses the severity and number of depression symptoms. Data completed through the Audio Computer Assisted Interview (ACASI) system are used for this outcome. A lower score indicates fewer depression symptom severity. Scores for all participants at a site were averaged. The site-specific averages were then analyzed.', 'We are assessing the percentage of participants with a response to treatment.The percentage of participants at each site with a response was calculated. These percentages were averaged for each treatment and the treatment averages were compared. A response to treatment is considered a decrease in Quick Inventory of Depression Symptomatology, Self Report (QIDS-SR) from Study entry to Week 24 by more than 50%. The week 0 value is generally considered the entry value. Priority is given to the ACASI score at week 0. In certain cases, the week 1 ACASI value is used if there is no ACASI score at week 0, but there is one at week 1. Paper form scores are used for ""study entry"" if there is no ACASI record, with the value at week 0 prioritized over the value at week 1. Otherwise, ACASI data are used for this outcome. The QIDS-SR is scored from 0 to 27 with a lower score indicating less symptomatology.', 'We computed the percentage of participants at each site with remission and then compared the percentages. Remission is defined as a Quick Inventory of Depression Symptomatology, self-report (QIDS-SR) score <= 5. ACASI data are used for this outcome. The QIDS-SR scale is from 0-27 with a lower score indicating tess symptomatology.', 'CD4 cell counts are cells/microL (uL). CD4 cell counts of all participants at a site were averaged. The averages were then analyzed.', 'Plasma HIV RNA data are calculated on the log10 scale as log10(week X RNA copies/mL)\n\nFor this analysis, HIV-1 RNA values (copies per mL) that were censored below the lower limit of quantification (LLQ) were imputed to be equal to the LLQ - 1. The LLQ was considered to be 40 copies/mL. Viral load was calculated on the log10 scale as log10(week X RNA). Viral load suppression was also measured as copies < 40.\n\nThe log10 (week X RNA) values were averaged by site and those averages were analyzed.', 'Adherence to anti-HIV medications at each assessment for the first 24 weeks (during active treatment) and at 48 weeks, as measured by self-report. Three questions were asked; these assess the number of days in the last 30 with any missed medication doses, how good the participant is at taking his medication as instructed and how often the participant takes medication correctly. Response scales are Likert from 1 to 6, with a higher score indicating better adherence. A 30 day time frame is used for these two questions also.', 'Adherence to anti-HIV medications at each assessment for the first 24 weeks (during active treatment) and at 48 weeks, as measured by self-report. Three questions were asked; these assess the number of days in the last 30 with any missed medication doses, how good the participant is at taking his medication as instructed and how often the participant takes medication correctly. Response scales are Likert from 1 to 6, with a higher score indicating better adherence. A 30 day time frame is used for these two questions also. 1=Very poor .... 6=Excellent', 'Adherence to anti-HIV medications at each assessment for the first 24 weeks (during active treatment) and at 48 weeks, as measured by self-report. Three questions were asked; these assess the number of days in the last 30 with any missed medication doses, how good the participant is at taking his medication as instructed and how often the participant takes medication correctly. Response scales are Likert from 1 to 6, with a higher score indicating better adherence. A 30 day time frame is used for these two questions also. 1=Never ... 6=Always', 'Adherence to psychiatric medications at each assessment for the first 24 weeks (during active treatment) and at 48 weeks, as measured by self-report for those participants taking psychiatric medications. Three questions were asked; these assess the number of days in the last 30 with any missed medication doses, how good the participant is at taking his medication as instructed and how often the participant takes medication correctly. Response scales are Likert from 1 to 6, with a higher score indicating better adherence. A 30 day time frame is used for these two questions also.', 'Adherence to psychiatric medications at each assessment for the first 24 weeks (during active treatment) and at 48 weeks, as measured by self-report tor those participants taking psychiatric medications. Three questions were asked; these assess the number of days in the last 30 with any missed medication doses, how good the participant is at taking his medication as instructed and how often the participant takes medication correctly. Response scales are Likert from 1 to 6, with a higher score indicating better adherence. A 30 day time frame is used for these two questions also.1=Very poor .... 6=Excellent', 'Adherence to psychiatric medications at each assessment for the first 24 weeks (during active treatment) and at 48 weeks, as measured by self-report for those participants taking psychiatric medications. Three questions were asked; these assess the number of days in the last 30 with any missed medication doses, how good the participant is at taking his medication as instructed and how often the participant takes medication correctly. Response scales are Likert from 1 to 6, with a higher score indicating better adherence. A 30 day time frame is used for these two questions also. 1=Never .... 6=Always', 'We will compute the number of scheduled counseling sessions attended. This number focuses on visits scheduled at study weeks 1, 6, 12, and 24. Analysis of secondary outcomes, even those pertaining to week 24, was planned to take place after study was completed and at the same time as week 48 data were analyzed.', 'We will compute the number of scheduled medication management sessions (COMB-R only) attended. This includes visits scheduled at planned study visits (weeks 1, 6, 12 and 24). Analysis of secondary outcomes, even those pertaining to week 24, was planned to take place after study was completed and at the same time as week 48 data were analyzed.', 'We will compute the # study visits completed as the number of scheduled study visits completed. Visits were scheduled at study weeks 0, 1, 6, 12, 24, 36 and 48. However in some cases, weeks 0 and 1 visits were done on the same day.', 'Quick Inventory of Depression Symptomatology, Self Report (QIDS-SR) Score over 48 Weeks. This scale goes from 0 to 27 with a lower score indicating less symptomatology. .Scores for participants at each site are averaged and the averages are analyzed.', 'The percentage of participants with a decrease in Quick Inventory of Depression Symptomatology, Self Report (QIDS-SR) score of more than 50% from week 0 to week X will be computed at each site and those percentages will be analyzed. Refer to above definition.', 'A remission is a Quick Inventory of Depression Symptomatology, Self Report (QIDS-SR) score <= 5. The percentage of participants at each site with remission will be computed and those percentages will be analyzed.', 'QIDS-SR score: Effect of moderators (Demographic: age (younger vs. older), gender. Mode of HIV acquisition category (perinatal vs. behavioral), initial level of depression (QIDS-SR categorized as severe/very severe vs. none/low/moderate severity); Biological: baseline CD4 (count/uL categorized as stage 3 = < 200 cells vs. less than stage 3), nadir CD4 at study entry (based on count/uL and considering worst classification across ages, defined below), plasma HIV RNA (suppressed at < 40 copies/mL vs. not suppressed), Center for Disease Control and Prevention (CDC) clinical stage at entry (Stage 3 vs. less than stage 3) on depression outcomes: Determination of nadir CD4 cell count as Stage 3 was based on the following: If any of the following were true, the overall CD4 nadir cell count was classified as Stage 3: <750 cells at < 1 year of age; < 500 cells at 1-5 years of age; <200 cells at 6+ years of age (from Revised Surveillance Case Definition for HIV Infection - United States, 2014)', 'Response to Treatment: Effect of moderators (Demographic: age (younger vs. older), gender. Mode of HIV acquisition category (perinatal vs. behavioral), initial level of depression (QIDS-SR categorized as severe/very severe vs. none/low/moderate severity); Biological: baseline CD4 (count/uL categorized as stage 3 = < 200 cells vs. less than stage 3), nadir CD4 at study entry (based on count/uL and considering worst classification across ages, defined below), plasma HIV RNA (suppressed at < 40 copies/mL vs. not suppressed), CDC clinical stage at entry (Stage 3 vs. less than stage 3) on depression outcomes: Determination of nadir CD4 cell count as Stage 3 was done based on the following: If any of the following were true, the overall CD4 nadir cell count was classified as Stage 3: <750 cells at < 1 year of age; < 500 cells at 1-5 years of age; <200 cells at 6+ years of age. (from the Revised Surveillance Case Definition for HIV Infection - United States, 2014)', 'Remission: Effect of moderators (Demographic: age (younger vs. older), gender. Mode of HIV acquisition category (perinatal vs. behavioral), initial level of depression (QIDS-SR categorized as severe/very severe vs. none/low/moderate severity); Biological: baseline CD4 (count/uL categorized as stage 3 = < 200 cells vs. less than stage 3), nadir CD4 at study entry (based on count/uL and considering worst classification across ages, defined below), plasma HIV RNA (suppressed at < 40 copies/mL vs. not suppressed), CDC clinical stage at entry (Stage 3 vs. less than stage 3) on depression outcomes: Determination of nadir CD4 cell count as Stage 3 was done based on the following: If any of the following were true, the overall CD4 nadir cell count was classified as Stage 3: <750 cells at < 1 year of age; < 500 cells at 1-5 years of age; <200 cells at 6+ years of age. (from the Revised Surveillance Case Definition for HIV Infection - United States, 2014)', 'Measured as follows: Ever used; past three months use frequency; # drinks per day; any binge drinking.', 'Measured as follows: Ever used; past three months use frequency', 'Measured as follows: Ever used; past three months use frequency for cannabis, cocaine, amphetamine, inhalants, sedatives, hallucinogens, opioids', 'Assessed as: condom use (importance, confidence, frequency), sex as exchange commodity, number of sex partners', 'We will count the total numbers of COMB-R and ESC counseling sessions administered over the intervention period, including both interim and scheduled visits. The average number of sessions will be computed for each site and those averages will be analyzed. Analysis of secondary outcomes, even those pertaining to week 24, was planned to take place after study was completed and at the same time as week 48 data were analyzed.', 'For COMB-R; Here, we will assess the types of cognitive behavioral therapy (CBT) items covered in the COMB-R group over the intervention period. Analysis of secondary outcomes, even those pertaining to week 24, was planned to take place after study was completed and at the same time as week 48 data were analyzed.', 'Here we will summarize the types of counseling approaches used by the ESC clinicians over the intervention period. Analysis of secondary outcomes, even those pertaining to week 24, was planned to take place after study was completed and at the same time as week 48 data were analyzed.', 'For COMB-R, we will compute the number of CBT Medication Management (MM) sessions attended over 24 weeks . We will also assess the stages of the MM algorithm in the COMB-R group. Analysis of secondary outcomes, even those pertaining to week 24, was planned to take place after study was completed and at the same time as week 48 data were analyzed.', 'We will assess whether or not participants were taking psychiatric medications at entry and at week 24 and compute the percent of participants at each site taking medications. We also will compute the percent of study time during which participants were taking psychiatric medications overall and by classes of psychiatric medications.from study entry through week 24. Analysis of secondary outcomes, even those pertaining to week 24, was planned to take place after study was completed and at the same time as week 48 data were analyzed.', 'We will develop an algorithm to count the number of interim visits with both counseling clinician and prescribing clinician, defined as those outside of the scheduled study visits. Site mean numbers will be compared across treatments. Analysis of secondary outcomes, even those pertaining to week 24, was planned to take place after study was completed and at the same time as week 48 data were analyzed.', 'Client satisfaction will be the mean of the 8 questionnaire items. Each is rated on a likert scale from 1-4, with 4 being the best acceptability. Site mean scores will be compared across treatments. Analysis of secondary outcomes, even those pertaining to week 24, was planned to take place after study was completed and at the same time as week 48 data were analyzed.', '5 items were rated on a Likert scale from 0-3 with one additional overall question. The mean of the 5 items and the single overall item will be compared between groups. Site mean scores will be compared across treatments. Analysis of secondary outcomes, even those pertaining to week 24, was planned to take place after study was completed and at the same time as week 48 data were analyzed.', 'The COMB-R MM acceptability scale included 3 items scored on a Likert scale from 0-4 and one overall question. The ESC acceptability scale included 2 items (similar to Questions 1 and 3 on the MM scale). The 3 COMB-R MM items will be averaged (mean) and the two items on the ESC scale will be averaged (mean) and these scores will be compared. The single overall score will be reported for the COMB-R MM clinicians. Site mean scores will be compared across treatments.\n\nAnalysis of secondary outcomes, even those pertaining to week 24, was planned to take place after study was completed and at the same time as week 48 data were analyzed.', 'In this analysis only ""new"" events are counted; as identified by MedDRA Preferred Term; that is, those which were first reported after study entry. The percent of participants at each site with each a grade 3 or higher adverse event, categorized as 1) a sign/symptom or 2) diagnosis and 3) participants with at least one ""trigger"" event (psychiatric hospitalization or suicide attempt) are computed. The average of these site-level percentages within each treatment arm will be compared. Note, in some cases due to sparseness (few events reported at sites within a treatment group), the lower bound of the 95% confidence interval was less than zero . In those cases, the bounds were truncated to zero.', 'In this analysis only ""new"" events are counted; as identified by MedDRA Preferred Term; that is, those which were first reported after study entry. The percent of participants at each site with each a grade 3 or higher adverse event, categorized as 1) a sign/symptom or 2) diagnosis and 3) participants with at least one ""trigger"" event (psychiatric hospitalization or suicide attempt) the mean of these percents will be compared across groups']","['95% Confidence Interval', '95% Confidence Interval', '95% Confidence Interval', '95% Confidence Interval', '95% Confidence Interval', '95% Confidence Interval']","['Mean', 'Mean', 'Mean', 'Mean', 'Mean', 'Mean']","['All participants who entered QIDS-SR data into the ACASI system were analyzed.', 'We analyzed data from all participants with ACASI data at weeks 0 and 24.', 'We analyzed data from all participants with an ACASI QIDS-SR score at week 24.', 'All participants with a CD4 cell count at week 24 were analyzed.', 'We analyzed data for all participants with a non-missing HIV RNA copies value at week 24.', 'This is the analysis for the Week 24 data. We count a participant if any new qualifying event was reported prior to the week 24 upper window (+30 days).']","['Posted', 'Posted', 'Posted', 'Posted', 'Posted', 'Not Posted', 'Not Posted', 'Not Posted', 'Not Posted', 'Not Posted', 'Not Posted', 'Not Posted', 'Not Posted', 'Not Posted', 'Not Posted', 'Not Posted', 'Not Posted', 'Not Posted', 'Not Posted', 'Not Posted', 'Not Posted', 'Not Posted', 'Not Posted', 'Not Posted', 'Not Posted', 'Not Posted', 'Not Posted', 'Not Posted', 'Not Posted', 'Not Posted', 'Not Posted', 'Not Posted', 'Not Posted', 'Posted', 'Not Posted']","['Week 24', 'Week 0 and Week 24', 'Week 24', 'Week 24', 'Week 24', 'Over 24 and 48 Weeks', 'Over 24 and 48 Weeks', 'Over 24 and 48 Weeks', 'Over 24 and 48 Weeks', 'Over 24 and 48 Weeks', 'Over 24 and 48 Weeks', 'Over 24 weeks', 'Over 24 weeks', 'Over 24 and 48 Weeks', 'Over 48 Weeks', 'Week 48', 'Week 48', 'Over 48 Weeks', 'Over 48 Weeks', 'Over 48 Weeks', 'Weeks 24 and 48', 'Weeks 24 and 48', 'Weeks 24 and 48', 'Weeks 24 and 48', 'over 24 weeks', 'over 24 Weeks', 'Over 24 weeks', '24 Weeks', '24 weeks', '24 Weeks', '24 Weeks', '24 Weeks', '24 Weeks', 'Over 24 Weeks', 'Over 48 weeks']","['Depression Outcomes: Quick Inventory of Depression Symptomatology - Self Report (QIDS-SR) Score', 'Depression Outcomes: Response to Treatment, Defined as a Decrease in QIDS-SR Score by >50%', 'Depression Outcomes: Remission, Defined as a QIDS-SR Score <= 5', 'Biological Outcomes: Cluster of Differentiation 4 (CD4) Cell Count at Week 24', 'Biological Outcomes: Plasma HIV RNA Level at Week 24', 'Adherence Outcomes: Adherence to Anti-HIV Medications - Number of Days in Last 30 With Any Missed Doses', 'Adherence Outcomes: Adherence to Anti-HIV Medications - How Good Participant Was at Taking Medicines as Instructed', 'Adherence Outcomes: Adherence to Anti-HIV Medications - How Often Did Participant Take Medications as Instructed', 'Adherence Outcomes: Adherence to Psychiatric Medications - Number of Days in Last 30 With Any Missed Doses', 'Adherence Outcomes: Adherence to Psychiatric Medications - How Good Participant Was at Taking Medications as Instructed', 'Adherence Outcomes: Adherence to Psychiatric Medications - How Often Did Participant Take Medicines as Instructed', 'Adherence Outcomes: Adherence to Psychotherapy Sessions', 'Adherence Outcomes: Adherence to COMB-R Medication Management Sessions', 'Adherence Outcomes: Adherence to Study Visits', 'Depression Outcomes: QIDS-SR Score Over 48 Weeks.', 'Depression Outcomes: QIDS-SR Response to Treatment Over 48 Weeks', 'Depression Outcomes: QIDS-SR Score Remission Over 48 Weeks', 'Effect of Demographic, Behavioral, and Biological Modifiers on Depression Outcomes: QIDS-SR Score (Defined Above)', 'Effect of Demographic, Behavioral, and Biological Modifiers on Depression Outcomes: Response to Treatment (Defined Above)', 'Effect of Demographic, Behavioral, and Biological Modifiers on Depression Outcomes: Remission (Defined Above)', 'Behavioral Risk Outcomes: Alcohol Use', 'Behavioral Risk Outcomes: Tobacco Use', 'Behavioral Risk Outcomes: Drug Use', 'Behavioral Risk Outcomes: Sex-Risk Behaviors', 'To Describe the Implementation Fidelity at COMB-R Sites and the Counseling Strategies and Medication Patterns at ESC Sites: The Total Numbers of Counseling Sessions', 'Implementation Fidelity (COMB-R Sites); Counseling Strategies (ESC Sites) - Types of Counseling Approaches COMB-R Sites', 'Implementation Fidelity (COMB-R Sites); Counseling Strategies (ESC Sites) - Types of Counseling Approaches ESC Sites', 'Implementation Fidelity (COMB-R Sites); Medication Management', 'Acceptability: Frequency of Psychiatric Medication Use', 'Acceptability: Number of Interim Visits', 'COMB-R and ESC Acceptability Among Participants', 'COMB-R and ESC Acceptability Among Counseling Clinicians', 'COMB-R MM and ESC Acceptability Among Prescribing Clinicians', 'Grade 3 or Higher Adverse Events (AE), Psychological Hospitalizations, and Suicide Attempts', 'Grade 3 or Higher Adverse Events (AE), Psychological Hospitalizations, and Suicide Attempts']","['Primary', 'Primary', 'Primary', 'Primary', 'Primary', 'Secondary', 'Secondary', 'Secondary', 'Secondary', 'Secondary', 'Secondary', 'Secondary', 'Secondary', 'Secondary', 'Secondary', 'Secondary', 'Secondary', 'Secondary', 'Secondary', 'Secondary', 'Secondary', 'Secondary', 'Secondary', 'Secondary', 'Secondary', 'Secondary', 'Secondary', 'Secondary', 'Secondary', 'Secondary', 'Secondary', 'Secondary', 'Secondary', 'Secondary', 'Secondary']","['site', 'site', 'site', 'site', 'site', 'site']","['units on a scale', 'site % with response', 'site % with remission', 'cells/uL', 'log10 HIV RNA (copies/mL)', 'percent']",[],"['OG000', 'OG001', 'OG000', 'OG001', 'OG000', 'OG001', 'OG000', 'OG001', 'OG000', 'OG001', 'OG000', 'OG001', 'OG000', 'OG001', 'OG000', 'OG001']"
0,133,['NCT03488264'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,134,['NCT01873482'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,135,['NCT02829073'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,136,['NCT01369030'],"['Participants', 'Participants', 'Participants']","['Subjects with depression who have been prescribed Deplin® daily.', 'Subjects with depression who have been prescribed Deplin® daily.', 'Subjects with depression who have been prescribed Deplin® daily.']",['9'],"['Deplin®', 'Deplin®', 'Deplin®']",[],[],[],"['The PHQ-9 is a depression scale used to assess brief depression severity by rating symptoms and functional impairment experienced in the last two weeks. The questionnaire contains a total of 9 questions, and each question is scored on a range from 0-3. The minimum value ""0"" represents not at all, ""1"" several days, ""2"" indicates more than half the days, and the maximum value ""3"" stands for nearly every day. The total possible range is 0-27. The total number of each 0, 1, 2, 3 is added and multiplied by its value (0=0, 1=1, etc.) to produce a total score generated from the subtotal sum. The PHQ-9 total score is interpreted as follows: 0-4 represents minimal depression, 5-9 as mild depression, 10-14 as moderate depression, 15-19 moderately severe depression, and 20-27 severe depression.', 'Mean satisfaction with medication was rated on 1 to 9 point scale, 1 indicating ""not at all satisfied"" and 9 as ""very satisfied.""']","['Standard Deviation', 'Full Range']","['Mean', 'Number', 'Mean']",['Analyses were performed on the 554 patients who had a baseline PHQ-9>=5 and further analyzed by baseline depression severity groups defined by baseline PHQ-9 scores: 5<=PHQ-9<=9; 10<=PHQ-9<=14; 15<=PHQ-9<=19; and 20<=PHQ-9<=27.'],"['Posted', 'Posted', 'Posted']","['Baseline to Endpoint (90 days)', 'Baseline to Endpoint (90 days)', 'Baseline to Endpoint (90 days)']","['Change in Depression Severity as Measured by the 9-item Patient Health Questionnaire (PHQ-9)', 'Proportion of Patients Reporting Difficulty in Daily Functioning Due to Depressive Symptoms', 'Change in Overall Patient Satisfaction With Deplin® Using a 9-point Satisfaction Scale']","['Primary', 'Secondary', 'Secondary']",[],"['units on a scale', 'percentage of participants', 'units on a scale']",[],"['OG000', 'OG000', 'OG000', 'OG000', 'OG000']"
0,137,['NCT01568424'],"['Participants', 'Participants', 'Participants', 'Participants', 'Participants', 'Participants', 'Participants']","['Patients with acute right ventricular failure from any cause requiring use of the CentriMag RVAS to sustain life.\n\nCentriMag RVAS placement: Patients will be treated with a CentriMag RVAS', 'Patients with acute right ventricular failure from any cause requiring use of the CentriMag RVAS to sustain life.\n\nCentriMag RVAS placement: Patients will be treated with a CentriMag RVAS', 'Patients with acute right ventricular failure from any cause requiring use of the CentriMag RVAS to sustain life.\n\nCentriMag RVAS placement: Patients will be treated with a CentriMag RVAS', 'Patients with acute right ventricular failure from any cause requiring use of the CentriMag RVAS to sustain life.\n\nCentriMag RVAS placement: Patients will be treated with a CentriMag RVAS', 'Patients with acute right ventricular failure from any cause requiring use of the CentriMag RVAS to sustain life.\n\nCentriMag RVAS placement: Patients will be treated with a CentriMag RVAS', 'Patients with acute right ventricular failure from any cause requiring use of the CentriMag RVAS to sustain life.\n\nCentriMag RVAS placement: Patients will be treated with a CentriMag RVAS', 'Patients with acute right ventricular failure from any cause requiring use of the CentriMag RVAS to sustain life.\n\nCentriMag RVAS placement: Patients will be treated with a CentriMag RVAS']","['22', '20', '24', '17', '16', '18', '18', '18', '106', '97', '104', '105', '90', '94', '82', '87', '3.8', '5.6', '5.6', '4.5', '7.7', '4.2', '3.0', '3.4', '73', '71', '95', '109', '101', '67', '72', '79', '123', '4.6', '3.7', '4.8', '5.2', '4.5', '2.8', '3.7', '4.2', '5.5', '6.6', '3.7', '7.1', '12.3', '6.4', '10.4', '9.9', '7.0', '7.2']","['Treatment Group', 'Treatment Group', 'Treatment Group', 'Treatment Group', 'Treatment Group', 'Treatment Group', 'Treatment Group']",[],[],[],"['In patients who recover and do not go on to transplantation or a long-term device: Survival to 30 days post-support or to hospital discharge (whichever is longer).\n\nIn patients who do not recover and are bridged to transplant or a long-term system: Survival to induction of anesthesia for implantation of a long-term device or heart transplant.', 'CVP is a measure of right heart filling pressure, or the preload to the right ventricle. During RVAD support, the CVP decreases as blood is drawn into the pump and then ejected into the pulmonary artery.', 'MAP is the mean value for the blood pressure in the arterial circulation. During RVAD support, this value provides information regarding the adequacy of cardiac output from the left ventricle.', 'Cardiac output (L/min) divided by the body surface area (m2)', 'BUN is a measure of renal function', 'Creatinine is a measure of renal function', 'Total bilirubin is a measure of hepatic function']","['Full Range', 'Full Range', 'Full Range', 'Full Range', 'Full Range', 'Full Range']","['Number', 'Median', 'Median', 'Median', 'Median', 'Median', 'Median']","['Patients with continuous RVAD support.', 'Patients with continuous RVAD support.', 'Patients with continuous RVAD support', 'Patients with continuous RVAD support', 'Patients with continuous RVAD support', 'Patients with continuous RVAD support']","['Posted', 'Posted', 'Posted', 'Posted', 'Posted', 'Posted', 'Posted']","['30 days post device removal', 'Baseline, Day 1, Day 2, Day 3, Week 1, Prior to Explant, 1 day after RVAD removal, 2 days after RVAD removal', 'Baseline, Day 1, Day 2, Day 3, Week 1, Prior to Explant, 1 day after RVAD removal, 2 days after RVAD removal.', 'Baseline, Day 1, Day 2, Day 3, Week 1, Prior to Explant, 1 day after RVAD removal, 2 days after RVAD removal.', 'Baseline, Day 1, Day 2, Day 3, Week 1, Prior to Explant, 1 day after RVAD removal, 2 days after RVAD removal, 30 days after RVAD removal', 'Baseline, Day 1, Day 2, Day 3, Week 1, Prior to Explant, 1 day after RVAD removal, 2 days after RVAD removal, 30 days after RVAD removal', 'Baseline, Day 1, Day 2, Day 3, Week 1, Prior to Explant, 1 day after RVAD removal, 2 days after RVAD removal, 30 days after RVAD removal']","['Survival', 'Central Venous Pressure (CVP)', 'Mean Arterial Pressure (MAP)', 'Cardiac Index (CI)', 'Blood Urea Nitrogen (BUN)', 'Creatinine', 'Total Bilirubin']","['Primary', 'Secondary', 'Secondary', 'Secondary', 'Secondary', 'Secondary', 'Secondary']",[],"['percentage of survival at 30 days', 'mmHg', 'mmHg', 'L/min/m2', 'mg/dl', 'mg/dl', 'mg/dl']",[],"['OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000', 'OG000']"
0,138,['NCT02406599'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,139,['NCT03965195'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,140,['NCT01368549'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,141,['NCT01370954'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,142,['NCT01339546'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,143,['NCT02252159'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,144,['NCT04072289'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,145,['NCT04423770'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,146,['NCT01358552'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,147,['NCT02856646'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,148,['NCT01940679'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,149,['NCT02951598'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,150,['NCT02988934'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,151,['NCT01028300'],"['Participants', 'Participants', 'Participants', 'Participants']","['ProDisc™-L Total Disc Replacement (TDR): The design is based on a ball and socket articulation, one surface being metal and the other an ultra-high molecular weight polyethylene (UHMWPE). Three components comprise this modular prosthesis.', 'ProDisc™-L Total Disc Replacement (TDR): The design is based on a ball and socket articulation, one surface being metal and the other an ultra-high molecular weight polyethylene (UHMWPE). Three components comprise this modular prosthesis.', 'ProDisc™-L Total Disc Replacement (TDR): The design is based on a ball and socket articulation, one surface being metal and the other an ultra-high molecular weight polyethylene (UHMWPE). Three components comprise this modular prosthesis.', 'ProDisc™-L Total Disc Replacement (TDR): The design is based on a ball and socket articulation, one surface being metal and the other an ultra-high molecular weight polyethylene (UHMWPE). Three components comprise this modular prosthesis.']",[],"['ProDisc L', 'ProDisc L', 'ProDisc L', 'ProDisc L']",[],[],[],[],[],[],"['Study was terminated early due to slow enrollment. 1 subject was enrolled but not treated due to study termination. 1 subject was enrolled and treated, but had no follow-up visits due to study termination. Only Two subjects were seen for follow-up visits, and only at 3 months post surgery.', 'Study was terminated early due to slow enrollment. 1 subject was enrolled but not treated due to study termination. 1 subject was enrolled and treated, but had no follow-up visits due to study termination. Only Two subjects were seen for follow-up visits, and only at 3 months post surgery.', 'Study was terminated early due to slow enrollment. 1 subject was enrolled but not treated due to study termination. 1 subject was enrolled and treated, but had no follow-up visits due to study termination. Only Two subjects were seen for follow-up visits, and only at 3 months post surgery.', 'Study was terminated early due to slow enrollment. 1 subject was enrolled but not treated due to study termination. 1 subject was enrolled and treated, but had no follow-up visits due to study termination. Only Two subjects were seen for follow-up visits, and only at 3 months post surgery.']","['Posted', 'Posted', 'Posted', 'Posted']","['24 months', '24 months', '24 months', '24 months']","['The Primary Endpoint of This Study is the Assessment of the Mean Oswestry Low Back Pain Disability Questionnaire (ODI) Improvement at the Twelve (12) Month and Twenty-four (24) Month Follow-up Visits Relative to Baseline.', 'Time to Return to Active Duty', 'No Re-operations, Revisions, Removals or Supplemental Fixation', 'No Implant Related Complications']","['Primary', 'Secondary', 'Secondary', 'Secondary']",[],[],[],[]
0,152,['NCT01034865'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,153,['NCT02352532'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,154,['NCT03198793'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,155,['NCT01112917'],"['Participants', 'Participants']","['VenaTech Convertible Vena Cava Filter: Prevention of Pulmonary Embolism\n\nVena Cava Filter Conversion: Conversion of VenaTech Convertible filter to open configuration.', 'VenaTech Convertible Vena Cava Filter: Prevention of Pulmonary Embolism\n\nVena Cava Filter Conversion: Conversion of VenaTech Convertible filter to open configuration.']",[],"['VenaTech Convertible Filter - Converted Filters', 'VenaTech Convertible Filter - Converted Filters']",[],[],[],"[""Technical success is defined as filter conversion without the loss of filter head components in the vasculature or incomplete opening of filtering legs. Further, in the analysis of the data, the sponsor did not count any filters as a 'technically' successful conversion when the operator was unable to snare the filter hook during an attempted conversion.""]",[],"['Number', 'Number']",['There was one subject (007-006) excluded as no 6-month images were available although a 6-month assessment was conducted.'],"['Posted', 'Posted']","['6-months', '6-months']","['Technical Success', 'Major Device-Related Adverse Events in Converted Subjects']","['Primary', 'Secondary']",[],"['participants', 'participants']",[],"['OG000', 'OG000']"
0,156,['NCT01764269'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,157,['NCT03346603'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,158,['NCT04281290'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,159,['NCT04601103'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,160,['NCT04600856'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,161,['NCT04599907'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,162,['NCT04593875'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,163,['NCT04589507'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,164,['NCT04586205'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,165,['NCT04585646'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,166,['NCT04584788'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,167,['NCT04584099'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,168,['NCT04577898'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,169,['NCT04577456'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,170,['NCT04569253'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,171,['NCT04567186'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,172,['NCT04562532'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,173,['NCT04558970'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,174,['NCT04558632'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,175,['NCT04558047'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,176,['NCT04557917'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,177,['NCT04557891'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,178,['NCT04556968'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,179,['NCT04556474'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,180,['NCT04547920'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,181,['NCT04547712'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,182,['NCT04544670'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,183,['NCT04542525'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,184,['NCT04540913'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,185,['NCT04537013'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,186,['NCT04536168'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,187,['NCT04534764'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,188,['NCT04532099'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,189,['NCT04529616'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,190,['NCT04529109'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,191,['NCT04524247'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,192,['NCT04523545'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,193,['NCT04513574'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,194,['NCT04510857'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,195,['NCT04508335'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,196,['NCT04502758'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,197,['NCT04501146'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,198,['NCT04500821'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,199,['NCT04499521'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,200,['NCT04496752'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,201,['NCT04493021'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,202,['NCT04488666'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,203,['NCT04483791'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,204,['NCT04476784'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,205,['NCT04474054'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,206,['NCT04469218'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,207,['NCT04466930'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,208,['NCT04455997'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,209,['NCT04455854'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,210,['NCT04450108'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,211,['NCT04437615'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,212,['NCT04422990'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,213,['NCT04419714'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,214,['NCT04409158'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,215,['NCT04403542'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,216,['NCT04400643'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,217,['NCT04394546'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,218,['NCT04388787'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,219,['NCT04388722'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,220,['NCT04386785'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,221,['NCT04378764'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,222,['NCT04377438'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,223,['NCT04338971'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,224,['NCT04335981'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,225,['NCT04332640'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,226,['NCT04330001'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,227,['NCT04324593'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,228,['NCT04320823'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,229,['NCT04319887'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,230,['NCT04318132'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,231,['NCT04314947'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,232,['NCT04314700'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,233,['NCT04313725'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,234,['NCT04310566'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,235,['NCT04307446'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,236,['NCT04306744'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,237,['NCT04305119'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,238,['NCT04303273'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,239,['NCT04299386'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,240,['NCT04299009'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,241,['NCT04298359'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,242,['NCT04296773'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,243,['NCT04295499'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,244,['NCT04287036'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,245,['NCT04285541'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,246,['NCT04281940'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,247,['NCT04279522'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,248,['NCT04277455'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,249,['NCT04263532'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,250,['NCT04252183'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,251,['NCT04247581'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,252,['NCT04244357'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,253,['NCT04243369'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,254,['NCT04243239'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,255,['NCT04239885'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,256,['NCT04237207'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,257,['NCT04236869'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,258,['NCT04230486'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,259,['NCT04224155'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,260,['NCT04223609'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,261,['NCT04220060'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,262,['NCT04219891'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,263,['NCT04211441'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,264,['NCT04210622'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,265,['NCT04207749'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,266,['NCT04206839'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,267,['NCT04206384'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,268,['NCT04203745'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,269,['NCT04202419'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,270,['NCT04201340'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,271,['NCT04200898'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,272,['NCT04196907'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,273,['NCT04195581'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,274,['NCT04194307'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,275,['NCT04192630'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,276,['NCT04189913'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,277,['NCT04189081'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,278,['NCT04186806'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,279,['NCT04184973'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,280,['NCT04178720'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,281,['NCT04177771'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,282,['NCT04177212'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,283,['NCT04176965'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,284,['NCT04175340'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,285,['NCT04166032'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,286,['NCT04162652'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,287,['NCT04158466'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,288,['NCT04153292'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,289,['NCT04152642'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,290,['NCT04151992'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,291,['NCT04151290'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,292,['NCT04141007'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,293,['NCT04136158'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,294,['NCT04134286'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,295,['NCT04130490'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,296,['NCT04127188'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,297,['NCT04121754'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,298,['NCT04119609'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,299,['NCT04116879'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,300,['NCT04116866'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,301,['NCT04112784'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,302,['NCT04112628'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,303,['NCT04112134'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,304,['NCT04106934'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,305,['NCT04096495'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,306,['NCT04087395'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,307,['NCT04085328'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,308,['NCT04083742'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,309,['NCT04082078'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,310,['NCT04081727'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,311,['NCT04079842'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,312,['NCT04079816'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,313,['NCT04078490'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,314,['NCT04073823'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,315,['NCT04069585'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,316,['NCT04068818'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,317,['NCT04065659'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,318,['NCT04064606'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,319,['NCT04060524'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,320,['NCT04057105'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,321,['NCT04056494'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,322,['NCT04055519'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,323,['NCT04055324'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,324,['NCT04054401'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,325,['NCT04046627'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,326,['NCT04043234'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,327,['NCT04040933'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,328,['NCT04036747'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,329,['NCT04035161'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,330,['NCT04033315'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,331,['NCT04032977'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,332,['NCT04031989'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,333,['NCT04031976'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,334,['NCT04030702'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,335,['NCT04011826'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,336,['NCT04008836'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,337,['NCT04005586'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,338,['NCT04003831'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,339,['NCT03999944'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,340,['NCT03997357'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,341,['NCT03996187'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,342,['NCT03995355'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,343,['NCT03992768'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,344,['NCT03991468'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,345,['NCT03972995'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,346,['NCT03971721'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,347,['NCT03969875'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,348,['NCT03967184'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,349,['NCT03964831'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,350,['NCT03953274'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,351,['NCT03950895'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,352,['NCT03949335'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,353,['NCT03944629'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,354,['NCT03942016'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,355,['NCT03941912'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,356,['NCT03934463'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,357,['NCT03934125'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,358,['NCT03931213'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,359,['NCT03925545'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,360,['NCT03920280'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,361,['NCT03918928'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,362,['NCT03912584'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,363,['NCT03911700'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,364,['NCT03898778'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,365,['NCT03897751'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,366,['NCT03897712'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,367,['NCT03895034'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,368,['NCT03888352'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,369,['NCT03872609'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,370,['NCT03872466'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,371,['NCT03871179'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,372,['NCT03864848'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,373,['NCT03864081'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,374,['NCT03862300'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,375,['NCT03858140'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,376,['NCT03851510'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,377,['NCT03839199'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,378,['NCT03835026'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,379,['NCT03812679'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,380,['NCT03805074'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,381,['NCT03799549'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,382,['NCT03790046'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,383,['NCT03789669'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,384,['NCT03788551'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,385,['NCT03782116'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,386,['NCT03779984'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,387,['NCT03771521'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,388,['NCT03771352'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,389,['NCT03764254'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,390,['NCT03748823'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,391,['NCT03748771'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,392,['NCT03748316'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,393,['NCT03748264'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,394,['NCT03736798'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,395,['NCT03730480'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,396,['NCT03729024'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,397,['NCT03728309'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,398,['NCT03716492'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,399,['NCT03713281'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,400,['NCT03708393'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,401,['NCT03706430'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,402,['NCT03704636'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,403,['NCT03700372'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,404,['NCT03700047'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,405,['NCT03696316'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,406,['NCT03692741'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,407,['NCT03685136'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,408,['NCT03682432'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,409,['NCT03681886'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,410,['NCT03681496'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,411,['NCT03678103'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,412,['NCT03677388'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,413,['NCT03670277'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,414,['NCT03663010'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,415,['NCT03642431'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,416,['NCT03641937'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,417,['NCT03631550'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,418,['NCT03628898'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,419,['NCT03617822'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,420,['NCT03614130'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,421,['NCT03613363'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,422,['NCT03611101'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,423,['NCT03604900'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,424,['NCT03604562'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,425,['NCT03604432'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,426,['NCT03601182'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,427,['NCT03600194'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,428,['NCT03599271'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,429,['NCT03589911'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,430,['NCT03586167'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,431,['NCT03578302'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,432,['NCT03574259'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,433,['NCT03564366'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,434,['NCT03560141'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,435,['NCT03550807'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,436,['NCT03540576'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,437,['NCT03538561'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,438,['NCT03525704'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,439,['NCT03523208'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,440,['NCT03508778'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,441,['NCT03502200'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,442,['NCT03500341'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,443,['NCT03497910'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,444,['NCT03488849'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,445,['NCT03488238'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,446,['NCT03482297'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,447,['NCT03477370'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,448,['NCT03467204'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,449,['NCT03465514'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,450,['NCT03462576'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,451,['NCT03451786'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,452,['NCT03442842'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,453,['NCT03441971'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,454,['NCT03441880'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,455,['NCT03441477'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,456,['NCT03439189'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,457,['NCT03435224'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,458,['NCT03435211'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,459,['NCT03431883'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,460,['NCT03423251'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,461,['NCT03421145'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,462,['NCT03418545'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,463,['NCT03408444'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,464,['NCT03388138'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,465,['NCT03384381'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,466,['NCT03372434'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,467,['NCT03372343'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,468,['NCT03371160'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,469,['NCT03366194'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,470,['NCT03351192'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,471,['NCT03345121'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,472,['NCT03345017'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,473,['NCT03339388'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,474,['NCT03336944'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,475,['NCT03329794'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,476,['NCT03323515'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,477,['NCT03315117'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,478,['NCT03299933'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,479,['NCT03275532'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,480,['NCT03272308'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,481,['NCT03269097'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,482,['NCT03268356'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,483,['NCT03268265'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,484,['NCT03267134'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,485,['NCT03257410'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,486,['NCT03251079'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,487,['NCT03246503'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,488,['NCT03242148'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,489,['NCT03239574'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,490,['NCT03236519'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,491,['NCT03235791'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,492,['NCT03233945'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,493,['NCT03230877'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,494,['NCT03230747'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,495,['NCT03219567'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,496,['NCT03198988'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,497,['NCT03190564'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,498,['NCT03182660'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,499,['NCT03172949'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,500,['NCT03150407'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,501,['NCT03148613'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,502,['NCT03147820'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,503,['NCT03147482'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,504,['NCT03147417'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,505,['NCT03143127'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,506,['NCT03142594'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,507,['NCT03142581'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,508,['NCT03138369'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,509,['NCT03138343'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,510,['NCT03134989'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,511,['NCT03132363'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,512,['NCT03132350'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,513,['NCT03129152'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,514,['NCT03128840'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,515,['NCT03128632'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,516,['NCT03127566'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,517,['NCT03127540'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,518,['NCT03127527'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,519,['NCT03127501'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,520,['NCT03127488'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,521,['NCT03125135'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,522,['NCT03125122'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,523,['NCT03125109'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,524,['NCT03125096'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,525,['NCT03125044'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,526,['NCT03124992'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,527,['NCT03124953'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,528,['NCT03124940'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,529,['NCT03124888'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,530,['NCT03124849'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,531,['NCT03124810'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,532,['NCT03124745'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,533,['NCT03124732'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,534,['NCT03124719'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,535,['NCT03124706'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,536,['NCT03124264'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,537,['NCT03124251'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,538,['NCT03123380'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,539,['NCT03123341'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,540,['NCT03122379'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,541,['NCT03120702'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,542,['NCT03100760'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,543,['NCT03098602'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,544,['NCT03073148'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,545,['NCT03072186'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,546,['NCT03066063'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,547,['NCT03038074'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,548,['NCT03035318'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,549,['NCT03034902'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,550,['NCT03021707'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,551,['NCT03021473'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,552,['NCT03019107'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,553,['NCT03017742'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,554,['NCT03003767'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,555,['NCT02995421'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,556,['NCT02986789'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,557,['NCT02972892'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,558,['NCT02970799'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,559,['NCT02966210'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,560,['NCT02957071'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,561,['NCT02956928'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,562,['NCT02948751'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,563,['NCT02938637'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,564,['NCT02922621'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,565,['NCT02919566'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,566,['NCT02918942'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,567,['NCT02916823'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,568,['NCT02913560'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,569,['NCT02911376'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,570,['NCT02910674'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,571,['NCT02907203'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,572,['NCT02904382'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,573,['NCT02888626'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,574,['NCT02872844'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,575,['NCT02870959'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,576,['NCT02870881'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,577,['NCT02863796'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,578,['NCT02863432'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,579,['NCT02862080'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,580,['NCT02858089'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,581,['NCT02856490'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,582,['NCT02849847'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,583,['NCT02842970'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,584,['NCT02841397'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,585,['NCT02833571'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,586,['NCT02811328'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,587,['NCT02810080'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,588,['NCT02805933'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,589,['NCT02805777'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,590,['NCT02800057'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,591,['NCT02799342'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,592,['NCT02799329'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,593,['NCT02795689'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,594,['NCT02787343'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,595,['NCT02784431'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,596,['NCT02771119'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,597,['NCT02764580'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,598,['NCT02761759'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,599,['NCT02756260'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,600,['NCT02746289'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,601,['NCT02746120'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,602,['NCT02719444'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,603,['NCT02716155'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,604,['NCT02712931'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,605,['NCT02711254'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,606,['NCT02699021'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,607,['NCT02698787'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,608,['NCT02698397'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,609,['NCT02697604'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,610,['NCT02686450'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,611,['NCT02684110'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,612,['NCT02680964'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,613,['NCT02680860'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,614,['NCT02662049'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,615,['NCT02638883'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,616,['NCT02634996'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,617,['NCT02634554'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,618,['NCT02634125'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,619,['NCT02631213'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,620,['NCT02626624'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,621,['NCT02624739'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,622,['NCT02622919'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,623,['NCT02599519'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,624,['NCT02597296'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,625,['NCT02596464'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,626,['NCT02579486'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,627,['NCT02576210'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,628,['NCT02561052'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,629,['NCT02553395'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,630,['NCT02548429'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,631,['NCT02543814'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,632,['NCT02540577'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,633,['NCT02540564'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,634,['NCT02535234'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,635,['NCT02525783'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,636,['NCT02517645'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,637,['NCT02506400'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,638,['NCT02495116'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,639,['NCT02480829'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,640,['NCT02474784'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,641,['NCT02474771'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,642,['NCT02474758'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,643,['NCT02458378'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,644,['NCT02455063'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,645,['NCT02441634'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,646,['NCT02436005'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,647,['NCT02430441'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,648,['NCT02405871'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,649,['NCT02403167'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,650,['NCT02396914'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,651,['NCT02388425'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,652,['NCT02383082'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,653,['NCT02380716'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,654,['NCT02380014'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,655,['NCT02365545'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,656,['NCT02365467'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,657,['NCT02364375'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,658,['NCT02353377'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,659,['NCT02343068'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,660,['NCT02340832'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,661,['NCT02327598'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,662,['NCT02325609'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,663,['NCT02322840'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,664,['NCT02312141'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,665,['NCT02300974'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,666,['NCT02289534'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,667,['NCT02284321'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,668,['NCT02283125'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,669,['NCT02280577'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,670,['NCT02275624'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,671,['NCT02272114'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,672,['NCT02271087'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,673,['NCT02268227'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,674,['NCT02255539'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,675,['NCT02239263'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,676,['NCT02231034'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,677,['NCT02223663'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,678,['NCT02218450'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,679,['NCT02195362'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,680,['NCT02195128'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,681,['NCT02191800'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,682,['NCT02187458'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,683,['NCT02167880'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,684,['NCT02166073'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,685,['NCT02142465'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,686,['NCT02142374'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,687,['NCT02142023'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,688,['NCT02141334'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,689,['NCT02134236'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,690,['NCT02124538'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,691,['NCT02108275'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,692,['NCT02089646'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,693,['NCT02086812'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,694,['NCT02085174'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,695,['NCT02082847'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,696,['NCT02070601'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,697,['NCT02036385'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,698,['NCT02020447'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,699,['NCT02006251'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,700,['NCT02004249'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,701,['NCT02003105'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,702,['NCT01989390'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,703,['NCT01989377'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,704,['NCT01988727'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,705,['NCT01988025'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,706,['NCT01984151'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,707,['NCT01973621'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,708,['NCT01966211'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,709,['NCT01957982'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,710,['NCT01951131'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,711,['NCT01950767'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,712,['NCT01940458'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,713,['NCT01940211'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,714,['NCT01937000'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,715,['NCT01936987'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,716,['NCT01916083'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,717,['NCT01906736'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,718,['NCT01905241'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,719,['NCT01896141'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,720,['NCT01894698'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,721,['NCT01883557'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,722,['NCT01882309'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,723,['NCT01877369'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,724,['NCT01874925'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,725,['NCT01867008'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,726,['NCT01859975'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,727,['NCT01854879'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,728,['NCT01847846'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,729,['NCT01835769'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,730,['NCT01835366'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,731,['NCT01827488'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,732,['NCT01820741'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,733,['NCT01801995'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,734,['NCT01801241'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,735,['NCT01795807'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,736,['NCT01795118'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,737,['NCT01792869'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,738,['NCT01790867'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,739,['NCT01787981'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,740,['NCT01777880'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,741,['NCT01773941'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,742,['NCT01773265'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,743,['NCT01747265'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,744,['NCT01738230'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,745,['NCT01738165'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,746,['NCT01733264'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,747,['NCT01733251'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,748,['NCT01724541'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,749,['NCT01721122'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,750,['NCT01715454'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,751,['NCT01700764'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,752,['NCT01697813'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,753,['NCT01697774'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,754,['NCT01674400'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,755,['NCT01670006'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,756,['NCT01662479'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,757,['NCT01660113'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,758,['NCT01658189'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,759,['NCT01652846'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,760,['NCT01643200'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,761,['NCT01640795'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,762,['NCT01630707'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,763,['NCT01629836'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,764,['NCT01627405'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,765,['NCT01614925'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,766,['NCT01613742'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,767,['NCT01610505'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,768,['NCT01610349'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,769,['NCT01607606'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,770,['NCT01604967'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,771,['NCT01597271'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,772,['NCT01591369'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,773,['NCT01582386'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,774,['NCT01575210'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,775,['NCT01564589'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,776,['NCT01560156'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,777,['NCT01558609'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,778,['NCT01556750'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,779,['NCT01546831'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,780,['NCT01546584'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,781,['NCT01533831'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,782,['NCT01533103'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,783,['NCT01532752'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,784,['NCT01532440'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,785,['NCT01524263'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,786,['NCT01515618'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,787,['NCT01513512'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,788,['NCT01499030'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,789,['NCT01494376'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,790,['NCT01480570'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,791,['NCT01476826'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,792,['NCT01473134'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,793,['NCT01470079'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,794,['NCT01464580'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,795,['NCT01463618'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,796,['NCT01462955'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,797,['NCT01450540'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,798,['NCT01443299'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,799,['NCT01443286'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,800,['NCT01442389'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,801,['NCT01436669'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,802,['NCT01436461'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,803,['NCT01414491'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,804,['NCT01414270'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,805,['NCT01412112'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,806,['NCT01408017'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,807,['NCT01403584'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,808,['NCT01392261'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,809,['NCT01379794'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,810,['NCT01374243'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,811,['NCT01370785'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,812,['NCT01367171'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,813,['NCT01365689'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,814,['NCT01358682'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,815,['NCT01336868'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,816,['NCT01313351'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,817,['NCT01313195'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,818,['NCT01311726'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,819,['NCT01307709'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,820,['NCT01297751'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,821,['NCT01286792'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,822,['NCT01258400'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,823,['NCT01246115'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,824,['NCT01240733'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,825,['NCT01239576'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,826,['NCT01234480'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,827,['NCT01230398'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,828,['NCT01201889'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,829,['NCT01194752'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,830,['NCT01194739'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,831,['NCT01194726'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,832,['NCT01183195'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,833,['NCT01180257'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,834,['NCT01171066'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,835,['NCT01166607'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,836,['NCT01164527'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,837,['NCT01158963'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,838,['NCT01150227'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,839,['NCT01148251'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,840,['NCT01147094'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,841,['NCT01145651'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,842,['NCT01145378'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,843,['NCT01143116'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,844,['NCT01140919'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,845,['NCT01127347'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,846,['NCT01112475'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,847,['NCT01108822'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,848,['NCT01106222'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,849,['NCT01103869'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,850,['NCT01100983'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,851,['NCT01098682'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,852,['NCT01097824'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,853,['NCT01092871'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,854,['NCT01077141'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,855,['NCT01070992'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,856,['NCT01067040'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,857,['NCT01062464'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,858,['NCT01062412'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,859,['NCT01062217'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,860,['NCT01057134'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,861,['NCT01043497'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,862,['NCT01039064'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,863,['NCT01037439'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,864,['NCT01030588'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,865,['NCT01029028'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,866,['NCT01022554'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,867,['NCT01016236'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,868,['NCT01008202'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,869,['NCT01000454'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,870,['NCT00993772'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,871,['NCT00990483'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,872,['NCT00990210'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,873,['NCT00986908'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,874,['NCT00981188'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,875,['NCT00979498'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,876,['NCT00979030'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,877,['NCT00969748'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,878,['NCT00968474'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,879,['NCT00961519'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,880,['NCT00960947'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,881,['NCT00957632'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,882,['NCT00957138'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,883,['NCT00956618'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,884,['NCT00955331'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,885,['NCT00946075'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,886,['NCT00944411'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,887,['NCT00942942'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,888,['NCT00935974'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,889,['NCT00932789'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,890,['NCT00924716'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,891,['NCT00911040'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,892,['NCT00906958'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,893,['NCT00906815'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,894,['NCT00906009'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,895,['NCT00905749'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,896,['NCT00903058'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,897,['NCT00901667'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,898,['NCT00900705'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,899,['NCT00889746'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,900,['NCT00878982'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,901,['NCT00877916'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,902,['NCT00865930'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,903,['NCT00865735'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,904,['NCT00863486'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,905,['NCT00863447'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,906,['NCT00858091'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,907,['NCT00850434'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,908,['NCT00850109'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,909,['NCT00846820'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,910,['NCT00843752'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,911,['NCT00840619'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,912,['NCT00824018'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,913,['NCT00821769'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,914,['NCT00820040'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,915,['NCT00819130'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,916,['NCT00818922'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,917,['NCT00810498'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,918,['NCT00810459'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,919,['NCT00809406'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,920,['NCT00806052'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,921,['NCT00802750'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,922,['NCT00800891'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,923,['NCT00799981'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,924,['NCT00794534'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,925,['NCT00791414'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,926,['NCT00790621'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,927,['NCT00789334'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,928,['NCT00788450'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,929,['NCT00788437'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,930,['NCT00782119'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,931,['NCT00781651'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,932,['NCT00781222'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,933,['NCT00780065'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,934,['NCT00779623'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,935,['NCT00777283'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,936,['NCT00776893'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,937,['NCT00776815'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,938,['NCT00776152'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,939,['NCT00773903'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,940,['NCT00773721'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,941,['NCT00769340'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,942,['NCT00767910'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,943,['NCT00766727'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,944,['NCT00764491'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,945,['NCT00764452'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,946,['NCT00760643'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,947,['NCT00759694'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,948,['NCT00758979'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,949,['NCT00758875'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,950,['NCT00758095'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,951,['NCT00756496'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,952,['NCT00754598'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,953,['NCT00748917'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,954,['NCT00748033'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,955,['NCT00747266'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,956,['NCT00739245'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,957,['NCT00732264'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,958,['NCT00732134'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,959,['NCT00728702'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,960,['NCT00727805'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,961,['NCT00727688'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,962,['NCT00726297'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,963,['NCT00726024'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,964,['NCT00725816'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,965,['NCT00725699'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,966,['NCT00716313'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,967,['NCT00690742'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,968,['NCT00681057'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,969,['NCT00680251'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,970,['NCT00678808'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,971,['NCT00676546'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,972,['NCT00676078'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,973,['NCT00670137'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,974,['NCT00660556'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,975,['NCT00659139'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,976,['NCT00653211'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,977,['NCT00639340'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,978,['NCT00630526'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,979,['NCT00617630'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,980,['NCT00617162'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,981,['NCT00616226'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,982,['NCT00615342'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,983,['NCT00608647'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,984,['NCT00597571'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,985,['NCT00591513'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,986,['NCT00589069'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,987,['NCT00588601'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,988,['NCT00587613'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,989,['NCT00587509'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,990,['NCT00586456'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,991,['NCT00579176'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,992,['NCT00578513'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,993,['NCT00578487'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,994,['NCT00576953'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,995,['NCT00561847'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,996,['NCT00542477'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,997,['NCT00529685'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,998,['NCT00506220'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,999,['NCT00448812'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
0,1000,['NCT00350259'],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[],[]
